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Sexualised drug use has previously been researched among men who have sex with men (MSM) 
in relation to sexual health and sexual risk behaviours. The topic has received more attention 
due to the emergence of chemsex as a public health issue, which is a particular form of 
sexualised drug use, but little research has been conducted to understand any possible 
relationship with psychological health. Additionally, motivations suggested for engaging in 
sexualised drug use and chemsex among MSM also apply to women who have sex with women 
(WSW) and trans people, but these groups have been under-researched comparatively.  
Aim 
The aim of this programme of research was to investigate sexualised drug use among all LGBT 
people, reasons for engagement, as well as associations with physical and psychological health. 
Methodology 
A sequential mixed methods design was used across three studies. For Study 1, a systematic 
review investigating sexualised drug use among LGBT people within the recent context of 
chemsex was conducted, and how this behaviour is associated with sexual health and health 
behaviours. In Study 2, a cross-sectional online survey was used (The LGBT+ Sex and 
Lifestyles Survey) that recruited 3,507 LGBT people (1,663 MSM, 1,152 WSW, and 500 trans 
people; groups not mutually exclusive). Multivariable logistic regression analyses were 
conducted to explore associations with drug use, sexualised drug use, and chemsex. In Study 
3, semi-structured interviews were conducted with 13 MSM service users and 16 sexual health 
service providers to further explore how engaging in sexualised drug use can impact physical 
and psychological health, as well as the standard of care received by people engaging in 
sexualised drug use. Interviews were analysed using thematic analysis. Findings from all three 
studies were triangulated and discussed in relation to the research objectives. 
Results 
The findings showed that LGBT people beyond MSM do engage in sexualised drug use, but 
chemsex was observed mostly among MSM. Engaging in chemsex among MSM appeared to 
be associated with greater sexual risk compared to other sexualised drug use. There was some 
evidence that drug use and sexualised drug use may be associated with physical and 
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psychological problems such as lower satisfaction with life and sexual assault, but not all of 
those engaging in sexualised drug use were experiencing negative associations with physical 
and psychological health. Sexual health services appeared to provide an adequate level of care 
for MSM engaging in sexualised drug use, but barriers to care existed within sexual health 
services (e.g. funding, access) and when engaging in other types of healthcare (e.g. mental 
health services). 
Discussion 
Overall, a harm reduction approach to sexualised drug use is needed to help those who engage 
in sexualised drug use reduce potential for physical and psychological harms, and support 
services should be available for those who need help managing or stopping their use. 
Additionally, LGBT people more broadly than MSM should be included in sexual health and 
drug research where appropriate.  
What was previously known on this topic? 
 MSM have been engaging in sexualised drug use for some time, but the topic has 
become a more prominent area of research due to the emergence of chemsex as a 
public health issue 
 Whilst associations with sexual health are documented, it is unknown whether 
sexualised drug use among MSM is associated with any psychological health 
problems 
 Reasons suggested for engaging in sexualised drug use and chemsex (internalised 
homophobia, experiencing discrimination, living with HIV) may also apply to 
WSW and trans people, but these groups have received little research in 
comparison 
What has this research added? 
 Sexualised drug use was observed among all LGBT people and was associated 
with a number of sexual and psychological health problems 
 MSM who engaged in chemsex appeared to be at greater risk of sexual health 
problems than MSM who engage in other forms of sexualised drug use 
 Whilst sexual health services appeared satisfactory from a service user and service 
provider perspective, MSM engaging in sexualised drug use who sought help 
outside sexual health settings experienced a number of barriers to care 
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Chapter 1: Introduction 
 
Overview of the thesis 
 
This programme of research aims to explore sexualised drug use among LGBT people: 
why people engage in the behaviour, and the impact this may have on physical and 
psychological wellbeing. Previous research regarding sexualised drug use has mostly focused 
on men who have sex with men (MSM), especially with the emergence of chemsex as a public 
health issue among MSM. Chemsex is the intentional use of certain drugs (crystal 
methamphetamine, GHB/GBL, ketamine) to prolong and intensify the sexual experience. This 
programme of research aims to understand if sexualised drug use and chemsex is also observed 
among other LGBT people, such as women who have sex with women (WSW) and trans people. 
This chapter will provide the background and context to drug use and sexualised drug use 
among LGBT people, discuss research detailing the emergence of chemsex among MSM, and 
then detail how this may relate to LGBT people more generally. It will discuss the aims of this 
programme of research, the research questions developed, and the rationale behind this 
research topic as based on previous research. An overview of the research approach will be 
given and the position of the researcher will be explored. In addition, the contribution to 
research will be considered. This chapter concludes with an overview of the subsequent 
chapters in the thesis. 
 
Drug use and LGBT people 
 
The exact population size of lesbian, gay and bisexual (LGB) people in the UK is 
currently unknown. However, it is estimated that 2.5% of the population identifies as lesbian, 
gay or bisexual (van Kampen, Fornasiero, Lee, & Husk, 2017), although this does not account 
for various other LGBT identities (e.g. trans, queer), and does not account for people who may 
engage in sex with someone of the same gender but does not identify as lesbian, gay, or bisexual. 
The Office of National Statistics (ONS) found that gay and bisexual adults were more likely to 
report illicit drug use in the last year compared to heterosexual adults (28% vs. 8%), and this 
difference was observed for most drugs (cannabis, cocaine powder, ecstasy, hallucinogens, 
amphetamines, methamphetamine, cannabis, tranquilisers, ketamine and amyl nitrate (poppers)) 
(Office of National Statistics, 2014). It was also observed that the prevalence of illicit drug use 
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was greater for gay and bisexual men compared to heterosexual men (33% vs. 11%), as well 
as for gay and bisexual women compared to heterosexual women (23% vs. 5%), with gay and 
bisexual men statistically more likely to use amyl nitrite, cocaine powder, ecstasy and ketamine 
compared to gay and bisexual women (Office of National Statistics, 2014). Additionally, 
research has found that young adults in the UK who identify as LGB reported more binge 
drinking, solvent use, cannabis and other drugs, compared to heterosexual young adults 
(Booker, Rieger, & Unger, 2017). This research also found that LGB young adults were more 
likely to have worse mental functioning, health satisfaction, and overall life satisfaction, when 
compared to heterosexual young adults, but it was not clear whether this was related to drug 
and substance use (Booker et al., 2017). 
Similar to LGB people, the population size of trans people in the UK is also unknown. 
Estimates of the proportion of people in the UK who identify as trans do not exist, but research 
conducted in other Western countries such as the USA have estimated that 0.6% of the 
population identify as trans (Flores, Herman, Gates, & Brown, 2016). Trans is an umbrella 
term that refers to people whose current gender identity differs from the gender they were 
assigned at birth, and/or differs from the traditional cultural male-female binary (e.g. 
transgender, trans male, trans female, gender queer/ non-binary) (Sevelius, Reznick, Hart, & 
Schwarcz, 2009). Although little research has been conducted in the UK to investigate trans 
peoples’ drug and alcohol use, the Trans Mental Health Study found high levels of illicit drug 
use (24%), with the most common drugs being cannabis, poppers (amyl nitrates), and ecstasy 
(McNeil, Bailey, Ellis, Morton, & Regan, 2012). In addition, 62% of respondents to the Trans 
Mental Health Study had scores that indicated dependent alcohol use or abuse when using the 
Alcohol Use Disorders Identification Test (AUDIT-C; Bush, Kivlahan, McDonell, Fihn, & 
Bradley, 1998). It is known that MSM in the UK have a high prevalence of HIV compared to 
the general population (O’Halloran et al., 2019); however, little research exists on trans 
women’s sexual health. This is despite a systematic review estimating that 19% of trans women 
internationally are living with HIV (Baral et al., 2013), although this may be reflective of the 
countries included in the review having poor access to HIV treatment and high-levels of 
survival sex work. 
Findings that lesbian, gay, bisexual, and trans (LGBT) people have high levels of 
alcohol and drug use are not exclusive to the UK. A high level of alcohol and drug use among 
young LGBT people has been observed in Australia (Kelly, Davis, & Schlesinger, 2015), 
among women who have sex with women (WSW) in Botswana, Namibia, South Africa, and 
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Zimbabwe (Muller & Hughes, 2016), lesbian and bisexual women in Israel (Mor et al., 2015), 
as well as transgender youth and transgender adults in the USA (Day, Fish, Perez-Brumer, 
Hatzenbuehler, & Russell, 2017; Gonzalez, Gallego, & Bockting, 2017). For men who have 
sex with men (MSM), and to some extent trans women (Herrera et al., 2016), much of the 
research into alcohol and drug use focuses on substances used in a sexual and/or party context 
(Bourne & Weatherburn, 2017), which has been observed internationally (Bourne, 2012).  
 
Chemsex and sexualised drug use 
 
Drug use has been researched among MSM alongside the HIV epidemic due to MSM 
having additional risk factors for HIV acquisition, such as condomless anal intercourse, but 
also because of behaviours associated with some methods drug use that may increase the risk 
of HIV acquisition, like needle sharing (Halkitis, Parsons, & Stirratt, 2001; Stall & Purcell, 
2000). Therefore, the association between drugs and sex has been a topic of research for some 
time (Leigh & Stall, 1993). Sexualised drug use can be defined as the intentional use of drugs 
to facilitate the sexual experience and increase arousal, which has also been a historical area of 
research among MSM due to its associations with condomless sex (Mattison, Ross, Wolfson, 
Franklin, & HNRC Group, 2001). However, sexualised drug use has become a more prominent 
area of interest due to the emergence of ‘chemsex’ as a public health issue. Chemsex 
(sometimes referred to as ‘party and play’) is a particular form of sexualised drug use among 
men engaging in sex with other men for long periods of time, with multiple sexual partners, 
and taking crystal methamphetamine, γ-hydroxybutyrate/ γ-butyrolactone (GHB/GBL), 
methedrone, cocaine, and/or ketamine immediately before or during sex (Bourne, Reid, 
Hickson, Torres Rueda, & Weatherburn, 2014). 
The rise of chemsex as a public health issue may be due to an increase in the number 
of people engaging in the behaviour, reported both by clinicians (Stuart, 2013), and men who 
engage in chemsex (Ahmed et al., 2016), both suggesting that geospatial networking apps and 
online sites to meet sexual partners have enabled this increase. However, a review of sexualised 
drug use and chemsex in the UK found that prevalence estimates for both behaviours differed 
substantially, due to the variations in definitions used and the method of participant recruitment 
(Edmundson et al., 2018). Quantitative research has also found a higher use of ‘barebacking’ 
(condomless sex) sexual networking applications among MSM engaging in chemsex (Hegazi 
et al., 2017). The European MSM Internet Survey (EMIS) found that the three European cities 
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with the highest prevalence of drug use that is associated with chemsex (defined as the use of 
crystal methamphetamine, GHB/GBL, ketamine and/or mephedrone) were Brighton (16.3%), 
Manchester (15.5%) and London (13.2%) (Schmidt et al., 2016).  
 Behaviourally, engaging in chemsex has been associated with having more sexual 
partners, group sex, condomless anal intercourse, fisting, sharing sex toys, injecting drug use, 
and higher alcohol consumption (Bourne et al., 2014; Glynn et al., 2018; Hegazi et al., 2017). 
When specifying particular drug use, GHB, crystal methamphetamine, erectile dysfunction 
drugs (EDD), and poppers have been associated with condomless anal intercourse among MSM 
in England (Melendez-Torres, Hickson, Reid, Weatherburn, & Bonell, 2017). The proportion 
of MSM reporting sexualised drug use including chemsex drugs, has been found to be higher 
among MSM diagnosed with a bacterial STI whilst attending a sexual health clinic in London 
(Ottaway, Finnerty, Amlani, et al., 2017), and a high proportion of MSM diagnosed with 
Shigella in England reported engaging in chemsex (Gilbart et al., 2015). Among sexual health 
clinic attendees in Dublin, MSM who engaged in chemsex were more likely to report having 
been treated for gonorrhoea in the past 12 months (Glynn et al., 2018). MSM reporting chemsex 
have been found to be more likely to be living with HIV, but MSM who do not have HIV and 
report engaging in chemsex are more likely to have accessed post-exposure prophylaxis (PEP), 
medication taken after possible exposure to HIV to reduce likelihood of acquisition (Hegazi et 
al., 2017; Ottaway, Finnerty, Buckingham, & Richardson, 2017). In Amsterdam, a higher 
proportion of MSM engaging in chemsex were taking pre-exposure prophylaxis (PrEP) 
compared to MSM not engaging in chemsex, a preventative medication taken to reduce 
likelihood of HIV acquisition (Druckler, van Rooijen, & de Vries, 2018), although this is yet 
to be investigated in the UK. Among MSM living with HIV, drug use has been associated with 
reduced antiretroviral therapy (ART) adherence and a detectable viral load, which makes the 
transmission of HIV possible (Daskalopoulou, Rodger, & Phillips, 2014; Pufall et al., 2018). 
Additionally, polydrug use (multiple drugs used on one occasion) among MSM living with 
HIV has found to be associated with increased condomless anal intercourse with a 
serodiscordant partner (Daskalopoulou et al., 2014).  
Whilst the term chemsex tends to be used to describe this behaviour in European and 
English speaking countries, sexualised drug use and the use of chemsex drugs among MSM 
have been observed internationally in countries such as Argentina (Balán et al., 2017), Peru 
(Ludford et al., 2013), China (Wang et al., 2015), and Israel (Brosh-Nissimov et al., 2012). 
Therefore, sexualised drug use, and in particular crystal methamphetamine use, is not exclusive 
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to Western cultures; however, collecting data from Western countries may be more easily 
facilitated due to similar gay cultural identities (Bryant et al., 2017). In addition, it can be 
argued that research regarding LGBT health issues may be easier to conduct in these countries 
due to more liberal values and beliefs.  
 
Sexualised drug use and psychological wellbeing 
 
Although researching sexualised drug use with a focus on its implications for sexual 
health is understandable in terms of health protection and health promotion, attempting to 
understand the impact on mental health and psychological wellbeing has been somewhat 
neglected (Desai, Bourne, Hope, & Halkitis, 2018). Research in Australia found that drug use 
among MSM was not associated with depression or anxiety, but drug use was not measured in 
a sexual context (Prestage et al., 2018). During qualitative interviews with MSM engaging in 
chemsex in London, it was reported that chemsex was having an impact on some men’s 
personal relationships and professional conduct (Bourne et al., 2015). In Dublin, a quarter of 
MSM attending a sexual health clinic reported that chemsex was having a negative impact on 
their lives, 17% reported losing consciousness whilst engaging in chemsex, and 6% stated their 
partners had lost consciousness (Glynn et al., 2018). Related to the loss of consciousness, MSM 
have reported in qualitative interviews that they have felt uncomfortable in situations due to 
issues regarding a person’s ability to consent to sex, and some participants expressed they had 
experienced non-consensual sexual contact because of chemsex (Bourne et al., 2015).  
In terms of help and support, MSM have stated a preference for drug services within 
sexual health clinics (Bourne et al., 2014; Evers et al., 2020; Tomkins, Vivancos, Ward, & 
Kliner, 2018). This preference for integrated sexual health and drug and alcohol services over 
specific drug and alcohol support has been suggested to be due to a believed lack of 
understanding from drug and alcohol services, as well as a fear among some MSM of disclosing 
their sexuality or sexual behaviours (Bourne et al., 2015). It has been suggested that sexual 
health clinics should adapt services for MSM engaging in sexualised drug use and chemsex, in 
addition to promoting existing services (Frankis & Clutterbuck, 2017; Stuart, 2014; Tomkins, 
Vivancos, et al., 2018). However, due to reduced funding for sexual health services over the 
past decade (BASHH/BHIVA, 2018), this may have negatively impacted any potential service 
development. London has received much of the research attention for chemsex due its high 
prevalence, and has developed a highly successful chemsex support clinic integrated into 
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sexual health services (Stuart & Weymann, 2015). However, a high prevalence of chemsex in 
other regions in the UK has also been observed (Schmidt et al., 2016), with prevalence of 
broader sexualised drug use likely to be higher (Edmundson et al., 2018; Tomkins, Vivancos, 
et al., 2018). Service user perspectives are needed to understand how to develop services for 
MSM engaging in chemsex and sexualised drug use, but service provider perspectives are also 
needed to understand what services are currently being provided, as well as any barriers to 
service development like funding constraints. 
 
Minority Stress Model 
 
 To understand LGBT mental health and psychological wellbeing in the context of 
sexualised drug use, the Minority Stress Model (Meyer, 2003) provides a conceptual 
framework to understand how minority stressors that are unique to LGB people lead to risk 
behaviours and poor health outcomes. It proposes three processes by which stressors can 
impact on health behaviours and outcomes: environmental stressors (general stressors not 
unique to minority status e.g. job loss); distal minority stressors (prejudice events such as 
discrimination or violence); and proximal minority stressors (internalised negative attitudes of 
minority status leading to hyper vigilance, expectations of discrimination, and internalised 
homophobia). The Minority Stress Model has also been extended to incorporate experiences 
resulting from gender identity and gender expression among trans people, such as increased 
risk of physical and sexual violence and internalised transphobia (Hendricks & Testa, 2012).  
Whilst evidence has provided support for the model in explaining mental health 
problems among LGB people (Kuyper & Fokkema, 2011; Shilo & Mor, 2014), it has also been 
suggested that the model does not account for environmental and genetic familial factors 
related to mental health, which can independently contribute to the increased risk of psychiatric 
disorders (Frisell, Lichtenstein, Rahman, & Langstrom, 2010). Although research has found 
minority stress factors to be associated with psychological distress and suicide attempts among 
LGB people, associations between minority stress factors and club drug use (cocaine, crystal 
methamphetamine, GHB, ketamine, speed) were not found (Lea, de Wit, & Reynolds, 2014). 
Additionally, an association between minority stress factors and engagement in condomless 
anal intercourse whilst using club drugs was not found (Dentato, Halkitis, & Orwat, 2013). 
However, findings from qualitative interviews with MSM engaging in chemsex found that 
some minority stress factors, such as internalised homophobia, have been suggested as 
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motivations for engagement in chemsex, in addition to HIV stigma and the intense sexual 
experience of chemsex (Weatherburn, Hickson, Reid, Torres-Rueda, & Bourne, 2017). 
Quantitative research recruiting MSM through Facebook advertising did not find an association 
between internalised homophobia, experiences of discrimination, and sex under the influence 
of alcohol and drugs in the UK, although the drugs used were not specified and alcohol was 
grouped with drugs (Chard, Metheny, Sullivan, & Stephenson, 2018). Therefore, the Minority 
Stress Model can be used to partially explain some of the variance in mental health inequalities 
experienced by LGBT people, but it is not yet fully understood what additional factors may 
contribute to substance use and sexualised drug use among LGBT people.  
 Minority stress factors that have been suggested as reasons for engaging in sexualised 
drug use, such as internalised homophobia, also apply to women who have sex with women 
(WSW). However, little research has been conducted attempting to understand drug use and 
sexualised drug use among WSW compared to MSM. A UK survey of people who inject drugs 
found that WSW were more likely than heterosexual women to report use of those drugs 
associated with chemsex among MSM, such as non-injected mephedrone and non-injected 
ketamine, but it was not asked if this was sexualised drug use (Heinsbroek, Glass, Edmundson, 
Hope, & Desai, 2018). Among lesbian, bisexual, and queer women in Australia, women who 
identified as queer or bisexual reported a higher proportion of recent illicit drug use, and higher 
proportions of sexual coercion since 16 years old compared to women who identified as 
lesbian/gay (Germanos, Deacon, & Mooney-Somers, 2015). In Australia, sexualised drug use 
has been observed among WSW, with 8% of those using methamphetamine, 9% of those using 
ecstasy, and 10% of those using cocaine having taken these drugs before or during sex 
(Mooney-Somers, Deacon, Scott, Price, & Parkhill, 2018). Whilst the focus on MSM may be 
important in terms of sexual risk, it should not be ignored that WSW can still be at greater 
sexual risk as well depending on the gender of their sexual partner. Research among LGB youth 
found that reporting a greater number of sexual partners was associated with cannabis use, but 
drug use was not specified to be during sex and data were not available specific to WSW 
(Zhang & Wu, 2017). 
There is a lack of research regarding sexualised drug use among trans and non-binary 
people. Although research into sexual risk behaviours among trans women has considered drug 
use, especially in the context of sex work (Hoffman, 2014; Reback & Fletcher, 2014), the topic 
is relatively understudied in comparison to MSM and the potentially high global prevalence of 
HIV among trans women (Baral et al., 2013). Additionally, research has suggested that over 
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60% of trans men identify as men who have sex with men (MSM) (Bauer, Redman, Bradley, 
& Scheim, 2013), but trans MSM are often excluded from research regarding MSM, despite 
potentially engaging in high-risk sexual behaviour like condomless anal intercourse (Wolton, 
Cameron, Ross-Turner, & Suchak, 2018).  
 
Research aims and objectives 
 
 
 So far, research has established an association between sexualised drug use and sexual 
risk taking behaviours among MSM. However, because of a focus on sexual risk, reasons for 
engagement in sexualised drug use and its broader impact on health and wellbeing have been 
somewhat neglected. Furthermore, where reasons for engagement have been suggested, these 
motivations apply to the whole LGBT community, but research into sexualised drug use among 
WSW and trans people is under-researched in comparison to MSM. When WSW and trans 
people are included, data is often grouped with MSM so any differences that may exist within 
the LGBT community are unclear. In addition to this, wellbeing is also not considered when 
WSW and trans people are included. Furthermore, research into chemsex has focused on 
Western countries but the drugs used for chemsex, as well as in other forms sexualised drug 
use, has been observed in a sexual context in non-Western countries. Due to the recent focus 
on chemsex, research on other drugs and substances used in a sexual context (e.g. cannabis, 
EDD, poppers/amyl nitrates) may have been neglected, but these drugs may still be associated 
with greater sexual risk. Therefore, the aim of this programme of research is to investigate 
sexualised drug use among LGBT people, with a particular focus on reasons for engagement, 
as well as the potential impact on physical health and psychological wellbeing.   
 
Therefore, the objectives for this programme of research are:  
1. To investigate the occurrence of general sexualised drug use in the context of chemsex 
among MSM and the wider LGBT community.  
2. To measure quantitatively the psychological reasons as to why some MSM engage in 
chemsex and/or sexualised drug use, and also investigate possible reasons for 
engagement in the wider LGBT community.  
3. To understand what potential impact engaging in sexualised drug use has in terms of 
sexual and physical health, and psychological wellbeing.  
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4. To investigate what services are currently available for LGBT people engaging in 
sexualised drug use and what service development is needed. 
 
There is some debate regarding appropriate terminology for LGBT people (Everett, 2013; 
Savin-Williams & Vrangalova, 2013; Young & Meyer, 2005). It is argued that terms like MSM 
and WSW erases identity, relationships, and community relating to sexual orientation (Young 
& Meyer, 2005). However, it is common practice in epidemiology, specifically epidemiology 
focusing on sexual behaviour, to group individuals by that behaviour as that is inclusive 
terminology for the risk being investigated (Levi, Tseng, & Landovitz, 2014; Mercer et al., 
2016; Mimiaga et al., 2011). There is evidence to suggest that heterosexually identifying MSM 
and WSW are distinct categories relating to sexual behaviour and risk, and therefore the role 
of identity in sexual behaviour cannot be ignored (Everett, 2013; Savin-Williams & Vrangalova, 
2013). Therefore, the terms MSM and WSW were deemed appropriate for this research as the 
primary focus was sexual behaviour, but identity relating to sexual orientation was measured 
and accounted for in analyses. Being trans is based upon gender identity and because no 
common sexual behaviour can group trans people (Sausa, Sevelius, Keatley, Iniguez, & Reyes, 





A mixed methods design utilising three studies was adopted to address these objectives 
for the programme of research (Figure 1). Study 1 was a systematic review examining the 
extent to which sexualised drug use among LGBT people has been researched internationally. 
This study also assessed the health outcomes and behaviours that have been researched in 
relation to sexualised drug use. A systematic review was chosen as opposed to a traditional 
literature review, because as seen in the introduction, this topic has been studied historically 
for some time, and there was sufficient evidence to conduct a systematic review with potential 
for meta-analyses. Additionally, the systematic review helped detail quantitative methods used 
for measuring drug use and health outcomes, which informed measurements in Study 2. An 
explanatory sequential design (QUAN→qual) was then used for Study 2 and 3 (Morse, 2003). 
Study 2 was a quantitative online cross-sectional survey conducted in the UK that investigated 
sexualised drug use and chemsex among LGBT people, reasons for engagement, and impact 
on psychological wellbeing. A cross-sectional survey was chosen as it is a quick and relatively 
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inexpensive method to obtain a large sample. The findings from Study 2 were then used to 
inform semi-structured interviews with service users and service providers to investigate 
service provision for people engaging in sexualised drug use. Sexual health service providers 
were included in Study 3 to provide a more holistic understanding of the standard of service 
delivery to MSM engaging in sexualised drug use by analysing multiple perspectives. Due to 
findings from each stage informing the subsequent stage in this programme of research, the 
method, results, and discussion for each stage were outlined separately, then the results from 
each stage combined using a triangulation method (Farmer, Robinson, Elliott, & Eyles, 2006) 
in the final chapter.  
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Figure 1. Research design 
Study 3a 
Semi-structured 
interviews with members 
of the public (service 
users) regarding 
sexualised drug use. 
(Objective 3 and 4) 
Study 1 
Systematic review 
exploring sexualised drug 
use among LGBT people 
and its impact on health 
and health behaviours 
(Objective 1 and 3) 
Study 2 
Online survey to explore 
sexualised drug use and 
reasons for engagement 
among LGBT people, and 
its impact on physical and 
psychological wellbeing 
(Objective 1, 2 and 3) 
Study 3b 
Semi-structured 
interviews with sexual 
health workers (service 
providers) regarding 
sexualised drug use. 





Pragmatism provides an epistemological position in which mixed methods research is 
conducted based upon the researcher’s logic in answering the research questions (Johnson, 
Onwuegbuzie, & Turner, 2007). Therefore, the research design and methods were developed 
as the most appropriate solution to answering the research questions (Johnson & Onwuegbuzie, 
2004). An explanatory sequential design was chosen as it was deemed most appropriate to 
achieve the research aims and objectives, due to these being mostly quantitative in nature and 
therefore the findings from the quantitative study can then be explored further in qualitative 
interviews with service users and service providers (Creswell & Clark, 2010). This allows for 
a comprehensive analysis of a topic, where the qualitative stage compliments the quantitative 
stage (Morse, 2003), and a broader range of research questions can be investigated without 
committing to a single research method (Johnson & Onwuegbuzie, 2004). Additionally, due to 
the cross-sectional nature of Study 2 causation cannot be inferred. Although the qualitative 
stage has a much smaller sample, participants provided a perspective on the cause and effect 
of psychological factors, drug use, and health behaviours. The generic qualitative research 
approach was used to guide the qualitative stage of this programme of research, due to its 
appropriateness to the research question and for use in mixed methods research (Caelli, Ray, 
& Mill, 2003). Findings from all three studies were then integrated using a triangulation method 
in the final chapter (Farmer et al., 2006).  
 
Patient and public involvement 
 
Patient and public involvement (PPI) aims to conduct research with rather than on 
members of the public, with the aim of improving healthcare provision (Thornton, 2008). It 
was the aim of this research to involve members of the public as researchers (Forbat, Hubbard, 
& Kearney, 2009), to ensure this research would be beneficial to the LGBT community and 
useful in terms of advocating for improvement of services. This approach is argued to be 
empowering for individuals, as opposed to being tokenistic, and broadens the impact of the 
research to individuals and organisations (Ocloo & Matthews, 2016). To ensure this, contacts 
at community organisations and known members of the public were contacted before the start 
of Study 2, and those that were interested were involved in the design, delivery, interpretation 
and dissemination of the research findings of Study 2. Details regarding how the PPI group 
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were involved in Study 2 can be found in the methodology chapter for this study (Chapter 3). 
It was aimed that the same level of public involvement be applied to Study 3; however, due to 
a limited number of organisations and a lack of capacity, this could not be implemented. 
 
Position of the researcher 
 
Before commencing this programme of research, I reflected upon my personal 
background coming into this research, and how this could potentially impact the current 
research. Before starting this PhD, I had been a researcher and epidemiologist in public health 
for two years, specifically HIV research. Through this experience I had worked on a number 
of sexual and LGBT health projects. Furthermore, I am aware that I am researching a 
community that I am a part of, and that itself comes with an awareness of LGBT health issues, 
as well as personal opinions regarding LGBT issues. Therefore, I had both personal and 
professional knowledge regarding the topic before commencing this research. Although this 
knowledge had the potential to frame the research and reduce the exploratory nature of the 
study, several steps were taken to ensure this previous experience did not influence the current 
research and to demonstrate transparency as a researcher. These included:  
 A research protocol for Study 1 was published at PROSPERO before the systematic 
review commenced and this protocol was followed (Chapter 2). 
 A PRISMA statement for conducting and reporting systematic reviews (Study 1) was 
followed (see Appendix 1).  
 Analyses for Stage 2 were discussed with the supervisory team and formulated before 
data had been analysed. 
 Personal reflections highlighting positionality and providing reflective commentary are 
included after Studies 2 and 3 (Chapters 5 and 8 respectively).  
 A framework for trustworthiness of qualitative research is outlined for Study 3 (Chapter 
6). 
 A protocol for the triangulation process was produced before triangulation of findings 
commenced (Chapter 9). 
 Presentation of the research at conferences, as well as publications in peer-reviewed 
journals, provided the opportunity for feedback from the scientific community. 
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 All three members of the supervisory team reviewed all stages of the research at regular 
intervals, including the design, analyses, interpretation of findings, and triangulation. 
The stages taken to ensure transparency as a researcher provide evidence of how previous 
experience was accounted for and documented, but maintaining scientific integrity was 
prioritised at all times during this programme of research. 
 
Contribution to research 
 
 This research was the first fully inclusive investigation into sexualised drug use among 
LGBT people. The systematic review (Study 1) was the first attempt to analyse the inclusion 
of WSW and trans people in the sexualised drug use literature. It also attempted to understand 
the scope of sexualised drug use internationally, and its associated health conditions and 
behaviours. The LGBT+ Sex and Lifestyles Survey (Study 2) conducted across the UK made 
numerous novel contributions to the research of sexualised drug use among LGBT people. 
Study 2 was the first research to quantitatively measure psychological reasons for engagement 
and psychological associations of engagement in chemsex among MSM, and placed this in the 
context of wider sexualised drug use. Secondly, whilst high rates of drug use among WSW 
have been observed previously, the online questionnaire was the first to compare sexual and 
psychosocial factors that are associated with drug use and those who engage in sexualised drug 
use among WSW. Thirdly, although there has been some research regarding trans women and 
sexualised drug use, Study 2 included not only trans women, but trans men and non-binary 
people as well. Additionally, very little UK research existed regarding trans people and drug 
use, therefore Study 2 helped to address this gap in the literature. Qualitative interviews with 
both service users (Study 3a) and service providers (Study 3b) gave an insight into service 
provision from both perspectives, and provided an understanding of possible barriers to care. 
Together, this programme of research highlighted a number of potential harms associated with 
drug use, sexualised drug use, and chemsex among LGBT people. This new understanding of 
the topic can be used to inform service providers of potentially compounding health factors 
associated with drug use, sexualised drug use, and chemsex among LGBT people, and 
highlighting any barriers to care can help to improve service provision and potentially reduce 




Overview of thesis chapters 
 
Chapter 1: Introduction. This chapter places the thesis in the context of current research 
regarding sexualised drug use and chemsex, outlining the aims and objectives of this thesis and 
the approach to achieving these.  
Chapter 2: Systematic review. This chapter describes the systematic review conducted, 
assessing the extent of research into sexualised drug use among LGBT people and its associated 
health behaviours. 
Chapter 3: Methodology for Study 2. This chapter outlines the methodology used to conduct 
the online quantitative survey (The LGBT+ Sex and Lifestyles Survey) that investigated 
sexualised drug use among LGBT people. 
Chapter 4: Results for Study 2. This chapter provides the data collected and the analyses that 
were conducted to investigate reasons for engagement in sexualised drug use among LGBT 
people, and its potential associations with physical health and psychological wellbeing.  
Chapter 5: Discussion and reflection on Study 2. This chapter discusses the findings from 
The LGBT+ Sex and Lifestyles Survey, how this relates and adds to previous literature, and 
provides personal reflection on the experience of conducting Study 2. 
Chapter 6: Methodology for Study 3. This chapter outlines the rationale and methodology 
for qualitative semi-structured interviews with service users (Study 3a) and service providers 
(Study 3b), how Study 2 helped inform the interviews and the analysis technique used. 
Chapter 7: Results for Study 3. This chapter describes the themes emerged from qualitative 
interviews with service users and service providers. 
Chapter 8: Discussion and reflection on Study 3. This chapter compares the themes from 
interviews with service users and service providers in relation to the study aims, places these 
findings in the context of previous research, discusses the strengths and limitations of Study 3, 
and provides personal reflection on conducting Study 3. 
Chapter 9: Discussion and triangulation of findings. This chapter combines findings from 
all three studies in the relation to the aims for this programme of research, placing the findings 
context of existing literature, describing contributions to research this programme of research 
has made, and making recommendations for future research.   
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Chapter 2: A systematic review and meta-analyses investigating sexualised 
drug use among LGBT+ people 
 
Rationale and overview 
 
Systematic reviews are an effective means of synthesising published data regarding a 
topic by limiting the influence of bias and providing data for informed decision making 
(Mulrow, 1994). Therefore, it was deemed appropriate to systematically synthesise previous 
research on sexualised drug use among LGBT people to help inform the design of Study 2. 
This chapter will outline the rationale for the systematic review, the method of searching for 
literature, findings of the systematic review and meta-analyses, and finally the discussion, 
which includes how these findings were used to help inform the next stage of the research 
programme.  
The ways of measuring sexualised drug use and health related outcomes can be grouped 
into three categories: global association, situational association, and event-level associations 
(Leigh & Stall, 1993). A global association is where general drug use is measured over a 
specific period (e.g. in the past 12 months) and sexual behaviour is measured over a specific 
period, and an analysis between the two is conducted. A situational association is where the 
drug use is measured in relation to sex over a specific period and sexual behaviour is measured 
over a specific period, and an analysis between the two is conducted. An event-level association 
is where drug use and sexual behaviour are asked about a specific sexual event (e.g. the last 
time you had sex using a drug, did you use a condom?). Despite the fact that causation cannot 
be inferred from any of these analyses, a systematic review concluded that greater use of event-
level associations is needed when researching sexualised drug use, as they provide more 
contextual information (Vosburgh, Mansergh, Sullivan, & Purcell, 2012).  
The introduction highlighted that chemsex was an emerging area of research among 
MSM, but historically sexualised drug use has been researched among MSM for some time 
(Mattison et al., 2001). Additionally, reasons suggested for engaging in sexualised drug use 
and chemsex provided by previous research (Weatherburn et al., 2017) and the Minority Stress 
Model (Meyer, 2003) also apply to WSW and trans people, but comparatively little research 
has been conducted on the latter groups. Furthermore, the term chemsex is usually used in a 
Western context, but the sexualised drug use of these specific drugs has been observed 
internationally (Bourne & Weatherburn, 2017). 
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Therefore, the primary aim of this review was to: 
 Investigate how representative research into sexualised drug use is of the whole LGBT 
population in relation to health outcomes. 
Secondary aims of this review were to:  
 Investigate the associations between sexualised drug use and health outcomes (HIV 
status, STI diagnoses and condom use), and conduct meta-analyses if there is sufficient 
data. 
 Analyse what methods are used to measure sexualised drug use and chemsex (global 
association, situational association or event-level association).  
 Investigate which countries have reported sexualised drug use among LGBT people, 




To enable transparency in the aims and methods of the systematic review, a protocol 
was registered at PROSPERO International Register of Systematic Reviews (ID 
CRD42018084366,). The protocol was designed and registered prior to the review 
commencing and is available at: 
www.crd.york.ac.uk/prospero/display_record.php?RecordID=84366. To ensure appropriate 
reporting of the systematic review, the PRISMA Statement (Moher, Liberati, Tetzlaff, & 
Altman, 2010) was used during the write up and can be seen in Appendix 1. 
Suitable search terms were gained from systematic reviews on similar topics (Choi, 
Wong, & Fong, 2017; Vosburgh et al., 2012). A preliminary search was then conducted using 
these terms on MEDLINE, where suitable articles were retrieved to find additional search terms. 
A modified version of the PICO (Population, Intervention, Comparison, Outcome) framework 
was used to form the search strategy (Methley, Campbell, Chew-Graham, McNally, & 
Cheraghi-Sohi, 2014), where the category ‘Intervention’ was replaced with ‘Exposure’. 
Therefore, the PECO framework for the search strategy was as follows: 
 Population – LGBT people (MSM, WSW, and trans people) 
 Exposure – Sexualised drug use 
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 Comparison – Between those engaging in sexualised drug use and those not 
 Outcome – Sexual health and sexual health behaviours 
The final list of search terms was discussed with a librarian to check for validity. Search 
terms were grouped into three concepts: “LGBT terms”, “Drug terms”, and “Sex terms” (Table 
1). Search terms within concepts were combined using the Boolean operator ‘OR’ and concepts 
were combined using the Boolean operator ‘AND’, so that searches used the string: “LGBT 
terms” AND “Drug terms” AND “Sex terms”. The search string was used to search MEDLINE, 
PsycINFO, CINAHL Plus, and Web of Science (EBSCO MEDLINE from 1879 to 31st March 
2018, ProQuest PsycINFO from 1806 to 31st March 2018, EBSCO CINAHL Plus from 1981 
to 31st March 2018, Web of Science Core Collection from 1900 to 31st March 2018). Where 
studies were not published in English, an attempt to find a translation was made. A period limit 
of 1st January 2010 to 31st March 2018 (inclusive) was imposed due to the end date of a previous 
systematic review on a similar topic (Vosburgh et al., 2012), although this systematic review 
was specific to MSM engaging in sexualised drug use and event-level condom use. A limit was 
also set on the period of data collection (January 2010-March 2018) to ensure that the review 
represented recent patterns of sexualised drug use. Chemsex drugs were defined as the ‘4 chems’ 
(crystal methamphetamine, GHB/GBL, ketamine and mephedrone) as in Schmidt et al. (2016), 
and are commonly accepted as drugs associated with chemsex (Bourne et al., 2014). An attempt 
to find grey literature from relevant community organisations and public health organisations 
was made, but no reports provided sufficient detail to be included.  
There were four stages involved when identifying studies for inclusion in the review: 
identification, screening, eligibility, and inclusion (Moher et al., 2010). A data extraction form 
with quality assessment was adapted from The Cochrane Public Health Group Data Extraction 
and Assessment Template, The Effective Public Health Practice Project (EPHPP) Quality 
Assessment Tool for Quantitative Studies, and the Center for Evidence-Based Management 
(CEMa) critical appraisal checklist for surveys. This form was created using online survey 
software Qualtrics (www.qualtrics.com). Crosstabs data regarding drug use and outcomes 
(HIV status, STI diagnoses, condom use) were collected, and where data was not available, 
unadjusted odds ratios were collected. Inverse variance meta-analyses were produced using 
RevMan v5.3. Screening and eligibility was conducted by two researchers independently and 
a third researcher was used for any disagreements. Data extraction was completed by one 
researcher and then checked by a second researcher. Quality assessment was conducted by two 
researchers independently and a third researcher was used for any disagreements. 
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Table 1. Results generated from each search term used for each database, April 2018.  
Database Keywords Articles retrieved 
  LGBT terms Drug terms Sex terms   
Medline 
Homosexuality (MH) Substance-related disorders (MH) "Sexual health" 
1,264 
Homosexuality, female (MH) "Substance use" Reproductive health (MH) 
Homosexuality, male (MH) Alcohol drinking (MH) "Sexual behavior" 
Homosexual* Alcohol "Sexual behaviour" 
Gay "Drug use" Sexual behavior (MH) 
Lesbian* Chemsex "Sexual risk" 
Bisexual* "Party and play" Risk-taking (MH)  
Transexual* Marijuana Unsafe sex (MH) 
Transsexual* GBL "Unsafe sex" 
Transgender* GHB  
Trans Ecstasy  
Transgender persons (MH) Cocaine  
Genderqueer Crack  
"Non binary" Methamphetamine  
"Men who have sex with men" Methadone  
"Sexual minorit*" Poppers  
Sexual minorities (MH) "Amyl nitrate*"  
LGBT* Ketamine  
 Viagra  
 "Erectile dysfunction drug*"  
   "Sildenafil Citrate" (MH)   
PsycINFO 
Homosexuality (SH) Substance-related disorders (SH) "Sexual health" 
1,064 
Homosexuality, female (SH) "Substance use" Reproductive health (SH) 
Homosexuality, male (SH) Alcohol drinking (SH) "Sexual behavior" 
Homosexual* Alcohol "Sexual behaviour" 
Gay "Drug use" Sexual behavior (SH) 
Lesbian* Chemsex "Sexual risk" 
Bisexual* "Party and play" Risk-taking (SH)  
Transexual* Marijuana Unsafe sex (SH) 
Transsexual* GBL "Unsafe sex" 
Transgender* GHB  
Trans Ecstasy  
Transgender persons (SH) Cocaine  
Genderqueer Crack  
"Non binary" Methamphetamine  
"Men who have sex with men" Methadone  
"Sexual minorit*" Poppers  
Sexual minorities (SH) "Amyl nitrate*"  
LGBT* Ketamine  
 Viagra  
 "Erectile dysfunction drug*"  
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   "Sildenafil Citrate" (SH)   
CINAHL Plus 
Homosexuality (MH) Substance-related disorders (MH) "Sexual health" 
452 
Homosexuality, female (MH) "Substance use" Reproductive health (MH) 
Homosexuality, male (MH) Alcohol drinking (MH) "Sexual behavior" 
Homosexual* Alcohol "Sexual behaviour" 
Gay "Drug use" Sexual behavior (MH) 
Lesbian* Chemsex "Sexual risk" 
Bisexual* "Party and play" Risk-taking (MH)  
Transexual* Marijuana Unsafe sex (MH) 
Transsexual* GBL "Unsafe sex" 
Transgender* GHB  
Trans Ecstasy  
Transgender persons (MH) Cocaine  
Genderqueer Crack  
"Non binary" Methamphetamine  
"Men who have sex with men" Methadone  
"Sexual minorit*" Poppers  
Sexual minorities (MH) "Amyl nitrate*"  
LGBT* Ketamine  
 Viagra  
 "Erectile dysfunction drug*"  
   "Sildenafil Citrate" (MH)   
Web of Science 
Homosexual* Substance-related disorders "Sexual health" 
938 
Gay "Substance use" "Sexual behavior" 
Lesbian* Alcohol "Sexual behaviour" 
Bisexual* "Drug use" "Sexual risk" 
Transexual* Chemsex "Risk-taking" 
Transsexual* "Party and play" "Unsafe sex" 
Transgender* Marijuana  
Trans GBL  
Genderqueer GHB  
"Non binary" Ecstasy  
"Men who have sex with men" Cocaine  
"Sexual minorit*" Crack  
LGBT* Methamphetamine  
 Methadone  
 Poppers  
 "amyl nitrate*"  
 Ketamine  
 Viagra  
 "Erectile dysfunction drug*"  
  "Sildenafil Citrate"   




1. A measure of drug use and sexual health risk (HIV status, STI diagnoses, condomless 
sex) within the same population. 
2. An association analysis conducted between the drug behaviour and the sexual 
behaviour and/or health risk. 
3. Population studied includes a sexual and/or gender minority population. 
4. Studies published and data collected in the date range January 2010 to March 2018 
(inclusive). 
Exclusion criteria: 
1. Articles not published in English and no translation available. 
2. Studies including children (aged equal to or less than 15 years). 
3. Articles that are not accessible through LJMU libraries or interlibrary loans. 
4. Studies that are not relevant to the research question (e.g. heterosexual populations only, 
medical drug trail studies). 




 The search yielded 1,971 unique citations, 1,220 of which were removed during title 
and abstract screening, 704 removed during full-text review, leaving 47 studies eligible for data 
extraction (Figure 2). The majority of studies were cross-sectional (n=45), one study was a 
cohort study, and one was a case-control study.  
Of the 47 studies included, 42 researched MSM and 5 researched trans women, across 
53 countries (Table 2). No studies researching sexualised drug use among WSW or trans 
men/non-binary people met the inclusion/exclusion criteria. The countries of included studies 
in which sexualised drug use had been researched among MSM or trans women or both are 






















Articles identified by electronic 
databases  
n = 3,718 
SCREENING: 
Titles and abstracts screen 
n = 1,971 
Citations removed as duplicates 
n = 1,751 
ELIGIBILITY: 
Full-text articles retrieved 
n = 751 
INCLUSION: 
47 studies included 
Citations removed due to 
irrelevance 
n = 1,220 
Full-text articles excluded, with 
reasons 
n = 704 
364 – data collected before 2010 
313 – insufficient data 
 14 – including children 
 13 – no English full-text 
 
IDENTIFICATION: 
Articles identified by searching for 
grey literature 
n = 4 
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Table 2. Summary of the characteristics of the included studies. 
Study Country (region if not national) Participants Drugs included Sexual health outcomes Analysis conducted 
Men who have sex with men 
Barron-Limon et al. (2012) Mexico (Tijuana) 260 MSM 
Amphetamine (speed), Cannabis, Cocaine, Ecstasy, Heroin, 
Poppers 
Condom use Situational association 
Bowden-Jones et al. (2017) UK (London) 
407 MSM attending a 
specialist drug clinic 
Crystal methamphetamine, Mephedrone  HIV Global association 
Card et al. (2017) Canada (Vancouver) 774 MSM 
Cannabis, Crystal methamphetamine, Ecstasy, EDD, 
GHB/GBL, Poppers 
Condom use Event-level association 
Daskalopoulou et al. (2014) UK 
2,248 MSM living with 
HIV 
Cannabis, Cocaine, Crystal methamphetamine, EDD, Poppers Condom use Global association 
Duan et al. (2017) China (Shenzhen) 1,935 MSM Cocaine,Crystal methamphetamine, Poppers 
Condom use, HIV, STIs 
(Syphilis) 
Global association 
Eaton et al. (2015) USA (Atlanta) 544 Black MSM Cocaine, Crystal methamphetamine, Ecstasy, EDD, Poppers HIV Global association  
Eaton et al. (2016) USA (Atlanta) 271 Black MSM Cannabis HIV Global association 
M. P. Fisher, Ramchand, Bana, and 
Iguchi (2013) 
USA 228 MSM  
Cannabis, Crystal methamphetamine, Ecstasy, EDD, 
GHB/GBL, Ketamine, Poppers 
HIV Global association 
Frankis, Flowers, McDaid, and Bourne 
(2018) 
Ireland, UK (Northern Ireland, Scotland, Wales) 2,428 MSM 
Chemsex/party drugs grouped (Crystal methamphetamine, 
GHB/GBL, Ketamine, Mephedrone) 
Condom use, HIV Situational association 
Gilbart et al. (2015) UK (England and Wales) 
34 MSM diagnosed with 
Shigella 
Chemsex/party drugs grouped (Crystal methamphetamine, 
GHB/GBL, Mephedrone) 
HIV Global association 
Glynn et al. (2018) Ireland (Dublin) 486 MSM 
Chemsex/party drugs grouped 
(Cocaine, Crystal methamphetamine, Ketamine, GHB/GBL, 
Mephedrone, NPS and other stimulants (including 
speed/amphetamine/ecstasy/eros/nexus/ smiles)) 




Goedel and Duncan (2016) USA (New York) 174 MSM Cannabis Condom use Global association 
González-Baeza et al. (2018) Spain (Madrid) 742 MSM living with HIV 
Chemsex/party drugs grouped (Amphetamines, Cocaine, 
Crystal methamphetamine, Ecstasy, GHB/GBL, Ketamine, 
Mephedrone or similar cathinones) 
Condom use, STIs 
(Chlamydia, 
Gonorrhoea, Hepatitis C, 
Syphilis) 
Situational association 
Halkitis et al. (2012) USA (New York) 199 MSM living with HIV Cannabis , Poppers Condom use Global association 
Hammoud et al. (2017) Australia 2,250 MSM EDD Condom use, HIV Global association 
Hammoud et al. (2018) Australia 3,190 MSM GHB/GBL Condom use, HIV Global association 
He et al. (2014) China (Shanghai) 200 MSM living with HIV Poppers STIs (Syphilis) Situational association 
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Heinsbroek et al. (2018) UK (England, Wales and Northern Ireland) 299 MSM who inject drugs Heroin, Ketamine, Mephedrone HIV Global association 
Kahler et al. (2015) USA (Boston) 109 MSM living with HIV Cannabis Condom use Global association 
Kecojevic, Silva, Sell, and Lankenau 
(2015) 
USA (Philadelphia)  
191 MSM aged 18-29 
years old 
Cannabis, Cocaine, Crystal methamphetamine, Ectasy, EDD Condom use 
Global association, 
Situational association  
Kelly, DiFranceisco, St Lawrence, 
Amirkhanian, and Anderson-Lamb 
(2014) 
USA (Milwaukee, Cleveland, Miami) 178 Black MSM Cannabis Condom use Event-level association 
Kelly, St Lawrence, Tarima, 
DiFranceisco, and Amirkhanian 
(2016) 
USA (Milwaukee, Cleveland, Miami) 445 Black MSM Cannabis Condom use Global association 
Kramer et al. (2016) 
Austria, Belarus, Belgium, Bosnia and 
Herzegovina, Bulgaria, Croatia, Cyprus, Czech 
Republic, Denmark, Estonia, Finland, France, 
Germany, Greece, Hungary, Ireland, Italy, 
Latvia, Lithuania, Luxembourg, Malta, 
Netherlands, Norway, Poland, Portugal, Republic 
of Macedonia, Republic of Moldova, Romania, 
Russia, Serbia, Slovakia, Slovenia, Spain, 
Sweden, Switzerland, Turkey, Ukraine, UK 
91,477 MSM 
EDD, Poppers, Chemsex/party drugs grouped (Amphetamines, 
Cocaine, Crystal methamphetamine, Ecstasy, GHB/GBL, 
Ketamine, Mephedrone) 
Condom use Global association 
Kupprat, Krause, Ompad, and Halkitis 
(2017) 
USA (New York) 
169 MSM living with HIV 
>=50 years old 
Cannabis Condom use Global association 
Lachowsky et al. (2016) Canada (Vancouver) 
436 self-reported HIV-
negative MSM  
Cannabis, Crystal methamphetamine, Ecstasy, EDD 
GHB/GBL, Poppers 
Condom use Event-level association 
Li & McDavid (2014)  UK (Scotland) 639 MSM EDD, Poppers Condom use, HIV  Situational association 
Li et al. (2014)  China 400 MSM Poppers 
Condom use, HIV, STIs 
(Syphilis) 
Global association 
Lim et al. (2015) Malaysia 1,235 MSM 
Chemsex/party drugs grouped (Crystal methamphetamine, 
Ecstasy, GHB/GBL, Ketamine) 
Condom use, HIV, STIs 
(unspecified) 
Global association 
Martinez et al. (2017) USA (New York) 240 Latino MSM Cannabis Condom use Global association 
Melendez-Torres, Hickson, Reid, 
Weatherburn, and Bonell (2016) 
UK (England) 321 MSM 
Cannabis, Cocaine, Crystal methamphetamine, Ecstasy, EDD, 
GHB/GBL, Ketamine, Mephedrone, Poppers 
Condom use Event-level association 
Melendez-Torres et al. (2017) UK (England) 2,142 MSM 
Cannabis, Cocaine, Crystal methamphetamine, Ecstasy, EDD 
GHB/GBL, Ketamine, Poppers 
Condom use Event-level association 
Mitchell, Pan, and Feaster (2016) USA 722 MSM 
Cannabis, Cocaine, Crystal methamphetamine, Ecstasy, EDD, 
GHB/GBL, Ketamine, Poppers  
Condom use Event-level association 
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Morgan et al. (2016) USA (Chicago) 202 Black MSM Cannabis Condom use, HIV Situational association 
Pylli, Middleton, Charalambous, and 
Raftopoulos (2014) 
Cyprus (Limassol, Paphos, Larnaca, Nicosia) 200 MSM Cocaine Condom use Global association 
Rendina, Moody, Ventuneac, Grov, 
and Parsons (2015) 
USA (New York) 371 MSM Cannabis Condom use Global association 
Sewell et al. (2017) UK 
1,484 HIV-negative or 
undiagnosed MSM 
Chemsex/party drugs grouped (Crystal methamphetamine, 
GHB/GBL, Mephedrone) 





Theodore, Durán, and Antoni (2014) USA (Florida) 197 MSM 
Cannabis , Cocaine, Crystal methamphetamine, Ecstasy, 
GHB/GBL, Ketamine, Poppers 
HIV Global association 
Tieu et al. (2014) USA (New York) 1,458 MSM 
Cannabis, Cocaine, Crack cocaine, Crystal methamphetamine, 
Poppers 
Condom use Global association 
Tomkins, Ahmad, et al. (2018) UK (Manchester) 357 MSM 
Chemsex/party drugs grouped (Crystal methamphetamine, 
GHB/GBL, mephedrone) 
HIV, STIs (Gonorrhoea, 
Hepatitis C, Syphilis) 
Global association 
Wei, Guadamuz, Lim, Huang, and Koe 
(2012) 
China, Hong Kong, Indonesia, Japan, Malaysia, 
Philippines, Singapore, South Korea, Thailand, 
Vietnam, Taiwan 
10,861 MSM 
Cannabis, Cocaine, Crystal methamphetamine, Ecstasy, EDD, 
GHB/GBL, Ketamine, Poppers 
HIV Global association 
Wu, Shen, Chiou, Fang, and Lo (2018) Taiwan  79 MSM living with HIV 
Cannabis, Crystal methamphetamine, Ecstasy, EDD, 
GHB/GBL, Ketamine, Mephedrone, Poppers, Chemsex/party 





Zhang et al. (2016) China (Bejing) 3,588 MSM Poppers 
Condom use, HIV, STIs 
(Syphilis) 
Global association 
Trans women      
Benotsch et al. (2016) USA (Mid-Atlantic region) 104 trans women Prescription drugs Condom use 
Global association, 
Situational association 
Colby et al. (2016) Vietnam (Ho Chi Minh City) 205 trans women Heroin HIV, STIs (Syphilis) Global association 
Grinsztejn et al. (2017) Brazil (Rio de Janerio) 345 trans women Cocaine HIV Global association 
Santos et al. (2014) USA (San Francisco) 314 trans women Cocaine, Crack cocaine, Crystal methamphetamine HIV 
Global association, 
Situational association 
Turner, Santos, Arayasirikul, and 
Wilson (2017) 
USA (San Francisco) 
263 trans women aged 16-
24 years old 
Crystal methamphetamine, Poppers Condom use Global association 
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Figure 3. Map of countries that have included studies on sexualised drug use among men who 




Men who have sex with men 
 
The most common drug studied among MSM was cannabis (n=23), followed by amyl 
nitrates/poppers (n=20), crystal methamphetamine (n=15), EDDs (n=14), cocaine (n=12), 
ecstasy (n=11), GHB/GBL (n=10), and ketamine (n=8). Other less studied drugs were 
mephedrone (n=4), heroin (n=2), and amphetamine and crack cocaine (n=1). Condom use for 
anal intercourse was the most common health outcome (n=31), with 18 studies conducting 
global association analyses, 6 conducting situational association analyses, 6 event-level 
association analyses, and one study using both global and situational association analyses 
depending on the drug measured. In 19 studies the outcome examined was HIV prevalence (15 
global association analyses, 4 situational association analyses), and 10 studies examined STI 
incidence (6 global association analyses, 3 situational association analyses, 1 global and 
situational association analyses). Over a third of studies among MSM were conducted in the 
USA (n=15, 36%), and around a quarter were conducted in the UK (n=10, 24%). 
Nine studies grouped drugs into chemsex/party drugs. The specific drugs grouped as 
chemsex/party drugs varied considerably, but crystal methamphetamine and GHB/GBL were 
included in all chemsex groups, and eight out of nine studies included crystal 
methamphetamine, GHB/GBL, and mephedrone. Four studies included the four drug 
commonly associated with chemsex (crystal methamphetamine, GHB/GBL, ketamine, 
mephedrone) in their chemsex group, although only one study exclusively included these four 
drugs in their chemsex group. At least one drug associated with chemsex had been investigated 
in the majority of countries (n=33/53, 62%; Figure 3). 
Meta-analyses were conducted to determine the association between specific drug use 
and HIV status, STI diagnoses, and condom use for anal intercourse. If three studies or more 
had investigated a specific drug in relation to the outcome then a meta-analysis was conducted. 
It was found that all drugs were associated with being HIV-positive (Figure 4). However, in 
some meta-analyses the findings were based on a small number of studies, and in four of the 
meta-analyses one larger study (Wei et al., 2012) weighted the outcome (cocaine, ecstasy, 
GHB/GBL and ketamine).  
Meta-analyses for the association of drug use on STI diagnoses were conducted if the 
STI measured was chlamydia, gonorrhoea, syphilis, or a combination of these. There were only 
enough studies for poppers and chemsex to be investigated in relation to STI diagnoses (Figure 
5). The association of poppers on STI diagnoses was minimal, with all four studies  
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investigating the association between poppers and syphilis in China. An association was 
observed between chemsex and STI diagnoses. 
One study (Kramer et al., 2016) heavily weighted the analyses for EDDs, poppers and 
chemsex meta-analyses, and due to the number of studies in these meta-analyses it was 
excluded. A consistent association between drug use and condomless sex was found across 
meta-analyses for global and situational associations (Figure 6). Similarly, a consistent 
association between drug use and condomless sex was found across meta-analyses for event-
level associations (Figure 7), although the effect of cannabis was marginal and fewer studies 
were included in these analyses. 
Trans women 
 
Among the five studies that researched trans women, a range of drugs were investigated 
(cocaine, crack cocaine, crystal methamphetamine, heroin, prescription drugs, poppers). Three 
studies conducted global association analyses and two studies conducted a combination of 
global and situational analyses. Three studies were conducted in the USA, one in Brazil, and 
one in Vietnam. There was not enough homogeneity of data for meta-analyses to be conducted, 
but bivariate associations were found between crystal methamphetamine and prescription drug 
use and condomless sex, as well as cocaine and methamphetamine use and HIV status. No 
association was found between heroin use and HIV status or syphilis diagnosis. 
 
Figure 5. Meta-analyses for specific drug use and STI diagnosis among men who have sex with 
men.   
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Figure 6. Meta-analyses for specific drug use and condomless anal intercourse (global and situational 




Figure 7. Meta-analyses for specific drug use and condomless anal intercourse (event-analyses) 




Quality assessment of the included studies 
 
The results from the quality assessment can be found in Appendix 2. The majority of 
studies had an overall rating of weak (n=20/47, 43%), 17 studies (36%) were rated as moderate, 
and 9 (19%) were rated as strong. The weakest sections tended to be the reporting of 
withdrawals and dropouts, where 20 studies (43%) were rated as weak, as well as the 




This systematic review aimed to investigate the extent to which sexualised drug use had 
been researched among LGBT people in relation to health outcomes, and it was found that the 
vast majority of research has been conducted among MSM. A smaller number of studies had 
been conducted among trans women; however, no studies were found that reported sexualised 
drug use among trans men or WSW. It should be noted that some studies among WSW were 
found, but they did not meet the inclusion criteria of this review due to data comparing WSW 
with heterosexual women. These few studies identified that WSW may be more likely to use 
ketamine (Heinsbroek et al., 2018), as well as cannabis and cocaine, compared to heterosexual 
women (Bauer, Jairam, & Baidoobonso, 2010), but these were not measured in a sexual context. 
One study did find that lesbian and bisexual women were more likely to engage in sexualised 
drug use (Estrich, Gratzer, & Hotton, 2014), but data were not available exclusively for WSW 
with regards to sexual risk and sexualised drug use. Further research is needed to understand 
sexualised drug use among WSW, and whether it is associated with greater sexual risk. Whilst 
a few studies were found researching trans women, due to the potentially high risk of HIV 
among trans women (Baral et al., 2013), more studies are needed to explore sexualised drug 
use and its related sexual and health implications among trans women. 
Associations between sexualised drug use among MSM and trans women was 
researched in 53 countries among the included studies. A narrative systematic review published 
after this review was conducted found that sexualised drug use among MSM had been 
researched in 43 countries (Tomkins, George, & Kliner, 2019). Due to the inclusion and 
exclusion criteria used in this review, sexualised drug use among LGBT people may have been 
researched in more countries, but the data provided demonstrates the range of countries this 
behaviour has been studied in. Additionally, the use of at least one of the drugs associated with 
chemsex among MSM has been observed in 33 of these countries spanning North America, 
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Europe, Asia, and Australasia. Therefore, describing chemsex as a Western behaviour may be 
limiting to research, because although research in Asia has not been as detailed as in Western 
countries, the sexualised use drugs associated with chemsex has been observed and examined 
in relation to sexual health outcomes. Similar to a literature review of sexualised drug use and 
chemsex in the UK (Edmundson et al., 2018), it was found that the definition of chemsex varied 
greatly, but crystal methamphetamine and GHB/GBL were common to all chemsex definitions. 
This variation in the definition of chemsex may be because the drugs used for chemsex differ 
internationally, or that the research had been conducted before a definition of which drugs used 
specifically constitute as chemsex. A consensus of what drugs constitute as chemsex may be 
hard to reach due to emerging new drugs, local availability of specific drugs, or personal 
preferences for the type of drugs use for chemsex. Therefore, an international definition of what 
drugs constitutes as chemsex may not be appropriate and instead more local definitions may be 
more suitable. However, it is useful to see which drugs are common internationally, so harm 
reduction and drug safety information can be shared across countries.  
A narrative systematic review regarding chemsex among MSM that was published after 
this review was conducted found that chemsex was associated with condomless anal intercourse 
and living with HIV (Maxwell, Shahmanesh, & Gafos, 2019), similar to a review regarding 
broader sexualised drug use among MSM (Tomkins et al., 2019). However, both of these 
reviews did not conduct meta-analyses. The meta-analyses conducted were secondary aims and 
therefore caution is needed in drawing conclusions from the data, because a more specific 
review for the sexual health outcomes may have yielded more results. However, it is of note 
that nearly all drugs were associated with greater sexual risk, regardless of the drug or outcome 
in question. This does give researchers some justification to group drugs as general drug use. 
Although, it is unclear the influence polydrug use may have on these findings, for example, 
whether individuals who use multiple drugs during the same sexual encounter then engage in 
greater risk taking. Certain patterns of drug use, such as chemsex, may be associated with HIV 
prevalence, STI diagnoses, and condomless anal intercourse more than other patterns of drug 
use, as observed when the outcome was HIV prevalence, and global and situational 
measurements of condomless anal intercourse. This may be because sex under the influence of 
chemsex drugs may lower inhibitions, and therefore impact on behaviour to a greater extent 
than other types of sexualised drug use, or social norms associated with chemsex may influence 
risk taking. Additionally, it could be that grouping drugs creates a more powerful analysis due 
to a greater number of observations included, and therefore this is why chemsex appears to be 
associated with greater risk.  
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There were similar associations between event-level analyses and global and situational 
associations for condom use, but a large number of studies relied on global associations of drug 
use and health outcomes, even when researching chemsex, which is by definition in a sexual 
context. Therefore, if future research is aiming to investigate sexualised drug use, situational 
and event-level analyses should be utilised for a potentially more accurate measurement. 
However, due to the nature of researching sexualised drug use, causation cannot be inferred 
regardless of the measurement method chosen, and it is possible another factor is influencing 
these associations between drug use and sexual risk behaviours. 
 
Strengths and limitations 
 
There may be a publication bias in the data, due to most studies finding an association 
with the health outcome researched. An attempt was made to find grey literature on the topic; 
however, no reports or publications were found where information had not already been 
published in peer-review journals, or that met the inclusion/exclusion criteria. Additionally, it 
was not possible to control for confounding variables that may influence drug use and HIV, STI 
diagnoses, and condom use, such as age and sexual identity, due to the heterogeneity among 
control variables in multivariable analyses. Collating data is also difficult due to different 
window periods of measurement (e.g. three months/six months/twelve months), and variability 
in the grouping of drugs associated with sex. Although the meta-analyses were secondary aims 
of this systematic review, and therefore caution is needed when drawing conclusions from these 
findings, the finding that sexualised drug use among MSM was associated with HIV prevalence, 
STI diagnoses, and condomless anal intercourse is still important when considering service 
delivery, as well as harm reduction services. This is due to the potentially confounding factors 
a person may experience (i.e. drug harms, living with HIV, greater sexual risk taking) when 




Meta-analyses among MSM revealed that for the majority of drugs examined, drug use 
was associated with living with HIV, STI diagnoses, and condomless sex where data were 
available. However, the measurement of sexualised drug use often relied on global associations 
between drug use and risk and so may be subject to misclassification bias. Therefore, more 
accurate measurements of sexualised drug use should be used. Definitions of what constitutes 
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chemsex varied across studies, making conclusions with regards to associated risks with 
chemsex difficult. The definition of what constitutes chemsex may be even more difficult when 
considering the behaviour internationally, as the availability of certain drugs will differ across 
countries, depending upon legal categorisation and common illicit drug markets.  
There is a lack of research on sexualised drug use among WSW, and while comparing 
to heterosexual women is useful to understand differences in behaviour, to further understand 
sexualised drug use and its associated behaviours and health implications among WSW, 
analyses exclusively among WSW are needed. Whilst there has been some research among 
trans women regarding sexualised drug use, due to the suspected high prevalence of HIV among 
this group, further research is needed to understand this behaviour and any potential risk of HIV 
transmission. Additionally, no studies indicated including trans men and non-binary people. 
Where trans men do identify as MSM, they are most often not included in analyses among men 
(Chard et al., 2018). Therefore, further research is needed among trans people generally to 
understand if sexualised drug use exists, and if so, whether it is associated with sexual risk.  
The systematic review identified gaps in the literature in relation to the lack of data 
regarding WSW and trans people. Whilst the focus on sexual risk is important for providing 
sexual health care, it is also equally important to consider psychological associations with these 
behaviours to provide a more holistic understanding of LGBT people and sexualised drug use. 
This could identify any other possible harms beyond sexual risk associated with sexualised drug 
use. The following chapter details how these gaps in the literature were addressed by Study 2, 
as well as how appropriate methods for measuring sexualised drug use (situational and event-




Chapter 3: Methodology for an online survey researching sexualised drug 




The systematic review (Study 1) provided useful insights into the measurement tools 
used for drug use and health behaviours, and highlighted a lack of research regarding WSW 
and trans people. This information was used to inform the methodology for Study 2. This 
chapter will describe how The LGBT+ Sex and Lifestyles Survey was designed, how 
participants were recruited, and describe the psychological and health measures used within the 




Findings from this study (Study 2) have been published in the following peer-reviewed 
publications: 
 
Hibbert, M. P., Brett, C. E., Porcellato, L. A., & Hope, V. D. (2019). Psychosocial and 
sexual characteristics associated with sexualised drug use and chemsex among men who 
have sex with men (MSM) in the UK. Sexually transmitted infections; 95, 342-250. 
 
Hibbert, M. P., Porcellato, L. A., Brett, C. E., & Hope, V. D. (2019). Associations with 
drug use and sexualised drug use among women who have sex with women (WSW) in 
the UK: Findings from the LGBT+ Sex and Lifestyles Survey. International Journal of 
Drug Policy, 74, 292-298. 
 
Hibbert, M. P., Wolton, A., Weeks, H., Ross, M., Brett, C. E., Porcellato, L. A., & Hope, 
V. D. (2019). Psychosocial and sexual factors associated with recent sexual health clinic 
attendance and HIV testing among trans people in the UK. BMJ Sexual & Reproductive 
Health. 46(2), 116-125.  
 
Hibbert, M. P., Brett, C. E., Porcellato, L. A., & Hope, V. D. (2020). STI diagnoses, 
sexualised drug use and associations with PrEP use among men who have sex with men 
in the UK. International Journal of STDS & AIDS, 31(3), 254-263. 
 
Where data presented in this thesis has been published, the reference to the publication 





A national convenience sample was used to recruit participants to take part in The 
LGBT+ Sex and Lifestyles Survey. This cross-sectional anonymous online survey was aimed 
at LGBT people and was developed using online survey software Qualtrics 
(www.qualtrics.com). Ethical approval for this study was obtained by the Liverpool John 
Moores University Research Ethics Committee (approval reference:18/PHI/011). To take part, 
participants had to be aged 18 years or over, currently live in the UK, and self-identify as MSM, 




Minimum sample size was calculated using the Raosoft.com sample size calculator with 
a margin of error at 5% and 95% confidence interval. For each sample group (MSM, WSW, 
trans), a sample size calculation was performed based upon estimates of the number of that 
population in the UK. Accurate and reliable data on the number of MSM or WSW living in the 
UK does not exist. Therefore, using the latest ONS data on the number of men and women aged 
18 or over living in the UK in 2016 (Office of National Statistics, 2017), and the Public Health 
England (PHE) estimate that 2.5% of the population in England are LGB (van Kampen et al., 
2017), the minimum sample size for both MSM and WSW was 384. The figures used to 
calculate this sample size does not include heterosexually identifying MSM and WSW as this 
population is hard to differentiate. However, due to the large target sample of LGBT people 
nationally, it is unlikely that including heterosexually identifying MSM and WSW in population 
estimates would have had a significant effect the minimum sample size. In addition, accurate 
and reliable data on the number of trans people living in the UK does not exist. Therefore, using 
the latest population estimate of number of people living in the UK in 2016 (Office of National 
Statistics, 2017), and the estimate that 0.6% of the adult population in the USA self-identify as 
trans (Flores et al., 2016), the minimum sample size for trans people was also 384. The target 
sample size for each group was rounded up to 400, giving a total target sample size of 1,200 







Table 3. Recommended sample size with margin of error at 5% and 95% confidence intervals. 






Men who have sex with men (MSM) 627,343 384 400 
Women who have sex with women (WSW) 652,565 384 400 
Trans people 307,178 384 400 
† Calculated using ONS general UK population estimate, and the PHE 2.5% estimate for proportion of LGB people in England, 




The survey was open from 12th April – 30th June 2018. Participants were recruited 
through social media using two methods. The first method was using LGBT organisations to 
share a link to the survey on their social media accounts (Facebook, Twitter, and Instagram). 
These organisations were part of the community organisations recruited for the PPI group due 
to work around drug and alcohol use among LGBT people (London Friend, Chemsex Open 
Access Support Team (COAST), Gay Men’s Health Collective (GMHC)), or because of work 
regarding trans inclusion in research (LGB&T Partnership). In their posts, organisers would 
specify that the research was regarding the sex and lifestyles of LGBT people, aged 18 or over, 
and currently living in the UK. Organisations were sent some suggested text and an image to 
use for their social media posts that can be found in Appendix 3. The term ‘LGBT+’ varied 
depending on the organisation e.g. organisations for men only were suggested to use the term 
‘men who have sex with men’. 
 The second method of recruitment was to use paid Facebook and Instagram advertising. 
A Facebook page was designed for the survey that hosted four adverts targeting MSM, WSW, 
trans people and LGBT+ people generally. Clicking on the advert directed participants to the 
Qualtrics page with the information sheet (Appendix 4). Alternatively, participants could click 
on the Facebook group title “The Sex and Lifestyles Survey” to be directed to the Facebook 
page. Previous UK research into sexualised drug use among MSM has mostly recruited 
participants via sexual health clinics or geospatial dating apps (Edmundson et al., 2018), which 
may bias the data as these methods may recruit individuals of a higher sexual risk. Facebook 
advertising was used as it has been found be a useful tool for recruiting participants for health 
research (Whitaker, Stevelink, & Fear, 2017), and studies using Facebook advertising have 
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shown samples to be representative of drug and alcohol users (Bauermeister et al., 2012), and 
sexual history and relationships (Jones, Saksvig, Grieser, & Young, 2012). Additionally, 
Facebook advertising has been used to research a similar topic among MSM in the UK (Chard 
et al., 2018), and given that LGBT people are not a substantial proportion of the general 
population, Facebook is a useful tool to recruit this hard to reach population. Also, Facebook 
may be a useful tool to recruiting MSM who are not attending sexual health clinics or on 
geospatial dating apps, as well as WSW and trans people, who may be less likely to engage in 
sexual health services. 
The MSM advert was targeted at males, aged 18-65 years and over, who lived in the 
UK, and showed interest in one of a number of LGBT or gay topics on Facebook (e.g. Gay 
pride, LGBT history, LGBT culture, Gay bar, etc.). The WSW advert was targeted at females, 
aged 18-65 years and over, who lived in the UK, and showed interest in one of many LGBT or 
lesbian topics on Facebook (e.g. Gay pride, LGBT history, Lesbian pride, etc.). The trans advert 
was targeted at people aged 18-65 years and over, who lived in the UK and had shown interest 
in a trans related topic (e.g. transgenderism, transgender activism) on Facebook. The LGBT+ 
advert targeted a predetermined audience of LGBT+ people on Facebook. An additional MSM 
advert was created to target MSM in London, Brighton, and Manchester, due to these being 
cities with a high prevalence of chemsex drug use among MSM (Schmidt et al., 2016), using 
the same topics on Facebook as for the previous MSM advert. The total cost of advertising was 
£1102.05. A full breakdown of advertising methods can be found in Appendix 3. 
An incentive of a prize draw for a £50 Amazon voucher, or one of two £25 Amazon 
vouchers, was used as an incentive to aid recruitment. Once participants completed the 
questionnaire, the debrief page contained a link to a separate survey where participants could 
then enter their details for the prize draw. A separate questionnaire was used so that participants’ 
details could not be linked to their answers. This additional questionnaire also asked participants 




 The survey was divided into three areas: demographics, sexual health and drug use, and 
psycholgical wellbeing (Appendix 4). Two screening questions asked potential participants if 
they currently lived in the UK and were aged 18 or over. An attempt was made to measure how 
participants had been recruited; however, this was deemed to be inaccurate as a significant 
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proportion of participants had selected community organisations before any community 
organisation recruitment had commenced. Where participants were forced to give a response, 
a prefer not to say option was offered. 
 
Gender identity  
An adapted version of a two-step questioning was used for participants to report their 
current gender identity and gender at birth (Sausa et al., 2009). The adapted version was revised 
with discussions between Public Health England, CliniQ, LGBT Foundation, Action for Trans 
Health, and The National LGB&T Partnership for the purpose of HIV monitoring in England 
(Jaspal, Nambiar, Delpech, & Tariq, 2018). The revised questions were as follows: 
Which of the following options best describes how you think of yourself? 
 Male (including trans man) 
 Female (including trans woman) 
 Non-binary 
 In another way, please specify: 
 Prefer not to say 
Is your gender identity the same as the gender you were given at birth? 
 Yes 
 No 
 Prefer not to say 
Participants were grouped as trans if they reported having a gender that was different than the 




Ethnicity was reported using the NHS standard category codes from the 2001 census 
(www.datadictionary.nhs.uk/data_dictionary/attributes/e/end/ethnic_category_code_de.asp), 
with the addition of Hispanic/Latino to include the Hispanic/Latino LGBT community living 
in the UK (Rawson et al., 2019). 
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Sexual orientation and behaviour 
Participants were asked their sexual orientation and the gender of people they have sex 
with. Questions were adapted from previous UK research (Pufall et al., 2018), and from 
suggestions from the PPI community members. Men who have sex with men (MSM) and 
Women who have sex with women (WSW) were identified by their gender and the gender of 
people they have sex with.  
 
Sexual health and sexualised drug use 
Questions regarding sexual health, such as genitourinary medicine (GUM) clinic 
attendance, HIV testing, STI diagnoses, PrEP use, sexual behaviour, and sexualised drug use 
were adapted from research on similar topics (Mercer et al., 2016; Weatherburn et al., 2013). 
Aligned with previous research, drug use and sexualised drug use were asked with regards to 
specific drugs, with individuals drugs listed rather than grouped, as this is likely to elicit more 
accurate reporting (Ryan et al., 2018). Participants were first asked if they had taken any of the 
14 listed drugs (including alcohol) in the past 12 months. Drug use was grouped as taking any 
of the listed drugs except alcohol. Sexualised drug use was grouped as participants who had 
stated they had been under the influence of cannabis during sex in the past 12 months, or stated 
having taken amphetamine, cocaine, crack cocaine, crystal methamphetamine, ecstasy, heroin, 
GHB/GBL, ketamine, mephedrone, Viagra or other erectile dysfunction drugs (EDDs), poppers, 
or another unspecified drug just before or during sex in the past 12 months. Chemsex was 
grouped as having taken crystal methamphetamine, GHB/GBL, ketamine, and/or mephedrone 
just before or during sex.  
Event-level condom use data was collected for each drug among MSM and trans women. 
For alcohol and cannabis, participants were asked: “thinking of the last time you were under 
the influence of any of the following during anal intercourse, did you use a condom? (Yes, all 
of the time/Yes, some of the time/No, none of the time/Not sure/I did not have anal intercourse).” 
For all other drugs, participants were asked: “Thinking of the last time you had the following 
just before or during anal intercourse, did you use a condom? (Yes, all of the time/Yes, some 
of the time/No, none of the time/Not sure/I did not have anal intercourse)”. If participants stated 
they did not have anal intercourse, they were excluded from event-level analyses. Consistent 
condom use (Yes, all of the time) was compared to all other responses (Yes, some of the 





Motivations for sexualised drug use 
Motivations for engaging in sexualised drug use were adapted from motivations and 
attitudes towards chemsex questions (Glynn et al., 2018). Participants were asked seven 
questions regarding engaging in and attitudes towards sexualised drug use that were measured 
on a 5-point Likert scale (Strongly disagree/Disagree/Neither agree nor 
disagree/Agree/Strongly agree). These questions were then modified and repeated for people 
who had engaged in sex while under the influence of alcohol. Participants who answered 
“strongly agree” or “agree” were compared to those who answered “strongly disagree”, 
“disagree”, or “neither agree or disagree”. 
 
Self-efficacy for sexual safety 
Questions regarding self-efficacy for sexual safety were asked to participants who stated 
having sex with men, due to the measurement tool used (Alvy et al., 2011) being designed for 
assessing sexual risk among MSM (e.g. condom use). Seven questions assessed a participant’s 
confidence in practicing safe sex, including questions regarding the influence of drugs and 
alcohol, on a 5-point Likert scale (Strongly disagree/Disagree/Neither agree nor 
disagree/Agree/Strongly agree) (Cronbach’s Alpha = 0.81). As instructed in the scale 
development, participants who answered “strongly disagree” or “disagree” to over half the 
questions were coded as having low self-efficacy for sexual safety. 
 
Sexual satisfaction scale 
Sexual satisfaction was measured using an adapted version of the New Sexual 
Satisfaction Scale (Stulhofer, Busko, & Brouillard, 2010). The 12 items were measured on a 5-
point scale (Not at all satisfied/A little satisfied/Moderately satisfied/Very satisfied/Extremely 
satisfied). The questions were adapted by replacing “my partner” with “the person I have sex 
with” to measure sexual satisfaction in general, and not specific to one partner (Cronbach’s 
Alpha = 0.92). Furthermore, the scale was pretexted with “If you have had sex with more than 
one person in the past 12 months, in the following questions, please think of ‘the person I have 
sex with’ as overall, rather than one person”. Higher scores on the New Sexual Satisfaction 





An adapted measure of a question asked in a GP setting was used to assess whether 
participants had experienced any sexual contact that was not consensual (Coxell, King, Mezey, 
& Gordon, 1999). The measure was adapted after a discussion with an LGBT sexual violence 
charity to the following: “In the past 12 months has a person(s) done sexual things to you or 
made you do sexual things without your consent? (Yes/No/Not sure/Prefer not to say)”. 
 
Internalised homophobia 
The Internalised Homophobia (IHP) scale (Herek, Cogan, Gillis, & Glunt, 1998) was 
used to measure internalised stigma among MSM and WSW. A systematic review of measures 
of internalised homophobia found IHP as well as the Internalized Homonegativity Inventory 
(IHNI; Mayfield, 2001) to be the most widely used and validated (Grey, Robinson, Coleman, 
& Bockting, 2013). Therefore, due to the shorter length and the inclusion of a social theme that 
was deemed appropriate for the questionnaire, in addition to the fact that the scale was originally 
developed and validated for use with both men and women, the IHP scale was chosen. The IHP 
contains nine items measured on a 5-point Likert scale (Strongly disagree/Disagree/Neither 
agree nor disagree/Agree/Strongly agree). Because the scale was asked to men and women who 
identify as LGB and anyone who has had sex with someone of the same gender regardless of 
sexual identity, “gay/bisexual” was replaced with “attracted to men” and “lesbian/bisexual” was 
replaced with “attracted to women”. In line with the categorisation used in the scale 
development (Herek et al., 1998), if a participant responded “strongly disagree” or “disagree” 
to any of the nine items, they were coded as high internalised homophobia (Cronbach’s Alpha 
MSM = 0.89; WSW = 0.86).  
 
Internalised transphobia 
Internalised transphobia (referred to from now on as self-stigma) was measured using 
an adapted version of the Internalised Transphobia Scale (ITS) originally developed from the 
Internalised Homophobia Scale (IHS; Ross & Rosser, 1996). The original scale contains 24 
items measured on a 4-point Likert scale (Strongly disagree/Disagree/Agree/Strongly agree) 
with four subscales: public identification; perception of stigma; social comfort with transgender 
people, and religious acceptability. Similarly to previous research (Mizock & Mueser, 2014), a 
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modified version of the scale was used without the religious acceptability subscale, due to a 
lack of relevance to the research question (Cronbach’s Alpha = 0.82). The scale was adapted 
for use in the UK by replacing the term “transgender” with “trans” and the question was 
pretexted with “The term trans will be used in the following questions, but please think of this 
term in whatever way you feel is the best fit (i.e. non-binary, gender variant, gender non-
conforming, etc.).” Higher scores on the ITS indicated a greater level of self-stigma. 
 
Body dissatisfaction 
To measure body image satisfaction, a modified version of the Objectified Body 
Consciousness scale (OBC; McKinley & Hyde, 1996) was used. A scale developed for use with 
preadolescent and adolescent youth (OBC-Youth; Hyde & McKinley, 2006) was chosen due to 
the simplification of the language used, so the scale was easier for participants who do not have 
English as a first language or those who might have poor reading comprehension. The 14 items 
were measured on a 7-point Likert scale (Strongly disagree/Disagree/Somewhat 
disagree/Neither agree nor disagree/Somewhat agree/Agree/Strongly agree/Not applicable to 
me). The OBC-Youth has three factors: body surveillance; body shame, and control beliefs. 
Due to the lack of relevance to the research question, questions regarding control beliefs were 
not included, and therefore nine items were included in the questionnaire (Cronbach’s Alpha = 
0.90). Higher scores on the OBC-Youth scale indicated greater body dissatisfaction. 
 
Image and performance enhancing drug use 
To measure image and performance enhancing drug use, a question was adapted from 
Public Health England’s ‘Unlinked Anonymous Monitoring Survey of People Who Inject 
Drugs’ (Public Health England, 2016). Participants were asked “Have you taken any image or 
performance enhancing drugs in the last 12 months (e.g. anabolic steroids, growth hormone, 
hCG, Melanotan)? (Yes/No/Prefer not to say)”. 
 
Discrimination 
An adapted version of the Krieger and Sidney (1996) measure of discrimination was 
used. The measure asks participants if they have experienced discrimination in various settings. 
The measure was adapted to account for more modern situations of discrimination (Krieger, 
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Smith, Naishadham, Hartman, & Barbeau, 2005) and for use with LGBT people (Burgess, Tran, 
Lee, & van Ryn, 2007). For discrimination based on sexuality, participants were asked: “In the 
last 12 months, have you experienced discrimination, been prevented from doing something, or 
been hassled or made to feel inferior in any of the following situations because of your sexuality 
(please tick all that apply)?” To measure discrimination based on gender identity “sexuality” 
was replaced with “gender”. The situations participants could select were: school; getting hired 
or getting a job; at work; getting housing; getting medical care; getting service in a store or 
restaurant; getting credit, bank loans, or a mortgage; on the street or in a public setting; from 
the police or in the courts; other (please specify), and none of the above.  
 
Loneliness 
Loneliness was measured using a short 3-item scale, adapted for use within large 
questionnaires and correlates well with longer measures of loneliness and social isolation 
(Hughes, Waite, Hawkley, & Cacioppo, 2004). Responses to the three questions asking “how 
often do you feel…” were measured on three points (Hardly ever/Some of the time/Always) 
(Cronbach’s Alpha = 0.82). 
 
Perceived health 
To measure perceived health, a modified single item measure was used (Idler & Kasl, 
1991), which asked “How do you rate your health at this present time?” and responses were 
measured on a 5-point scale (Very Poor/Poor/Fair/Good/Very Good). A binary variable was 
created comparing participants who rated their health as good or very good, with those who 
rated their health very poor, poor or fair.  
 
Psychological wellbeing 
Two scales were used to measure psychological wellbeing: the Satisfaction With Life 
Scale (SWLS; Diener, Emmons, Larsen, & Griffin, 1985), and the Kessler Psychological 
Distress Scale (K10; Andrews & Slade, 2001). The SWLS (Cronbach’s Alpha = 0.90) was  used 
as a stable measure of wellbeing generally, where higher scores indicated a greater satisfaction 
with life. The K10 psychological distress scale (Cronbach’s Alpha = 0.94) was used as a 
measure of current psychological wellbeing, as this measure was specific to feelings over the 
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past 30 days. Psychological distress scores were categorised into normal (<=15), moderate (16-
21), high (22-29) and very high (30-50), as in previous research (Stallman, McDermott, 
Beckmann, Kay Wilson, & Adam, 2010). 
 
Patient and public involvement (PPI) 
 
The survey was circulated to PPI community members, and recommended changes 
around wording for trans sexual health measures were incorporated, as well as adding queer as 
an option to the sexual orientation question. The survey was then piloted on 16 LGBT 
colleagues and community members to test for clarity, question routing, and survey flow, which 
resulted in changes made to question routing, and wording of questions that were misinterpreted, 
and any typos and spelling errors were corrected. The median time taken for participants to 
compete the survey was 10 minutes. This was used to inform participants the survey would take 




Analyses are presented in the next chapter, and were conducted using SPSS 25 (IBM, 
New York). Forward stepwise multivariable logistic regression analyses were used to explore 
factors associated with drug use, sexualised drug use, and chemsex (entry p<0.05, removal 
p>0.10). Factors approaching significance at the bivariate level (p<0.10) were included in the 
multivariable model.  
For MSM, forward stepwise multivariable logisic regression analyses were conducted 
comparing MSM who reported sexualised drug use with those who did not, and those who 
reported engaging in chemsex with those who reported engaging in sexualised drug use. Chi-
square analyses and Fisher-exact tests (where cell values were <=5) were used to compare 
categorical outcomes of motivations for and effects of engaging in chemsex, other sexualised 
drug use and sex under the inlfuence of alcohol for MSM. Additionally, Chi-square analyses 
and Fisher-exact tests (where cell values were <=5) were used to compare drug use, sexualised 
drug use and event-level condom use under the influence of drugs between those who reported 
PrEP use and those who did not.  
Due to the small number of WSW and trans people who reported chemsex, forward 
stepwise multivariable logisic regression analyses were conducted comparing those who had 
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engaged with drug use with those who had not, and those who had engaged in sexualised drug 
use with those who had engaged in general drug use among WSW and trans people seperately. 
Similarly, due to the small number of WSW and trans people who reported chemsex, Chi-square 
analyses and Fisher-exact tests (where cell values were <=5) were used to compare motivations 
for and effects of engaging in intentional sexualised drug use, sex under the influence of 
cannabis, and sex under the influence of alcohol among WSW and trans people seperately.   
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Chapter 4: Results from The LGBT+ Sex and Lifestyles Survey 
  
This chapter will present the findings from The LGBT+ Sex and Lifestyles Survey 
(Study 2). Firstly, where data were available, participants who completed the survey were 
compared to those who did not. Secondly, the demographics of the MSM, WSW, and trans 
people were explored, as well as descriptive data regarding drug use, sexualised drug use, and 
chemsex. Thirdly, the bivariate and multivariable analyses as outlined in the methodology were 
conducted for MSM, WSW, and trans people seperately. 
Of the 4,690 surveys started, 53 participants were excluded for not living in the UK, 43 
participants were excluded for being aged under 18 years, and 1,014 did not complete the survey 
sufficiently to be included in analyses (completion rate of 76%). Completion was defined by 
answering answering all questions on the last scale (the Satisfaction With Life Scale). A further 
73 did not fit into MSM, WSW, or trans categories, because they either identified as 
heterosexual and did not report engaging in sex with someone of the same gender, or identified 
as asexual and did not report having sex with someone of the same gender, and were therefore 
excluded from analyses. Of the 3,507 participants included, 1,663 participants were grouped as 
MSM, 1,513 participants were grouped as WSW, and 500 participants were grouped as trans 
(groups not mutually exclusive). Table 4 compares participants’ demographics of those who 
completed the survey and those who did not where data were avaliable. Participants who 
completed the survey differed on gender, sexuality, education, and relationship status compared 
to those who did not. The median time taken to complete the survey was 12 minutes.  
Table 5 displays demographics for MSM, WSW, and trans participants. Statistical 
analyses could not be conducted between these three groups because being trans was not 
mutually exclusive with being a MSM or WSW. A higher proportion of WSW identified as 
bisexual and a higher proportion of trans participants identified as heterosexual. A higher 
proportion of trans participants also reported a younger age and were currently a student. The 
majority of participants were of white ethnicity, with similar proportions across participant 
categories, and a higher proportion of MSM and trans participants reported being single. Figure 
8 displays the geographic distribution across the UK of the participants. Although the 
proportion of participants recruited from each local authority displayed in Figure 8 will vary, 
this figure demonstrates that participants were recruited from across the UK.  
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Table 4. Demographics of participants who completed the survey and those who did not. 
 Not completed (n=734) % Completed survey (n=3,507) % 
Gender***     
Male (including trans man) 391 53% 1706 49% 
Female (including trans woman) 287 39% 1536 44% 
Non-binary 45 6% 244 7% 
In another way 8 1% 21 0.6% 
Prefer not to say 3 0.4% 0 0% 
Trans status     
Cisgender 635 87% 3007 86% 





Gay/lesbian/homosexual 435 59% 2333 67% 
Bisexual 151 21% 705 20% 
Straight/heterosexual 22 3% 36 1% 
Queer 36 5% 223 6% 
Asexual 20 3% 42 1% 
In another way 30 4% 166 5% 
Prefer not to say 2 0.3% 2 0.1% 




18-25 303 41% 1280 36% 
25-34 263 36% 1338 38% 
35-49 123 17% 693 20% 





White 697 95% 3363 96% 
Person of colour 32 4% 138 4% 




UK 617 84% 3076 88% 





University or higher 352 48% 1953 56% 
Qualifications at 18 265 36% 1123 32% 
Qualifications at 16 92 13% 333 9% 
Primary School or lower 5 0.7% 13 0.4% 




Full time 370 50% 1938 55% 
Part time 74 10% 331 9% 
Student 154 21% 688 20% 
Unemployed 38 5% 126 4% 
Other (sick leave, retired, carer) 88 12% 390 11% 




Living with partner 235 32% 1310 37% 
Relationship not living with partner 143 19% 816 23% 
Relationship with multiple 29 4% 103 3% 
Single 321 44% 1274 36% 




East Midlands 38 5% 199 6% 
East of England 30 4% 200 6% 
London 93 13% 383 11% 
North East 28 4% 167 5% 
North West 128 17% 649 19% 
South East 78 11% 408 12% 
South West 59 8% 273 8% 
West Midlands 48 7% 227 6% 
Yorkshire and Humber 49 7% 298 8% 
Northern Ireland 28 4% 100 3% 
Scotland 97 13% 377 11% 
Wales 41 6% 202 6% 














Sexuality       
Gay/lesbian/homosexual 1423 86% 848 56% 105 21% 
Bisexual 153 9% 499 33% 113 23% 
Straight/heterosexual 1 0.1% 5 0.3% 30 6% 
Queer 50 3% 80 5% 131 26% 
Asexual 7 0.4% 9 0.6% 33 7% 
In another way 29 2% 72 5% 87 17% 
Prefer not to say 0 0% 1 0.1% 1 0.2% 
Age band      
18-25 538 32% 574 38% 260 52% 
25-34 646 39% 588 39% 145 29% 
35-49 364 22% 280 19% 74 15% 
>=50 112 7% 87 6% 18 4% 
Ethnicity       
White 1584 95% 1469 97% 474 95% 
Person of colour 76 5% 43 3% 24 5% 
Country of Birth      
UK 1446 87% 1346 89% 442 88% 
Not UK 182 11% 131 9% 45 9% 
Education      
University or higher 984 59% 819 54% 212 42% 
Qualifications at 18 473 28% 508 34% 225 45% 
Qualifications at 16 157 9% 148 10% 47 9% 
Primary School or lower 7 0.4% 4 0.3% 3 0.6% 
Work Status      
Full time 1049 63% 782 52% 164 33% 
Part time 116 7% 175 12% 55 11% 
Student 266 16% 334 22% 138 28% 
Unemployed 61 4% 39 3% 41 8% 
Other (sick leave, retired, carer) 161 10% 166 11% 92 18% 
Relationship status     
Living with partner 589 35% 629 42% 135 27% 
Relationship not living with partner 321 19% 403 27% 136 27% 
Relationship with multiple 35 2% 44 3% 34 7% 
Single 715 43% 436 29% 195 39% 
UK Region      
East Midlands 78 5% 98 6% 38 8% 
East of England 81 5% 96 6% 36 7% 
London 266 16% 94 6% 36 7% 
North East 62 4% 85 6% 25 5% 
North West 350 21% 255 17% 63 13% 
South East 203 12% 163 11% 63 13% 
South West 103 6% 142 9% 43 9% 
West Midlands 101 6% 104 7% 30 6% 
Yorkshire and Humber 108 6% 160 11% 47 9% 
Northern Ireland 42 3% 51 3% 9 2% 
Scotland 172 10% 163 11% 67 13% 
Wales 87 5% 90 6% 36 7% 
Prefer not to say 8 0.5% 12 1% 7 1% 
Statistical comparisons could not be made between groups as groups are not mutually exclusive.
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Questions regarding drugs and alcohol was completed by 1,649 MSM, 1,507 WSW, 
and 496 trans participants. The proportion of participants reporting taking alcohol or drugs, 
being under the influence of these during sex, or having taken these just before or during sex 
in the past 12 months for MSM, WSW, and trans people are given in Table 6. Drug use 
excluding alcohol was reported among 55% of MSM, 39% of WSW, and 45% of trans people, 
and sexualised drug use was reported by 41% of MSM, 17% of WSW, and 21% of trans people. 
The use of chemsex drugs for sex were more frequently reported among MSM (6%), but a 
small proportion of WSW (0.6%) and trans people (1%) also reported taking these drugs. 
Among MSM, the proportion of those who had taken crystal methamphetamine and GHB/GBL 
that had taken them before or during sex was high (>80%). Two out of the three trans and 
WSW taking GHB/GBL stated taking the drug before or during sex. Viagra and other erectile 
dysfunction drugs (EDDs) were largely taken before or during sex across participant groups, 
but more frequently reported among MSM. Poppers were most frequently reported by MSM 
and a large proportion used them for sex. Similar proportions of MSM, WSW, and trans people 
had been under the influence of cannabis during sex, but a slightly lower proportion of trans 
participants reported being under the influence of alcohol for sex than MSM and WSW. 
 
Sexualised drug use and chemsex among MSM 
 
The majority of MSM identified as gay/homosexual (86%), were of white ethnicity 
(95%), with a median age of 28 years (IQR=23-36, range 18-76), and 43% stated they were 
single/not in a relationship (Table 5). Half of participants (n=825/1636) had attended a GUM 
clinic in the past 12 months, 4% (n=74/1648) were living with HIV, 6% (n=99/1648) were 
taking PrEP, and 5% (n=78/1634) reported having had sexual contact without consent in the 
past 12 months. There was no statistical difference between London (45%, n=121/264) and 
outside of London (39%, n=545/1375) for sexualised drug use, and no statistical difference 
between MSM reporting recent chemsex between London (11%, n=30/263) and other densely 
populated areas (9%, n=25/287). 
 The majority of MSM had drank alcohol in the past 12 months (94%), and 71% of these 
(66% of the total sample) had engaged in sex under the influence of alcohol (Table 6). Among 
the 41% of MSM reporting sexualised drug use: 28% of MSM had taken amyl nitrates (poppers) 
immediately before/during sex; 13% had been under the influence of cannabis during sex; 12% 
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Table 6. Alcohol and drug use, sexualised drug use, and engagement in chemsex among MSM, WSW and trans people. 
 MSM (n=1,649) WSW (n=1,507) Trans (n=496) 

























Alcohol 1553 94% 1095 66% 71% 1411 94% 947 63% 67% 442 89% 231 47% 52% 
Amphetamine 64 4% 18 1% 28% 41 3% 11 0.7% 27% 12 2% 4 0.8% 33% 
Cannabis 488 30% 221 13% 45% 495 33% 206 14% 42% 194 39% 82 17% 42% 
Cocaine 359 22% 159 10% 44% 165 11% 47 3% 28% 45 9% 10 2% 22% 
Crack cocaine 7 0.4% 4 0.2% 57% 1 0.1% 0 0% 0% 2 0.4% 0 0% 0% 
Ecstasy 210 13% 64 4% 30% 116 8% 26 2% 22% 45 9% 10 2% 22% 
EDD 218 13% 203 12% 93% 2 0.1% 2 0.1% 100% 7 1% 6 1% 86% 
Heroin 1 0.1% 0 0% 0% 0 0% - - - 3 0.6% 1 0.2% 33% 
Poppers 569 35% 468 28% 82% 114 8% 28 2% 25% 48 10% 24 5% 50% 
Other illicit drug 39 2% 10 0.6% 26% 32 2% 14 1% 44% 28 6% 3 0.6% 11% 
Chemsex drugs               
Crystal methamphetamine 39 2% 32 2% 82% 0 0% - - - 1 0.2% 0 0% 0% 
Ketamine 116 7% 37 2% 32% 38 3% 6 0.4% 16% 14 3% 4 0.8% 29% 
GHB/GBL 67 4% 54 3% 81% 3 0.2% 2 0.1% 67% 3 0.6% 2 0.4% 67% 
Mephedrone 85 5% 54 3% 64% 7 0.5% 2 0.1% 29% 2 0.4% 0 0% 0% 
Any chemsex drug 190 12% 99 6% 52% 43 3% 9 0.6% 21% 16 3% 5 1% 31% 
Any drug excluding alcohol 915 55% 670 41% 73% 587 39% 263 17% 45% 222 45% 105 21% 47% 
†Percentage of those that had used the drug for sex among those that reported taking the drug in the past 12 months
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had taken EDD before or during sex, and 10% had taken cocaine before or during sex. Less 
prevalent drugs taken before or during sex were ecstacy (4%), GHB/GBL (3%), mephedrone 
(3%), crystal methamphetamine (2%), ketamine (2%), amphetamines (1%), and other drug not 
specified (0.6%). The sexualised use of crystal methamphetamine, GHB/GBL, ketamine, and 
mephedrone were grouped as chemsex and 99 MSM (6%) had engaged in chemsex. Those who 
reported chemsex (n=77/96, 80%) were signicantly more likely to report polydrug use the last 
time they used drugs for sex, than those who reported other sexualised drug use (n=93/285, 
25%)(p<0.001). 
Table 7 displays the multivariable analysis describing sexual and psychosocial 
characteristics of MSM who had engaged in any sexualised drug use in the past 12 months 
compared to MSM who did not report any sexualised drug use. As only one MSM identified 
as heterosexual, this category was not included in the analysis. Due to the strong association 
between the number of male anal intercourse partners and number of condomless male anal 
intercourse partners in the past 12 months (p<0.001), only the latter was included in the 
multivariable analysis due to its greater sexual risk. There was a borderline association between 
psychological distress and sexualised drug use, but psychological distress was not included in 
the multivariable analysis due to the strong correlation between psychological distress scores 
and satisfaction with life scores (r=-0.59, p<0.001). Factors associated with sexualised drug 
use in the multivariable analysis were being aged 35 years and over, having a poor or very poor 
percieved health, having a recent STI diagnosis, having recently attended a GUM clinic, having 
a greater number of condomless male anal intercourse partners, recent image and performance 
enhancing drug use, having a lower satisfaction with life, and greater sexual satisfaction.  
This analysis was then repeated for factors associated with chemsex compared to other 
forms of sexualised drug use in the past 12 months (Table 8). Factors associated with chemsex 
in the multivariable analysis were having a country of birth that was not the UK, living in a 
more densely populated area, having six or more condomless male anal intercourse partners, 
and having low sexual self-efficacy. 
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Table 7. Bivariate and multivariable analyses for factors associated sexualised drug use in the past 12 months among MSM. 
      Bivariate Adjusted model† 
 
MSM not engaged in sexualised 
drug use (n=978) 
MSM engaged in sexualised drug use 
(n=670) 
OR (95% CI) aOR (95% CI) 
 n or mean % or SD n or mean % or SD Row %     
Sexuality          
Homosexual 824 84% 587 88% 42% ref.  
Bisexual 108 11% 44 7% 29% 0.57 (0.40, 0.83)  
Queer 24 2% 26 4% 52% 1.52 (0.86, 2.68)  
Age group        
18-24 359 37% 174 26% 33% ref. ref. 
25-34 403 41% 240 36% 37% 1.23 (0.97, 1.56) 1.07 (0.80, 1.43) 
35-49 171 17% 186 28% 52% 2.24 (1.70, 2.96) 2.44 (1.75, 3.41) 
>=50 44 4% 68 10% 61% 3.19 (2.10, 4.85) 3.73 (2.25, 6.18) 
Ethnicity        
White 934 96% 637 95% 41% ref.  
Person of colour 42 4% 32 5% 43% 1.12 (0.70, 1.79)  
Country of Birth        
UK 855 87% 577 86% 40% ref.  
Not UK 106 11% 76 11% 42% 1.06 (0.78, 1.45)  
Education        
University or higher 578 59% 401 60% 41% ref.  
Qualifications at 18 290 30% 176 26% 38% 0.88 (0.70, 1.10)  
Qualifications at 16 or lower 87 9% 75 11% 46% 1.24 (0.89, 1.74)  
Work Status        
Full time 615 63% 426 64% 41% ref.  
Part time 69 7% 44 7% 39% 0.92 (0.62, 1.37)  
Student 185 19% 79 12% 30% 0.62 (0.46, 0.83)  
Unemployed 35 4% 24 4% 41% 0.99 (0.58, 1.69)  
Other (sick leave, retired, carer) 70 7% 91 14% 57% 1.88 (1.34, 2.62)  
Relationship status        
Living with partner 355 36% 232 35% 40% ref.  
Relationship not living with partner 197 20% 120 18% 38% 0.93 (0.70, 1.23)  
Relationship with multiple 17 2% 18 3% 51% 1.62 (0.82, 3.21)  
Single 408 42% 299 45% 42% 1.12 (0.90, 1.40)  
Population density per hectare       
<5 225 23% 136 20% 38% ref.  
5 - 20  219 22% 127 19% 37% 0.96 (0.71, 1.30)  
20 - 41  233 24% 166 25% 42% 1.18 (0.88, 1.58)  
>41  287 29% 236 35% 45% 1.36 (1.04, 1.79)  
Internalized homophobia       
Low 616 63% 444 66% 42% ref.  
High 354 36% 213 32% 38% 0.84 (0.68, 1.03)  
Discrimination sexuality        
None 534 55% 340 51% 39% ref.  
Any setting 414 42% 297 44% 42% 1.13 (0.92, 1.38)  
Perceived health        
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Fair/good/very good 877 90% 580 87% 40% ref. ref. 
Very poor/poor 101 10% 90 13% 47% 1.35 (1.00, 1.82) 1.54 (1.04, 2.28) 
Psychological distress        
Normal 206 21% 153 23% 43% ref.  
Moderate 220 22% 154 23% 41% 0.94 (0.70, 1.26)  
High 267 27% 152 23% 36% 0.77 (0.57, 1.02)  
Very high 275 28% 203 30% 42% 0.99 (0.75, 1.31)  
Diagnosed STI in the past 12 months      
None 903 92% 511 76% 36% ref. ref. 
STI diagnosis 42 4% 135 20% 76% 5.68 (3.95, 8.17) 2.58 (1.67, 4.00) 
Not stated 33 3% 24 4% 42% 1.29 (0.75, 2.20) 1.41 (0.74, 2.66) 
Attended GUM in the past 12 months      
No 594 61% 199 30% 25% ref. ref. 
Yes 368 38% 457 68% 55% 3.71 (3.00, 4.58) 2.48 (1.91, 3.23) 
Not sure 9 1% 9 1% 50% 2.99 (1.17, 7.62) 3.62 (1.14, 11.53) 
No. of men anal intercourse in the past 12 months     
0-1 622 63% 182 27% 23% ref.  
2-5 261 27% 190 28% 42% 2.49 (1.94, 3.19)  
6-10 52 5% 126 19% 71% 8.28 (5.76, 11.90)  
>10 40 4% 171 26% 81% 14.61 (9.97, 21.40)  
No. of men without a condom anal intercourse in the past 12 months   
0-1 811 83% 362 54% 31% ref. ref. 
2-5 137 14% 170 25% 55% 2.79 (2.16, 3.60) 1.84 (1.36, 2.49) 
6-10 17 2% 63 9% 79% 8.33 (4.80, 14.43) 4.13 (2.27, 7.52) 
>10 7 1% 74 11% 91% 23.75 (10.83, 52.06) 8.34 (3.63, 19.15) 
Sexual contact without consent in the past 12 months     
No 925 95% 595 89% 39% ref.  
Yes 37 4% 41 6% 53% 1.72 (1.09, 2.72)  
Unsure 12 1% 24 4% 67% 3.11 (1.54, 6.26)  
HIV status        
Negative 807 83% 496 74% 38% ref.  
Negative, on PrEP 28 3% 71 11% 72% 4.12 (2.63, 6.48)  
Positive 19 2% 55 8% 74% 4.71 (2.76, 8.03)  
Don't know 124 13% 48 7% 28% 0.63 (0.44, 0.90)  
Sexual self-efficacy        
High  934 96% 615 92% 40% ref.  
Low 34 3% 44 7% 56% 2.03 (1.28, 3.22)  
Taken image or performance enhancing drugs in the past 12 months       
No 959 98% 629 94% 40% ref. ref. 
Yes 19 2% 36 5% 65% 2.89 (1.64, 5.08) 3.88 (1.89, 7.96) 
Body dissatisfaction 42.0 11.8 41.3 12.7  1.00 (0.99, 1.00)  
Loneliness score 5.5 1.8 5.5 1.8  1.01 (0.96, 1.07)  
Satisfaction with life  20.6 7.1 19.6 7.6  0.98 (0.97, 1.00) 0.97 (0.95, 0.99) 
Sexual satisfaction 40.6 9.2 42.5 8.7  1.02 (1.01, 1.04) 1.03 (1.02, 1.05) 
† Factors included in the multivariable model: Sexuality, Age group, Work status, Population density per hectre, Internalised homophobia, Poor health, Diagnosed STI in the past 12 months, Attended GUM in the 
past 12 months, No. of men without a condom anal intercourse in the past 12 months, sexual contact without consent in the past 12 months, HIV status, Sexual self-efficacy, Taken image or performance enhancing 
drug use in the past 12 months, Satisfaction with life.
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Around three quarters (74%) of the sample had engaged in any type of sexualised drug 
use or sex under the influence of alcohol. Figure 9 compares motivations for and effects of 
engaging in chemsex, other sexualised drug use, and sex under the influence of alcohol in the 
past 12 months. Chi-square analyses showed MSM engaging in chemsex were more likely to 
do so because it gave them a more intense sexual experience, allowed them to have sex for 
longer, were more likely to have sex without a condom, and do things they would not do sober, 
compared to other sexualised drug use and those having sex under the influence of alcohol. 
MSM engaging in chemsex were also more likely to report engagement was having a negative 
impact on their life and were doing so because of pressure from friends.  
 Due to the association between PrEP and sexualised drug use and chemsex at the 
bivariate level but not in multivariable analyses, event-level analyses regarding condom use 
under the influence of specific drugs by current PrEP use were conducted and can be seen in 
Table 9. Participants taking PrEP were more likely to have taken cocaine, crystal 
methampetamine, esctacy, GHB/GBL, mephedrone, poppers and EDDs, and were more likely 
to report having had sex under the influence of alcohol and cannabis, and more likely to have 
taken cocaine, GHB/GBL, mephedrone, and poppers immediately before or during sex. Among 
those participants who had engaged in anal intercourse under the influence of alcohol or 
cannabis, those who engaged in condomless anal intercourse were more likely to be taking 
PrEP. Additionally, among those who had taken poppers or EDDs immediately before or 
during anal intercourse, those who engaged in condomless anal intercourse were also 
statistically more likely to be taking PrEP. 
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Table 8. Bivariate and multivariable analyses for factors associated with engaging in chemsex in the past 12 months compated to other sexualised drug use among 
MSM. 
      Bivariate Adjusted model† 
 
MSM engaged in other sexualised 
drug use (n=570) 
MSM engaged in chemsex (n=99) OR (95% CI) aOR (95% CI) 
 n or mean % or SD n or mean % or SD Row %  
Sexuality       
Homosexual 497 87% 90 91% 15% ref.  
Bisexual 40 7% 4 4% 9% 0.55 (0.19, 1.58)  
Queer 23 4% 3 3% 12% 0.72 (0.21, 2.45)  
Age group        
18-24 154 27% 20 20% 11% ref.  
25-34 198 35% 42 42% 18% 1.63 (0.92, 2.90)  
35-49 152 27% 34 34% 18% 1.72 (0.95, 3.13)  
>=50 65 11% 3 3% 4% 0.36 (0.10, 1.24)  
Ethnicity        
White 548 96% 89 90% 14% ref.  
Person of colour 22 4% 10 10% 31% 2.80 (1.28, 6.11)  
Country of Birth        
UK 497 87% 80 81% 14% ref. ref. 
Not UK 57 10% 19 19% 25% 2.07 (1.17, 3.66) 1.98 (1.04, 3.80) 
Education        
University or higher 337 59% 64 65% 16% ref.  
Qualifications at 18 154 27% 22 22% 13% 0.75 (0.45, 1.27)  
Qualifications at 16 or lower 63 11% 12 11% 16% 1.00 (0.51, 1.97)  
Work Status        
Full time 356 62% 70 71% 16% ref.  
Part time 38 7% 6 6% 14% 0.80 (0.33, 1.97)  
Student 73 13% 6 6% 8% 0.42 (0.18, 1.00)  
Unemployed 20 4% 4 4% 17% 1.02 (0.34, 3.07)  
Other (sick leave, retired, carer) 78 14% 13 13% 14% 0.85 (0.45, 1.61)  
Relationship status        
Living with partner 202 35% 31 31% 13% ref.  
Relationship not living with partner 105 18% 15 15% 13% 0.93 (0.48, 1.80)  
Relationship with multiple 14 2% 4 4% 22% 1.85 (0.57, 6.00)  
Single 250 44% 49 49% 16% 1.27 (0.78, 2.07)  
Population density per hectre       
<5 126 22% 10 10% 7% ref. ref. 
5 - 20  120 21% 7 7% 6% 0.74 (0.27, 1.99) 0.60 (0.21, 1.73) 
20 - 41  139 24% 27 27% 16% 2.45 (1.14, 5.26) 1.90 (0.84, 4.31) 
>41  181 32% 55 56% 23% 3.83 (1.88, 7.80) 2.70 (1.27, 5.76) 
Internalized homophobia        
Low 373 65% 71 72% 16% ref.  
High 189 33% 24 24% 11% 0.67 (0.41, 1.09)  
Discrimination sexuality        
None 294 52% 46 46% 14% ref.  
Any setting 248 44% 49 49% 16% 1.26 (0.82, 1.95)  
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Perceived health        
Fair/good/very good 499 88% 81 82% 14% ref.  
Very poor/poor 72 13% 18 18% 20% 1.54 (0.87, 2.72)  
Psychological distress        
Normal 130 23% 23 23% 15% ref.  
Moderate 131 23% 23 23% 15% 0.99 (0.53, 1.86)  
High 133 23% 19 19% 13% 0.81 (0.42, 1.55)  
Very high 172 30% 31 31% 15% 1.02 (0.57, 1.83)  
Diagnosed STI in the past 12 months        
None 448 79% 63 64% 12% ref.  
STI diagnosis 99 17% 36 36% 27% 2.59 (1.63, 4.12)  
Not stated 24 4% 0 0% 0% -  
Attended GUM in the past 12 months        
No 186 33% 13 13% 7% ref.  
Yes 374 65% 83 84% 18% 3.18 (1.72, 5.85)  
Not sure 7 1% 2 2% 22% 4.09 (0.77, 21.70)  
No. of men anal intercourse in the past 12 months      
0-1 175 31% 7 7% 4% ref.  
2-5 171 30% 19 19% 10% 2.78 (1.14, 6.78)  
6-10 105 18% 21 21% 17% 5.00 (2.06, 12.16)  
>10 119 21% 52 53% 30% 10.92 (4.80, 24.87)  
No. of men without a condom anal intercourse in the past 12 months    
0-1 338 59% 23 23% 6% ref. ref. 
2-5 143 25% 27 27% 16% 2.78 (1.54, 5.00) 2.17 (0.86, 5.46) 
6-10 49 9% 14 14% 22% 4.20 (2.03, 8.70) 4.09 (1.63, 10.29) 
>10 39 7% 35 35% 47% 13.19 (7.08, 24.56) 7.93 (3.41, 18.47) 
Sexual contact without consent in the past 12 months     
No 512 90% 83 84% 14% ref.  
Yes 34 6% 7 7% 17% 1.27 (0.55, 2.96)  
Unsure 15 3% 9 9% 38% 3.70 (1.57, 8.73)  
HIV status        
Negative 443 78% 53 54% 11% ref.  
Negative, on PrEP 50 9% 21 21% 30% 3.51 (1.96, 6.29)  
Positive 35 6% 20 20% 36% 4.78 (2.57, 8.87)  
Don't know 43 8% 5 5% 10% 0.97 (0.37, 2.56)  
Sexual self-efficacy        
High  538 94% 77 78% 13% ref. ref. 
Low 25 4% 19 19% 43% 5.31 (2.79, 10.10) 4.43 (2.14, 9.22) 
Taken image or performance enhancing drugs in the past 12 months      
No 538 94% 91 92% 14% ref.  
Yes 30 5% 6 6% 17% 1.18 (0.48, 2.92)  
Body dissatisfaction 41.0 12.6 42.9 13.1  1.01 (1.00, 1.03)  
Loneliness score 5.5 1.8 5.5 1.7  1.00 (0.89, 1.13)  
Satisfaction with life  19.7 7.7 19 7.1  0.99 (0.96, 1.02)  
Sexual satisfaction 42.3 8.9 43.6 7.5  1.02 (0.99, 1.04)  
† Factors included in the multivariable model: Age group, Ethnicity, Country of birth, Work status, Population density per hectre, Diagnosed STI in the past 12 months, Attended GUM in the past 12 months, No. of 
men without a condom anal intercourse in the past 12 months, sexual contact without consent in the past 12 months, HIV status, Sexual self-efficacy.  
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Table 9. Drug use, sexualised drug use and event-level condom use under the influence of drugs by PrEP use 
among MSM. 
 Current PrEP use 
 No (n=1,473) Yes (n=99) 
 n % n % 
Alcohol     
Taken 1388 94% 91 92% 
Had sex under the influence of*** 960 69% 80 88% 
 Of those who had anal intercourse**     
 Condom used 230 29% 8 11% 
 CAI 577 71% 68 89% 
Cannabis     
Taken 439 30% 29 29% 
Had sex under the influence of* 191 44% 19 67% 
 Of those who had anal intercourse*     
 Condom used 52 33% 1 6% 
 CAI 106 67% 15 94% 
Cocaine     
Taken* 301 20% 31 31% 
Taken immediately before or during sex* 122 41% 20 65% 
 Of those that had anal intercourse     
 Condom used 23 21% 2 11% 
 CAI 88 79% 17 89% 
Crystal meth     
Taken*** 18 1% 13 13% 
Taken immediately before or during sex 13 72% 11 85% 
 Of those that had anal intercourse     
 Condom used 1 8% 0 0% 
 CAI 11 92% 11 100% 
Ecstasy     
Taken** 176 12% 21 21% 
Taken immediately before or during sex 46 26% 9 43% 
 Of those that had anal intercourse     
 Condom used 8 21% 2 22% 
 CAI 30 79% 7 78% 
GHB/GBL     
Taken*** 37 3% 17 17% 
Taken immediately before or during sex* 25 68% 16 94% 
 Of those that had anal intercourse     
 Condom used 6 26% 0 0% 
 CAI 17 74% 16 100% 
Mephedrone     
Taken*** 55 4% 17 17% 
Taken immediately before or during sex* 29 53% 14 82% 
 Of those that had anal intercourse     
 Condom used 4 15% 0 0% 
 CAI 22 85% 14 100% 
Poppers     
Taken*** 460 31% 61 62% 
Taken immediately before or during sex* 366 80% 56 92% 
 Of those that had anal intercourse***     
 Condom used 109 33% 4 7% 
 CAI 226 67% 51 93% 
EDD     
Taken*** 161 11% 32 32% 
Taken immediately before or during sex 147 91% 31 97% 
 Of those that had anal intercourse***     
 Condom used 43 31% 0 0% 
 CAI 95 69% 31 100% 
Taken percentage is of total taking/not taking PrEP. Had sex under the influence of/taken immediately before or during sex percentage is of 
those who reported taking the substance. Condom use/CAI (condomless anal intercourse) percentage is of those who reported sex under the 
influence or taken immediately before or during sex, excluding those that did not report anal intercourse. 
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Drug use and sexualised drug use among WSW 
 
Over half of the 1,507 WSW identified as homosexual/gay/lesbian (56%), 97% were of 
white ethnicity, and 29% were single/not in a relationship (Table 5). The median age was 27 
years (IQR=22-34, range 18-71) and two thirds (n=994/1484) reported high or very high levels 
of psychological distress. Seven percent (n=101/1481) of WSW reported sexual contact 
without consent in the past 12 months, the majority of whom identified as bisexual (n=57/101, 
56%). 
The majority of WSW had drank alcohol in the past 12 months (94%), and 67% of these 
(63% of total sample) had engaged in sex under the influence of alcohol (Table 6). Because no 
WSW reported taking crystal methamphetamine, it was not included in the chemsex drug group. 
Overall, 39% of WSW reported taking a drug in the last 12 months, 45% of these (17% of the 
total sample) reported engaging in sexualised drug use. Women reporting sexualised drug use 
were more likely to report having sex with both men and women compared to women only 
(25% vs. 11%, p<0.001). The drug most commonly taken generally and sexually was cannabis 
(33% and 14% respectively). Over one-quarter of cocaine users and one-fifth of ecstacy users 
reported taking the drug just before or during sex. The most commonly used drug associated 
with chemsex was ketamine (3%), followed by mephedrone (0.5%), and GHB/GBL (0.2%). 
Of those who had taken a chemsex related drug, 21% reported taking that drug just before or 
during sex. Of the nine WSW who reported sexualised use of a chemsex related drug, seven 
reported having sex with both men and women. 
Table 10 displays the bivariate and multivariable analyses for the psychosocial and 
sexual factors associated with engaging in drug use compared to no drug use. Four out of the 
five heterosexual identifying WSW reported engaging in sexualised drug use; however, due to 
the small number of WSW identifying as heterosexual, they were not included in the analyses. 
One WSW did not disclose a sexual orientation and was not included in the analyses. Due to 
the strong correlation between psychological wellbeing measures (psychological disress and 
satisfaction with life; r=-0.60, p<0.001), only psychological distress was included in the 
multivariable analyses due to this measuring recent feelings of distress (past 30 days). The 
factors associated with engaging in drug use with the highest odds ratios were having greater 
than or equal to five female sexual partners in the past 12 months and experiencing sexual 
contact without consent in the past 12 months. Other factors associated with engaging in drug  
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Table 10. Bivariate and multivariable analysis for factors associated with drug use in the past 12 months among WSW. 
 No drugs taken (n=918) Taken drugs (n=583) Bivariate Adjusted model† 
 n or mean % or SD n or mean % or SD Row % OR (95% CI) aOR (95% CI) 
Sexuality        
Lesbian/homosexual 550 60% 297 51% 35% ref. ref. 
Bisexual 276 30% 217 37% 44% 1.46 (1.16, 1.83) 1.19 (0.91, 1.55) 
Queer 35 4% 45 8% 56% 2.38 (1.50, 3.79) 1.87 (1.08, 3.24) 
In another way 57 6% 24 4% 30% 0.78 (0.47, 1.28) 0.60 (0.33, 1.07) 
Age 30.6 10.0 26.4 7.8  0.95 (0.94, 0.96) 0.96 (0.95, 0.98) 
Ethnicity        
White 897 98% 560 96% 38% ref.  
Person of colour 20 2% 23 4% 53% 1.84 (1.00, 3.39)  
Country of Birth       
UK 829 90% 509 87% 38% ref. ref. 
Not UK 67 7% 61 10% 48% 1.48 (1.03, 2.13) 1.88 (1.24, 2.85) 
Education       
University or higher 517 56% 298 51% 37% ref.  
Qualifications at 18 280 31% 226 39% 45% 1.40 (1.12, 1.76)  
Qualifications at 16 or lower 96 10% 50 9% 34% 0.90 (0.62, 1.31)  
Work Status       
Full time 526 57% 249 43% 32% ref.  
Part time 108 12% 67 11% 38% 1.31 (0.93, 1.84)  
Student 152 17% 181 31% 54% 2.52 (1.93, 3.27)  
Unemployed 23 3% 16 3% 41% 1.47 (0.76, 2.83)  
Other (sick leave, retired, carer) 96 10% 66 11% 41% 1.45 (1.03, 2.06)  
Relationship status       
Living with partner 433 47% 193 33% 31% ref.  
Relationship not living with partner 228 25% 170 29% 43% 1.67 (1.29, 2.17)  
Relationship with multiple 25 3% 19 3% 43% 1.71 (0.92, 3.17)  
Single 231 25% 201 34% 47% 1.95 (1.51, 2.52)  
Population density per hectare      
<5 244 27% 142 25% 37% ref.  
5 - 20  283 31% 150 26% 35% 0.91 (0.68, 1.21)  
20 - 41  220 24% 145 25% 40% 1.13 (0.84, 1.52)  
>41  162 18% 140 24% 46% 1.49 (1.09, 2.02)  
Internalized homophobia      
Low 636 69% 355 61% 36% ref.  
High 259 28% 221 38% 46% 1.53 (1.23, 1.91)  
Discrimination sexuality in the past 12 months     
None 486 53% 273 47% 36% ref.  
Any setting 406 44% 288 49% 41% 1.26 (1.02, 1.56)  
Sexual contact without consent in the past 12 months    
No  861 94% 488 84% 36% ref. ref. 
Yes 31 3% 70 12% 69% 3.98 (2.57, 6.17) 2.51 (1.51, 4.16) 
Unsure 14 2% 17 3% 55% 2.14 (1.05, 4.38) 1.61 (0.64, 3.81) 
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Number of women sexual partners in the past 12 months    
0-1 774 85% 415 71% 35% ref. ref. 
2-4 129 14% 136 23% 51% 1.97 (1.50, 2.57) 1.76 (1.30, 2.38) 
>=5 13 1% 32 5% 71% 4.59 (2.38, 8.84) 4.05 (1.93, 8.52) 
Diagnosed STI in the past 12 months        
None 878 96% 556 95% 38% ref.  
STI diagnosis 7 0.7% 13 2% 65% 2.93 (1.16, 7.40)  
Not stated 33 4% 14 2% 30% 0.67 (0.36, 1.26)  
Attended GUM in the past 12 months        
No 778 85% 411 70% 35% ref.  
Yes 132 14% 160 27% 55% 2.29 (1.77, 2.98)  
Not sure 6 0.6% 6 7% 50% 1.89 (0.61, 5.91)  
Perceived health       
Fair/good/very good 779 85% 462 79% 37% ref.  
Very poor/poor 139 15% 121 21% 47% 1.47 (1.12, 1.92)  
Psychological distress       
Normal 149 16% 48 8% 24% ref. ref. 
Moderate 200 22% 93 16% 32% 1.44 (0.96, 2.17) 1.13 (0.72, 1.78) 
High 226 25% 145 25% 39% 1.99 (1.35, 2.93) 1.61 (1.04, 2.49) 
Very high 334 36% 289 50% 46% 2.69 (1.87, 3.86) 1.68 (1.10, 2.56) 
Body dissatisfaction 41.3 13.3 43.9 12.1  1.02 (1.01, 1.02)  
Loneliness score 5.3 1.7 5.8 1.8  1.20 (1.13, 1.28)  
Satisfaction with life  21.3 7.2 19.4 7.4  0.97 (0.95, 0.98)  
† Factors included in the multivariable model: Sexuality, Age group, Ethnicity, Country of birth, Education, Work status, Relationship status, Population density per hectre, Internalised homophobia, Sexual contact 
without consent in the past 12 months, No. of women sexual partners in the past 12 months, Diagnosed STI in the past 12 months, Attended GUM in the past 12 months, Perceived health, Psychological distress, 
Body dissatisfaction.  
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use were identifying as queer, having a country of birth outside of the UK, having 2-4 women 
sexual partners in the past 12 months, and having high or very high levels of psychological 
distress. Older age was associated with a decreasing liklihood of reported drug use. 
These analyses were repeated to examine factors associated with sexualised drug use 
compared to drug use (Table 11). Factors that were associated of sexualised drug use were 
identifying as bisexual or in another way, having a highest level of education qualifications at 
age 16 or lower, and having 2 or more sexual partners in the past 12 months. Being single was 
associated with reduced likelihood of engaging in sexualised drug use. 
Figure 10 compares the motivations for and effects of intentional sexualised drug use, 
sex under the influence of cannabis, and sex under the influence of alcohol. WSW who reported 
intentional sexualised drug use were more likely to report doing so because it gives an intense 
sexual experience and allows them to have sex for longer. WSW who reported engaging in 
sexualised drug use and those who reported engaging in sex under the influence of alcohol 
were more likely to report doing things they would not do sober. 
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Table 11. Bivariate and multivariable analyses for factors associated with sexualised drug use in the past 12 months compared to drug use among WSW. 
 Taken drugs (n=323) Sexualised drug use (n=260) Bivariate Adjusted model† 
 n or mean % or SD n or mean % or SD Row % OR (95% CI) aOR (95% CI) 
Sexuality        
Lesbian/homosexual 188 58% 109 42% 37% ref. ref. 
Bisexual 101 31% 116 45% 53% 1.98 (1.39, 2.83) 2.30 (1.56, 3.40) 
Queer 25 8% 20 8% 44% 1.38 (0.73, 2.60) 1.41 (0.70, 2.83) 
In another way 9 3% 15 6% 63% 2.88 (1.22, 6.79) 2.96 (1.16, 7.56) 
Age 26.7 8.0 25.9 7.5  0.99 (0.97, 1.01)  
Ethnicity        
White 311 96% 249 96% 44% ref.  
Person of colour 12 4% 11 4% 48% 1.15 (0.50, 2.64)  
Country of Birth       
UK 286 89% 223 86% 44% ref.  
Not UK 30 9% 31 12% 51% 1.33 (0.78, 2.26)  
Education       
University or higher 174 54% 124 48% 42% ref. ref. 
Qualifications at 18 124 38% 102 39% 45% 1.15 (0.81, 1.64) 0.95 (0.65, 1.39) 
Qualifications at 16 or lower 19 6% 31 12% 62% 2.29 (1.24, 4.24) 2.22 (1.11, 4.40) 
Work Status       
Full time 149 46% 100 38% 40% ref.  
Part time 37 11% 30 12% 45% 1.21 (0.70, 2.08)  
Student 99 31% 82 32% 45% 1.23 (0.84, 1.82)  
Unemployed 7 2% 9 3% 56% 1.92 (0.69, 5.31)  
Other (sick leave, retired, carer) 29 9% 37 14% 56% 1.90 (1.10, 3.29)  
Relationship status       
Living with partner 107 33% 86 33% 45% ref. ref. 
Relationship not living with partner 82 25% 88 34% 52% 1.34 (0.88, 2.02) 0.75 (0.46, 1.20) 
Relationship with multiple 6 2% 13 5% 68% 2.70 (0.98, 7.39) 1.00 (0.30, 3.30) 
Single 128 40% 73 28% 36% 0.71 (0.47, 1.06) 0.31 (0.18, 0.52) 
Population density per hectare      
<5 77 24% 65 25% 46% ref.  
5 - 20  87 27% 63 24% 42% 0.86 (0.54, 1.36)  
20 - 41  80 25% 65 25% 45% 0.96 (0.61, 1.53)  
>41  77 24% 63 24% 45% 0.97 (0.61, 1.55)  
Internalized homophobia      
Low 197 61% 158 61% 45% ref.  
High 122 38% 99 38% 45% 1.01 (0.72, 1.42)  
Discrimination sexuality in the past 12 months    
None 158 49% 115 44% 42% ref.  
Any setting 153 47% 135 52% 47% 1.21 (0.87, 1.69)  
Sexual contact without consent in the past 12 months   
No 280 87% 208 80% 43% ref.  
Yes 31 10% 39 15% 56% 1.69 (1.02, 2.81)  
Unsure 9 3% 8 3% 47% 1.20 (0.45, 3.15)  
Number of women sexual partners in the past 12 months   
0-1 250 77% 165 63% 40% ref. ref. 
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2-4 61 19% 75 29% 55% 1.86 (1.26, 2.75) 2.14 (1.40, 3.28) 
>=5 12 4% 20 8% 63% 2.53 (1.20, 5.30) 2.98 (1.36, 6.54) 
Diagnosed STI in the past 12 months        
None 309 96% 247 95% 44% ref.  
STI diagnosis 5 2% 8 3% 62% 2.00 (0.65, 6.20)  
Not stated 9 3% 5 2% 36% 0.70 (0.23, 2.10)  
Attended GUM in the past 12 months        
No 247 76% 164 63% 40% ref.  
Yes 70 22% 90 35% 56% 1.94 (1.34, 2.80)  
Not sure 3 1% 3 1% 50% 1.51 (0.30, 7.55)  
Perceived health       
Fair/good/very good 263 81% 199 77% 43% ref.  
Very poor/poor 60 19% 61 23% 50% 1.34 (0.90, 2.01)  
Psychological distress      
Normal 31 10% 17 7% 35% ref. ref. 
Moderate 61 19% 32 12% 34% 0.96 (0.46, 1.99) 0.75 (0.35, 1.62) 
High 89 28% 56 22% 39% 1.15 (0.58, 2.26) 0.92 (0.45, 1.90) 
Very high 135 42% 154 59% 53% 2.08 (1.10, 3.93) 1.51 (0.76, 2.99) 
Body dissatisfaction 42.7 12.6 45.6 11.3  1.02 (1.01, 1.03)  
Loneliness score 5.7 1.8 6.0 1.8  1.10 (1.01, 1.21)  
Satisfaction with life  20.0 7.4 18.7 7.3  0.97 (0.95, 1.00)  
† Factors included in the multivariable model: Sexuality, Education, Work status, Relationship status, Sexual contact without consent in the past 12 months, No. of women sexual partners in the past 12 months, 
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Drug use and sexualised drug use among trans people 
 
A minority of trans participants identified as straight/heterosexual (6%) and the 
majority were of white ethnicity (95%)(Table 5). Median age of trans participants was 24 years 
(IQR=20-31, range 18-71). Over four fifths (n=398/489, 81%) of trans people reported high or 
very high levels of psychological distress. One participant reported living with HIV (trans man), 
and three were currently taking PrEP (trans man, trans woman, and non-binary trans man [self-
identified]). 
The majority of trans people had drank alcohol in the past 12 months (89%) and 52% 
of these (47% of total sample) had engaged in sex under the influence of alcohol (Table 6). 
Overall, 45% of trans people reported taking a drug in the last 12 months, 47% of these (21% 
of the total sample) reported engaging in sexualised drug use. The drug most commonly taken 
generally and sexually was cannabis (39% and 17% respectively). Twenty-two percent of 
participants who had taken either ecstacy or cocaine reported taking the drug immediately 
before or during sex. The most commonly taken drug associated with chemsex was ketamine 
(3%), followed by GHB/GBL (0.6%). Of those who had taken a chemsex related drug, 31% 
reported taking that drug just before or during sex. One participant reported taking crystal 
methamphetamine and two participants reported taking mephedrone, but did not report taking 
that drug just before or during sex. 
Table 12 displays the bivariate and multivariable analyses for the psychosocial and 
sexual factors associated with engaging in drug use compared to no drug use. Due to the strong 
association between the number of male anal intercourse partners and number of condomless 
male anal intercourse partners in the past 12 months (p<0.001) and the small numbers in the 
condomless category, only the former was included in the multivariable analysis. 
Psychologcial distress had a borderline association with sexualised drug use, but was not 
included in the multivariable analysis due to the strong correlation between psychological 
distress and satisfaction with life scores (r=-0.53, p<0.001). Factors associated with drug use 
were younger age, experiencing sexual contact without consent, having 2-4 female sexual 
partners, and having attended a GUM clinic in the past 12 months. 
These analyses were repeated to examine factors associated with sexualised drug use 
compared to drug use (Table 13). Factors that were associated with sexualised drug use were 
being a trans person of colour, having 2-4 male anal partners, having attended a GUM in the 
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past 12 months, and having a poor percieved health. Being single was associated with a reduced 
likelihood of sexualised drug use. 
Figure 11 compares the motivations for and effects of intentional sexualised drug use, 
sex under the influence of cannabis, and sex under the influence of alcohol. Trans people who 
engaged in intentional sexualised drug use were more likely to report doing so because it allows 
them to have sex for longer and it gives a more intense experience, compared to those who 
engaged in sex under the influence of alcohol or cannabis. 
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Table 12. Bivariate and multivariable analysis for factors associated with drug use in the past 12 months among trans people. 
 No drugs taken (n=274) Taken drugs (n=222) Bivariate Adjusted model† 
 n or mean % or SD n or mean % or SD Row % OR (95% CI) aOR (95% CI) 
Gender        
Trans man 82 30% 63 28% 43% ref.  
Trans woman 57 21% 31 14% 35% 0.71 (0.41, 1.22)  
Non-binary 121 44% 121 55% 50% 1.30 (0.86, 1.97)  
In another way 14 5% 7 3% 33% 0.65 (0.25, 1.71)  
Sexuality        
Homosexual 55 20% 49 22% 47% ref.  
Bisexual 63 23% 49 22% 44% 0.87 (0.51, 1.49)  
Heterosexual 17 6% 13 6% 43% 0.86 (0.38, 1.95)  
Queer 62 23% 69 31% 53% 1.25 (0.75, 2.09)  
In another way 76 28% 42 19% 36% 0.62 (0.36, 1.06)  
Age 28.6 10.3 25.3 8.4  0.96 (0.94, 0.98) 0.97 (0.95, 0.99) 
Ethnicity        
White 260 95% 210 95% 45% ref.  
Person of colour 12 4% 12 5% 50% 1.24 (0.55, 2.81)  
Country of Birth       
UK 247 90% 191 86% 44% ref.  
Not UK 21 8% 24 11% 53% 1.48 (0.80, 2.74)  
Education       
University or higher 129 47% 83 37% 39% ref.  
Qualifications at 18 107 39% 115 52% 52% 1.67 (1.14, 2.45)  
Qualifications at 16 or lower 30 11% 20 9% 40% 1.04 (0.55, 1.94)  
Work Status       
Full time 102 37% 61 27% 37% ref.  
Part time 31 11% 23 10% 43% 1.24 (0.66, 2.32)  
Student 64 23% 74 33% 54% 1.93 (1.22, 3.07)  
Unemployed 23 8% 17 8% 43% 1.24 (0.61, 2.50)  
Other (sick leave, retired, carer) 48 18% 43 19% 47% 1.50 (0.89, 2.52)  
Relationship status       
Living with partner 86 31% 48 22% 36% ref.  
Relationship not living with partner 65 24% 69 31% 51% 1.90 (1.17, 3.10)  
Relationship with multiple 18 7% 16 7% 47% 1.60 (0.75, 3.41)  
Single 105 38% 89 40% 46% 1.52 (0.97, 2.39)  
Population density per hectre      
<5 81 30% 52 23% 39% ref.  
5 - 20  66 24% 47 21% 42% 1.12 (0.67, 1.85)  
20 - 41  83 30% 64 29% 44% 1.20 (0.75, 1.94)  
>41  35 13% 53 24% 60% 2.36 (1.36, 4.09)  
Discrimination gender in the past 12 months     
None 72 26% 51 23% 41% ref.  
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Any setting 182 66% 153 69% 46% 1.19 (0.78, 1.80)  
Sexual contact without consent in the past 12 months    
No  248 91% 164 74% 40% ref. ref. 
Yes 9 3% 41 18% 82% 6.89 (3.26, 14.55) 4.34 (1.98, 9.50) 
Unsure 8 3% 7 3% 47% 1.32 (0.47, 3.72) 1.18 (0.39, 3.60) 
No. of men anal intercourse in the past 12 months        
0-1 261 95% 194 87% 43% ref.  
2-4 9 3% 17 8% 65% 2.54 (1.11, 5.82)  
>=5 4 1% 11 5% 73% 3.70 (1.16, 11.79)  
No. of men condomless anal intercourse in the past 12 months        
0-1 56 20% 46 21% 45% ref.  
2-4 2 1% 9 4% 82% 5.48 (1.13, 26.62)  
>=5 1 0% 4 2% 80% 4.87 (0.53, 45.09)  
Number of women sexual partners in the past 12 months        
0-1 248 91% 173 78% 41% ref. ref. 
2-4 23 8% 41 18% 64% 2.56 (1.48, 4.41) 2.20 (1.18, 4.07) 
>=5 3 1% 8 4% 73% 3.82 (1.00, 14.61) 1.68 (0.39, 7.22) 
Diagnosed STI in the past 12 months        
None 265 97% 207 93% 44% ref.  
STI diagnosis 2 1% 10 5% 83% 6.40 (1.39, 29.53)  
Not stated 7 3% 5 2% 42% 0.91 (0.29, 2.92)  
Attended GUM in the past 12 months        
No 216 79% 137 62% 39% ref. ref. 
Yes 53 19% 79 36% 60% 2.35 (1.56, 3.54) 1.87 (1.18, 2.97) 
Not sure 4 1% 3 1% 43% 1.18 (0.26, 5.36) 1.11 (0.21, 5.91) 
Perceived health       
Fair/good/very good 200 73% 155 70% 44% ref.  
Very poor/poor 74 27% 67 30% 48% 1.17 (0.79, 1.72)  
Psychological distress       
Normal 19 7% 9 4% 32% ref.  
Moderate 42 15% 21 9% 33% 1.06 (0.41, 2.73)  
High 69 25% 53 24% 43% 1.62 (0.68, 3.87)  
Very high 141 51% 135 61% 49% 2.02 (0.88, 4.62)  
Self-stigma 51.5 7.5 51 8.0  0.99 (0.97, 1.02)  
Body dissatisfaction 42.7 12.1 44.0 12.0  1.01 (0.99, 1.02)  
Loneliness score 6.17 1.7 6.4 1.7  1.07 (0.97, 1.20)  
Satisfaction with life  17.8 7.0 16.6 7.1  0.98 (0.95, 1.00)  
† Factors included in the multivariable model: Sexual orientation, Age, Education, Work status, Relationship status, Population density per hectre, Sexual contact without consent in the past 12 months, No. of men 
anal intercourse in the past 12 months, Number of women sexual partners in the past 12 months, Diagnosed STI in the past 12 months, Attended GUM in the past 12 months, Satisfaction with life. 
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Table 13. Bivariate and multivariable analyses for factors associated with sexualised drug use in the past 12 months compared to drug use among trans people. 
 Taken drugs (n=117) Sexualised drug use (n=105) Bivariate Adjusted model† 
 n or mean % or SD n or mean % or SD Row % OR (95% CI) aOR (95% CI) 
Gender        
Trans man 34 29% 29 28% 46% ref.  
Trans woman 15 13% 16 15% 52% 1.25 (0.53, 2.96)  
Non-binary 67 57% 54 51% 45% 0.95 (0.51, 1.74)  
In another way 1 1% 6 6% 86% 7.03 (0.80, 61.87)  
Sexuality        
Homosexual 30 26% 19 18% 39% ref.  
Bisexual 21 18% 28 27% 57% 2.11 (0.94, 4.72)  
Heterosexual 7 6% 6 6% 46% 1.35 (0.40, 4.64)  
Queer 32 27% 37 35% 54% 1.83 (0.87, 3.84)  
In another way 27 23% 15 14% 36% 0.88 (0.37, 2.06)  
Age 24.4 7.2 26.2 9.6  1.03 (1.00, 1.06)  
Ethnicity        
White 115 98% 95 90% 45% ref. ref. 
Person of colour 2 2% 10 10% 83% 6.05 (1.30, 28.30) 5.45 (1.03, 28.85) 
Country of Birth       
UK 103 88% 88 84% 46% ref.  
Not UK 10 9% 14 13% 58% 1.64 (0.69, 3.87)  
Education       
University or higher 43 37% 40 38% 48% ref.  
Qualifications at 18 64 55% 51 49% 44% 0.86 (0.49, 1.51)  
Qualifications at 16 or lower 8 7% 12 11% 60% 1.61 (0.60, 4.35)  
Work Status       
Full time 30 26% 31 30% 51% ref.  
Part time 12 10% 11 10% 48% 0.89 (0.34, 2.32)  
Student 47 40% 27 26% 36% 0.56 (0.28, 1.11)  
Unemployed 8 7% 9 9% 53% 1.09 (0.37, 3.20)  
Other (sick leave, retired, carer) 18 15% 25 24% 58% 1.34 (0.61, 2.95)  
Relationship status       
Living with partner 19 16% 29 28% 60% ref. ref. 
Relationship not living with partner 34 29% 35 33% 51% 0.67 (0.32, 1.42) 0.66 (0.29, 1.51) 
Relationship with multiple 7 6% 9 9% 56% 0.84 (0.27, 2.65) 0.37 (0.09, 1.48) 
Single 57 49% 32 30% 36% 0.37 (0.18, 0.76) 0.29 (0.13, 0.67) 
Population density per hectre      
<5 27 23% 25 24% 48% ref.  
5 - 20  23 20% 24 23% 51% 1.13 (0.51, 2.48)  
20 - 41  42 36% 22 21% 34% 0.57 (0.27, 1.20)  
>41  22 19% 31 30% 58% 1.52 (0.70, 3.29)  
Discrimination gender in the past 12 months    
None 25 21% 26 25% 51% ref.  
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Any setting 80 68% 73 70% 48% 0.88 (0.47, 1.65)  
Sexual contact without consent in the past 12 months   
No  90 77% 74 70% 45% ref.  
Yes 19 16% 22 21% 54% 1.41 (0.71, 2.80)  
Unsure 4 3% 3 3% 43% 0.91 (0.20, 4.21)  
No. of men anal intercourse in the past 12 months        
0-1 111 95% 83 79% 43% ref. ref. 
2-4 4 3% 13 12% 76% 4.35 (1.37, 13.81) 7.76 (2.17, 27.70) 
>=5 2 2% 9 9% 82% 6.02 (1.27, 28.59) 4.89 (0.91, 26.30) 
No. of men condomless anal intercourse in the past 12 months        
0-1 20 17% 26 25% 57% -  
2-4 0 0% 9 9% 100% -  
>=5 0 0% 4 4% 100% -  
Number of women sexual partners in the past 12 months        
0-1 93 79% 80 76% 46% ref.  
2-4 19 16% 22 21% 54% 1.35 (0.68, 2.66)  
>=5 5 4% 3 3% 38% 0.70 (0.16, 3.01)  
Diagnosed STI in the past 12 months        
None 109 93% 98 93% 47% ref.  
STI diagnosis 4 3% 6 6% 60% 1.67 (0.46, 6.09)  
Not stated 4 3% 1 1% 20% 0.28 (0.03, 2.53)  
Attended GUM in the past 12 months        
No 85 73% 52 50% 38% ref. ref. 
Yes 30 26% 49 47% 62% 2.67 (1.51, 4.72) 3.38 (1.73, 6.59) 
Not sure 1 1% 2 2% 67% 3.27 (0.29, 36.95) 4.89 (0.91, 26.30) 
Perceived health       
Fair/good/very good 88 75% 67 64% 43% ref. ref. 
Very poor/poor 29 25% 38 36% 57% 1.72 (0.97, 3.07) 2.03 (1.04, 3.95) 
Psychological distress      
Normal 4 3% 5 5% 56% ref.  
Moderate 14 12% 7 7% 33% 0.40 (0.08, 1.98)  
High 32 27% 21 20% 40% 0.53 (0.13, 2.18)  
Very high 65 56% 70 67% 52% 0.86 (0.22, 3.35)  
Self-stigma 50.5 8.2 51.6 7.7  1.02 (0.98, 1.06)  
Body dissatisfaction 43.6 11.9 44.5 12.2  1.01 (0.98, 1.03)  
Loneliness score 6.5 1.7 6.3 1.7  0.94 (0.80, 1.10)  
Satisfaction with life  16.7 6.8 16.4 7.5  0.99 (0.96, 1.03)  
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Chapter 5: Discussion and reflection on The LGBT+ Sex and Lifestyles 
Survey 
  
The LGBT+ Sex and Lifestyles Survey aimed to investigate sexualised drug use in the 
context of chemsex among all LGBT people in the UK, and whilst a higher proportion of MSM 
reported sexualised drug use and specifically chemsex, around one fifth of both WSW and trans 
people had engaged in sexualised drug use generally. Chemsex was observed among WSW and 
trans people as well, albeit at very small proportions. The proportion of participants reporting 
the use of certain drugs and substances was similar to that from previous literature, such as use 
of cannabis and poppers were commonly reported among MSM (Office of National Statistics, 
2014), and use of cannabis was commonly reported among WSW and trans people (McNeil et 
al., 2012; Office of National Statistics, 2014).  
The survey also aimed to investigate associations between physical and psychological 
health and sexualised drug use and chemsex. Association analyses for MSM, WSW, and trans 
people were conducted separately, due to probable differences in psychological and physical 
health factors, as well as the differences in the proportion of participants reporting sexualised 
drug use and chemsex across groups. This chapter will discuss the findings among MSM, WSW, 
and trans people separately, as well as the general strengths and limitations of Study 2, and then 
providing a conclusion on The LGBT+ Sex and Lifestyles Survey, as well as personal 
reflections on the study. 
 
Men who have sex with men 
 
The MSM findings provided novel insights into how the relationships with wellbeing 
and self-efficacy varied between MSM engaging in broader sexualised drug use and those 
engaging in chemsex. Engaging in sexualised drug use was associated with more condomless 
anal intercourse with male partners than those who did not engage in sexualised drug use, and 
engaging in chemsex was associated with more condomless anal intercourse than other types 
of sexualised drug use. Engaging in sexualised drug use was also associated with the use of 
image and performance enhancing drugs in the past 12 months, but this difference was not 
observed when comparing those who engage in chemsex with engaging in other sexualised drug 
use. This could be due to the inclusion of EDDs in the sexualised drug use category, and 




(Begley, McVeigh, & Hope, 2017). MSM may be subject to additional body image pressures 
such as from using gay dating apps (Filice, Raffoul, Meyer, & Neiterman, 2019), as well as 
community pressures relating to sex, status and competition (Pachankis et al., 2020). Therefore, 
sexual competition and the use of gay dating apps may be more common among MSM engaging 
in chemsex (Bourne et al., 2014), but further research is needed to understand any possible 
associations between image and performance enhancing drug use and sexualised drug use. 
Similar to previous research, MSM engaging in sexualised drug use were more likely 
to have engaged in condomless anal intercourse (Bourne et al., 2014; Glynn et al., 2018; Hegazi 
et al., 2017; Melendez-Torres et al., 2017). Additionally, MSM engaging in sexualised drug use 
were also more likely to have attended a GUM clinic in the past 12 months and received an STI 
diagnosis, as previously observed (Druckler et al., 2018; Hegazi et al., 2017; Ottaway, Finnerty, 
Amlani, et al., 2017). However, when comparing MSM engaging in chemsex with MSM 
engaging in other types of sexualised drug use, this difference did not hold at the multivariable 
level, possibly due to the overlap with number of condomless anal intercourse partners.  
MSM engaging in chemsex were more likely to be taking PrEP compared to MSM 
engaging in other forms of sexualised drug use, which is similar to findings in Amsterdam 
(Druckler et al., 2018), but possibly due to the overlap between taking PrEP and number of 
condomless anal intercourse partners, this was not significant at the multivariable level. When 
analysing event-level drug and condom use, MSM taking PrEP and engaging in sex under the 
influence of alcohol or cannabis, or taking poppers or EDDs immediately before or during sex, 
were more likely to have condomless anal intercourse. This may be unsurprising given that past 
condomless anal intercourse and intention to have condomless anal intercourse are criteria for 
accessing PrEP in England (Girometti et al., 2018). Whilst higher proportions of MSM on PrEP 
and using chemsex related drugs for sex had condomless anal intercourse (GHB/GBL, crystal 
methamphetamine, and mephedrone), these findings were not significant, possibly due to the 
small number of MSM reporting sexualised use of these drugs. Alternatively, these findings 
may not be significant, because a high proportion of MSM not on PrEP taking chemsex related 
drugs for sex also engaged in condomless anal intercourse. 
Although the stigma of living with HIV has been suggested as motivation for engaging 
in chemsex (Weatherburn et al., 2017), living with HIV was not significantly associated with 
sexualised drug use or chemsex once other factors were controlled for. However, this could be 
due to an association with confounding variables such as condomless anal intercourse, and due 
to the higher proportion of MSM living with HIV engaging in chemsex, support services for 




qualitative study had suggested internalised homophobia and experiences of discrimination as 
possible reasons for engaging in chemsex (Weatherburn et al., 2017), but this was not observed 
here.  
Engaging in sexualised drug use was associated with lower life satisfaction and poorer 
perceived health, but there was no significant difference in life satisfaction or perceived health 
between those engaging in chemsex and those engaging in other types of sexualised drug use. 
Previous research has mostly focused on the sexual health effects of sexualised drug use and 
neglected possible psychological associations. It is unclear whether the association between 
poorer perceived health and sexualised drug use was related to mental, sexual, or physical health. 
Therefore, a more detailed exploration of this is needed. Additionally, MSM engaging in 
chemsex were more likely to report their sexualised drug use having a negative impact on their 
life. The proportion of MSM engaging in chemsex and reporting a negative impact is similar to 
research in Ireland (Glynn et al., 2018); however, this is the first study to investigate how this 
differs between chemsex, other forms of sexualised drug use, and sex under the influence of 
alcohol. Those engaging in sexualised drug use reported greater sexual satisfaction compared 
to those not engaging in sexualised drug use, but no difference was observed between engaging 
in chemsex and engaging in other forms of sexualised drug use. Although, MSM engaging in 
chemsex were more likely to report doing so because of the intense sexual experience and being 
able to have sex for longer. A higher proportion of MSM who engage in chemsex also reported 
they were less likely to use a condom compared to MSM engaging in other forms of sexualised 
drug use. Additionally, those engaging in chemsex had a lower sexual self-efficacy compared 
to MSM engaging in other forms of sexualised drug use, suggesting MSM engaging in chemsex 
may have less control over their sexual behaviour when engaging in chemsex. Overall, these 
findings suggest that the perceived benefits, risks, and possible negative impacts from engaging 
in sexualised drug use and chemsex are complex, and future research is needed to understand 
these further.  
In the bivariate analyses, MSM engaging in sexualised drug use were more likely to 
report having experienced or being unsure of having sexual contact without consent in the past 
12 months, and when comparing chemsex with other sexualised drug use, MSM engaging in 
chemsex were more likely to report being unsure of sexual contact without consent. These 
associations did not remain in the multivariable analyses, possibly due to small numbers 
reporting recent sexual contact without consent and this being associated with other factors. 




sexualised drug use and chemsex, which has been highlighted by previous qualitative research 
(Bourne et al., 2015). 
These results highlighted how sexualised drug use and chemsex may be associated with 
the health and wellbeing of MSM and differences in motivations for engaging in these 
behaviours. Whilst it is encouraging to find that a higher proportion of MSM engaging in 
sexualised drug use and chemsex were taking PrEP, further research is needed to understand 
possible associations between PrEP adherence, drug interactions, and possible barriers for 
MSM engaging in sexualised drug use and chemsex taking PrEP, due to the elevated sexual 
risk associated with these behaviours. Furthermore, these results should promote awareness 
among clinicians around the issue of consent and sexualised drug use, and ensure referral 
pathways and patient safeguarding strategies are in place. 
 
Women who have sex with women 
 
 
WSW engaging in sexualised drug use had been largely neglected from previous 
research, and this study found variation in the types of drugs and sexualised drugs used that had 
not previously been investigated. Sexualised drug use was common among WSW when 
considering the use of a wide range of drugs in a sexual context and the most commonly 
reported drug used was cannabis. Higher levels of ecstasy and cocaine use for sex were 
observed in this sample when compared to research among Australian LBQ women (Mooney-
Somers et al., 2018); however, no women in the current research reported taking crystal 
methamphetamine, regardless of whether it was for sexual purposes. When considering 
intentional sexualised drug use, reported motivations for engaging in this were similar to those 
reported among MSM, such as giving an intense sexual experience and having sex for longer, 
but these motivations were reported at much lower proportions. Similar to previous research, 
the use of drugs associated with chemsex was reported among WSW (Heinsbroek et al., 2018), 
and we found evidence that these drugs were sometimes being used in a sexual context among 
WSW, albeit by a very small proportion (<1%), particularly when compared to MSM. 
Overall, 7% of participants reported experiencing sexual contact without consent 
(sexual assault) and this was associated with drug use. Although, the direction of this 
relationship is unclear. For example, it could be that drug use is a coping mechanism used by 
WSW who experience sexual assault. Alternatively, it could be that WSW who engage in drug 




the influence of drugs. In bivariate analyses, WSW engaging in sexualised drug use were more 
likely to report experiencing sexual assault compared to those engaging in non-sexualised drug 
use. However, this was not significant in multivariable analyses, possibly because the majority 
of women experiencing sexual assault were bisexual, which is similar to previous research 
(Germanos et al., 2015) and a higher proportion of bisexual women reported sexualised drug 
use. It is not clear whether the sexual assault related to male or female partners, and due to the 
sensitive nature of the topic, it is ethically challenging to collect event-level detail regarding 
sexual assault. A broad measure of sexual assault was used in our study, because diverse 
populations were being recruited into The LGBT+ Sex and Lifestyles Survey and to avoid a 
focus on penetrative assault, which limits our exploration of the nature of these assaults. Future 
research is needed to fully understand this association between drug use and sexual assault, and 
support services need to be available for WSW who experience sexual assault. 
Engaging in drug use was associated with a higher number of recent female sexual 
partners, and engaging in sexualised drug use was further associated with a higher number of 
recent female sexual partners. Sexualised drug use was mostly under the influence of cannabis, 
which reflects previous research among LGB youth that found an association between cannabis 
use and number of sexual partners (Zhang & Wu, 2017). However, the current research found 
this association specifically among WSW and when measuring drug use in a sexual context.  
Discrimination and internalised homophobia were associated with drug use in bivariate 
analyses, which is similar to previous research (Lehavot & Simoni, 2011), but possibly due to 
the association between these issues and psychological distress, this effect was not observed in 
the multivariable analysis. Discrimination and internalised homophobia were not associated 
with sexualised drug use among those taking drugs in this study. Further research is needed to 
understand the influence internalised homophobia may have on influencing drug use behaviour 
among WSW.  
Similar to previous research, identifying as queer was found to be associated with drug 
use (Germanos et al., 2015). Previous research has also found that bisexual men and women 
were more likely to engage in drug use (Booker et al., 2017). The current study did not find an 
association between drug use and identifying as bisexual, but WSW identifying as bisexual 
were more likely to report sexualised drug use compared to general drug use in the multivariable 
analysis. Similarly, research has previously found that bisexual women were more likely to 
have reported sex with a man while under the influence of drugs compared to heterosexual 
women (Bauer et al., 2010; Estrich et al., 2014). Despite the slightly young age of the sample, 




with drug use among WSW, similar to previous research (Booker et al., 2017). Attending a 
GUM clinic and being diagnosed with an STI were associated with drug use at the bivariate 
level, and attending a GUM clinic was also associated with sexualised drug use at the bivariate 
level. These were not significant at the multivariable level, possibly due to an overlap with other 
sexual variables. However, sexual health clinics may be able to play a role in future research 
regarding drug use and sexualised drug use among WSW due to this association, as well as 
providing a place of support for WSW engaging in drug and sexualised drug use. 
These results demonstrated that sexualised drug use does occur among WSW in the UK 
and this may be associated with a number of potential harms, in addition to drug use more 
generally. Services that come into contact with WSW (e.g. sexual health clinics, drug services) 
should be aware of potentially compounding factors like psychological distress and sexual 




 Sexualised drug use and chemsex was observed among trans participants, but to a lesser 
extent than observed in MSM. Ketamine and GHB/GBL were the only chemsex drugs that had 
been used for sex and these were used by a minority of trans participants (1%). Just under half 
of trans participants (45%) reported any drug use in the past 12 months and over one-fifth of 
participants (21%) reported broader sexualised drug use, of which cannabis was the most 
commonly reported sexualised drug used. A higher proportion of participants in this study 
reported drug use compared to the Trans Mental Health Study (45% vs. 24%) (McNeil et al., 
2012), but the most commonly reported drugs were similar (i.e. cannabis, poppers, ecstasy). 
Both studies had a similar number of participants and age distribution; however, the Trans 
Mental Health Study primarily used word-of-mouth to recruit. Therefore, the difference in 
reported drug use observed in this study may be due to using Facebook as a recruitment tool, 
as the recruitment method has been effective previously at representing drug and alcohol users 
(Bauermeister et al., 2012), as well as sexual history and relationships (Jones et al., 2012), 
compared to the general population.  
 The factors associated with drug use among trans people were similar to those 
associated with drug use among WSW, such as younger age, experiencing sexual assault, and 
having 2-4 female sexual partners. Younger age has been associated with higher levels of drug 




trans people as well. Similar to WSW, experiencing sexual assault was associated with drug 
use, but it is unclear whether taking drugs may be a coping mechanism for those who have 
experienced sexual assault, or whether using drugs may make someone more vulnerable to 
sexual assault. Sexual violence experienced by trans people has previously been suggested as a 
determinant of health behaviours (Hendricks & Testa, 2012). Sex work was not measured in 
this survey, and due to the association between sex work among trans people and drug use 
(Hoffman, 2014; Reback & Fletcher, 2014), this may also be a contributing factor to 
experiencing sexual assault and drug use. Future research is needed to understand this potential 
association further. 
 Both female sexual partners and male anal intercourse partners were associated with 
drug use at the bivariate level. Having 2-4 female sexual partners was associated with drug use 
when controlling for other factors. Greater than or equal to five sexual partners was not 
associated with drug use, but this may be due to small numbers reporting this, because this 
category did have a higher proportion of drug use. The reason female partners may be associated 
with drug use but not male partners, is that only anal intercourse with male partners was 
measured, thereby not including vaginal sex with male partners. It could be that people who 
have an increased number of sexual partners are more likely to engage in drug use, regardless 
of the gender of their partner. Only a quarter of trans participants identified as either 
heterosexual or homosexual (27%), and future research should account for this by measuring a 
variety of sexual behaviours. 
Having 2-4 male anal intercourse partners was associated with sexualised drug use at 
the bivariate level and in the multivariable analysis. A high proportion of those who reported 
greater than or equal to five male anal intercourse partners reported sexualised drug use, but 
again, this may not have been significant at the multivariable level due to small numbers of 
participants in this category. A higher number of female sexual partners was not associated with 
sexualised drug use among trans people, and therefore sexualised drug use may be a more 
common practice among trans people with male sexual partners. Engaging in drug use and 
sexualised drug use were both associated with recent attendance at a GUM clinic, and whilst 
engaging in drug use is not a sexual risk, it is associated with a greater number of sexual partners 
in this sample. It therefore appears that trans people who are taking greater sexual risks are 
more likely to attend a GUM clinic.  
Similar to MSM, poorer perceived health was associated with sexualised drug use 
among trans people. It is unclear the direction of this association, for example, it could be that 




Alternatively, it could be that sexual drug use has an impact on a person’s perceived health, due 
to its associations with sexual health and psychological factors, as well as the possible negative 
effects of drug use such as addiction. Despite the small proportion of people of colour recruited, 
being a trans person of colour was associated with sexualised drug use. Being single was 
associated with a reduced likelihood of engaging in sexualised drug use and therefore may be 
more common among trans people in relationships, although it is unclear about participants’ 
relationship status at the time of engaging in sexualised drug use and further research would be 
needed to confirm this. Only one participant who engaged in sex under the influence of cannabis 
and no participants who engaged in sexualised drug use reported doing so because of pressure 
from their partner, suggesting it is mostly a consensual act within relationships. Similar 
motivations for engaging in intentional sexualised drug use were reported as among MSM and 
WSW, such as to give a more intense sexual experience and to have sex for longer, although 
the proportion of MSM and trans people reporting these motivations was much higher. This 
may be reflective of different types of sexual intercourse between MSM, WSW, and trans 
people that could influence these motivations for sexualised drug use more than other types of 
intercourse. Alternatively, this could be explained by partner type and social norms within these 
subcategories of LGBT people.  
Poorer life satisfaction and psychological distress was associated with drug use at the 
bivariate level, but satisfaction with life was not significant in the multivariable analyses. No 
other psychological or social factors such as self-stigma, body dissatisfaction, or experiences 
of discrimination were associated with drug use or sexualised drug use. Therefore, it appears 
that these trans specific stress factors, as adapted from the Minority Stress Model (Hendricks 
& Testa, 2012), may not influence these specific behaviours.  
Similar to the WSW findings, this research found that sexualised drug use is observed 
among trans people in the UK, and that both drug use and sexualised drug use may have a 
number of associated harms. Whilst the causal direction of these relationships between drug 
use and specific harms is unknown, it is positive that trans people who use drugs and those who 
engage in sexualised drug use are more likely to attend a sexual health clinic than those who do 
not. This provides an opportunity for not only sexual health care, but referrals for further 






Strengths and limitations 
 
The use of community organisations and the PPI group not only helped aid recruitment 
of certain groups of participants (i.e. trans people), but improved the research so that it speaks 
with LGBT people and not at/for LGBT people. Facebook advertising enabled a large sample 
size to be obtained in a short time period. Although an attempt was made to measure whether 
participants were recruited from Facebook advertising or community organisations, this was 
deemed invalid due to reporting of recruitment methods that had not yet been initiated. However, 
it is assumed that Facebook advertising was responsible for the majority of the sample, as the 
majority of participants were recruited as the adverts were running. Additionally, based on the 
recruitment log (Appendix 5), the community organisation social media posts tended to have 
little engagement in comparison to paid advertising. Although answers to the recruitment 
question appeared to be invalid, it is likely to be due to a lack of understanding among the public 
regarding how Facebook advertising works and assuming the advert was from a community 
organisation, rather than a piece of research from a university.  
Whilst Facebook was a great tool for achieving the sample size, it may also reflect some 
biases observed in the sample. Participants were relatively young and majority white ethnicity 
compared to the general population. Additionally, very few heterosexual-identifying MSM and 
WSW were recruited. Despite the slightly skewed age range, age still appeared to be associated 
with drug use or sexualised drug use behaviour among MSM, WSW, and trans people. 
Representation from LGBT people of colour has been noted as an issue in other UK-based 
LGBT research (McNeil et al., 2012). Although a higher proportion of WSW of colour engaged 
in drug use, this was not significant, possibly due to the overlap with country of birth and the 
small number of people of colour recruited. Despite the small proportion of participants who 
were people of colour, being a person of colour was still associated with chemsex among MSM 
at the bivariate level and sexualised drug use among trans people at the multivariable level. It 
could be that LGBT people of colour are less likely to engage in LGBT content on Facebook, 
and were therefore less likely to be shown the adverts, or that LGBT people of colour were less 
likely to engage with the adverts. Future research should aim to be more reflective of LGBT 
people of colour to investigate this further and to reflect the lives and experiences of all LGBT 
people by utilising organisations specific for LGBT people of colour.  
The sample who completed the survey differed to the sample who did not on a number 
of demographic characteristics (gender, sexuality, education, and relationship status), but 




of a lack of inclusion of LGBT people in UK national data collection. Additionally, targeted 
Facebook ads for MSM were ran in Brighton, London, and Manchester to aid the recruitment 
of MSM engaging in chemsex. Although this may have biased the prevalence of MSM engaging 
in chemsex in this study, the aim of this research was not to find an accurate prevalence rate for 
MSM engaging in chemsex, but to find psychosocial and sexual factors associated with the 
behaviour. It may be that there are common factors related to MSM in these locations and those 
who engage in chemsex, but controlling for population density hopefully negated some of these 
differences. 
Heterosexual identifying WSW and MSM were excluded from analyses due to small 
numbers. However, previous research has found heterosexual identifying WSW were more 
likely to engage in drug use and sexualised drug use (Bauer et al., 2010). Additionally, 
internalised homophobia has been suggested as a reason for engaging in chemsex among MSM 
(Weatherburn et al., 2017), and although not observed in this sample, that may be because of 
the small number of heterosexual identifying MSM recruited. The small number of MSM and 
WSW identifying as heterosexual is probably reflective of using Facebook advertising for 
recruitment, as people had to engage with LGBT content on Facebook to be shown the advert, 
which heterosexual identifying MSM and WSW may be less likely to do. Future studies should 
consider the use of other recruitment approaches to reach more heterosexual identifying MSM 
and WSW. Due to their focus on collecting sexual history rather than identity, sexual health 
clinics may be more appropriate venues for recruiting heterosexual identifying MSM and WSW.  
There were difficulties in creating a fully inclusive LGBT survey regarding sexual 
behaviour. Whilst event-level data was collected among MSM in regards to condom use, event-
level data among WSW and the majority of trans people was not, due to a lack of previous 
research on which to base any event-level assumptions. This data would have been able to give 
more context for sexualised drug use among these populations, as gender of partner and sexual 
behaviour will influence sexual health needs. Despite this, novel findings regarding sexualised 
drug use among trans people and WSW were observed, and future research specific to each 
population group would be able to collect more event-level details of sexualised drug use.  
Online surveys are a useful tool for recruitment, but this method meant a reliance on 
self-report measures, and though where possible standardised tools and questions were used, 
responses may still be subject to recall bias. The cross-sectional nature of this survey also meant 
that causation cannot be inferred from the findings. The additional incentive of a prize draw 
and the anonymity of online recruitment methods can lead to fraudulent responses (Riggle, 




for example, participants who had skipped mostly through the survey to get to the prize draw 
were not included in the analyses, as well as participants who tended to only answer one 
question on scales with multiple questions. Fraudulent responses could also be identified and 
then excluded from analyses by checking answers to certain questions, such as using the gender 
identity question to identify as an “attack helicopter” or a “gender fluid non binary trans 
microwave”. It cannot be said with certainty that all fraudulent responses were removed; 
however, it is believed that these would be the minority of responses and therefore very unlikely 




Despite the limitations, The LGBT+ Sex and Lifestyles Survey made a number of novel 
contributions to the literature. Chemsex was measured in the context of broader sexualised drug 
use among MSM and associations with psychological factors were measured, which had been 
previously neglected from research. Drug use and sexualised drug use among WSW and trans 
people was previously under-researched in comparison to MSM, and a number of potential 
confounding health and psychological factors were associated with these behaviours among 
trans people and WSW. Additionally, research among trans people tended to focus on solely 
trans women, whereas in this research, trans men and non-binary people were included as well. 
Whilst creating an inclusive survey was difficult, it has highlighted a number of potential health 
inequalities experienced by LGBT people who engage in drug and sexualised drug use, which 
warrant further investigation so that appropriate harm reduction services can be developed, and 
existing services for LGBT people can further develop using the knowledge of potential 




My experience of conducting Study 2 was mostly positive. I did not expect to achieve 
such a high response rate in such a short period. However, this did have an impact on my 
personal life. To run Facebook adverts and set up a Facebook page, this needs to be linked to a 
Facebook account and I used my personal account. Due to the large success of the survey, I 
would get notifications to my phone whenever anyone commented or interacted with the survey, 




my personal account. I also felt the need to deal with comments quickly, because although most 
were neutral comments such as people stating they had completed the survey, some had the 
potential to discourage future participants. These comments included someone incorrectly 
stating that the survey was not inclusive of bisexual people in a relationship with someone of 
the opposite gender. Although a bisexual person will have had to have had a same gender 
partner to take part that not all bisexual people will have had, but this was fundamentally a 
survey about sex and sexual behaviour. Other commenters called the survey a fix because 
participants had missed the link to the prize draw at the end, and even when given the link to 
the prize draw in a private message, some still insisted there was no link. I believe these 
comments were written without realising a person was behind the account, and the anonymity 
of internet no doubt influenced the harshness and negative tone of these particular comments. 
It was hard to take a step back from these comments and see them in perspective compared to 
the vast majority of participants who completed the survey without complaints. Also, any 
comments which had the potential to deter other participants were deleted and I feel this raises 
some ethical questions, because these were participants’ experiences and I was effectively 
silencing them. However, my primary focus was recruitment and I did not want these negative 
opinions to interfere with that, and my own bias that these comments were unfair and unjustified 
definitely contributed to their removal. Although this recruitment method can be considered 
successful given the sample size and the relatively little amount spent on advertising, if I were 
to use this method again, I would have a separate Facebook account to link the adverts to, so I 
could have more of a barrier between professional and personal life. 
I placed a lot of value on the use of community organisations and community members 
in the design and distribution of the survey, because I wanted this research to advocate for the 
community. Using the organisations helped ensure the research was attempting to understand a 
topic, whilst speaking with the community and not for the community. The gender identity 
question was derived from previous work with community organisations, as well as feedback 
from community members in the PPI group. Although I am happy to have used gender questions 
that trans community members were happy with, these questions were used as an opportunity 
to voice opinions that I see as transphobic. This included poking fun at people with different 
gender identities, such as “attack helicopter” or a “gender fluid non binary trans microwave” as 
previously mentioned, but also included comments that were more direct in their transphobia 
like “Female (trans women not included)”, and “female bugger all to do wuth[sic] trans do not 
limp[sic] them together”. For the latter, these participants were recoded into the correct gender 




because of their distaste for the category “Female (including trans women)”. I find these 
comments quite upsetting, as they conflict with my own strong opinions of trans inclusion and 
trans rights and I don’t like that my survey was used as an opportunity to air these opinions. As 
much as these opinions conflict with my own, I had to put these biases aside and still include 
them in analyses. 
It is important to remember that these are the definite minority of cases and that some 
comments were constructive. Two commenters stated they found the survey overwhelmingly 
negative and therefore it didn’t apply to them, one of which stating they dropped out. It is 
sometimes easy to forget that many of the tools used and experiences researched are on the 
more negative side of the human experience. This is why positive psychology exists (Sheldon 
& King, 2001), and is something I will consider in research going forwards to try to not only 
focus on these ‘negative’ experiences and attempt to retain participants who feel these questions 
are not a reflection of their experiences. There were also some light-hearted comments among 
what seemed at the time to be a sea of negativity, such as someone tagging their friend to take 
part in the survey asking them to not mention the hamster (implying a type of sexual act that 
was not measured in the survey).  
I did come into this research with my own biases around MSM who engaged in chemsex 
based upon previous research, as well as news articles regarding chemsex, and I had to confront 
these when analysing the data. I did believe the narrative that people who engage in this 
behaviour do so because they are repressed and/or distressed, which was not reflected in the 
data. Whilst this may be some people’s experiences of engaging in chemsex, it does not appear 
to be reflective of MSM engaging in chemsex as a whole. It is also important to note that as 
humans, we give more weight to negative experiences than positive ones (Rozin & Royzman, 
2001). Therefore, news stories about overdosing or coming into harm are going to attract more 
attention than an opinion that people are engaging in chemsex and everything is fine. A minority 
of MSM stated that chemsex was having a negative effect on their life. Whether more are in 
denial about the negative effects of chemsex is unclear, but regardless, I feel that you cannot 
force help upon someone who doesn’t want it or isn’t ready for it. Therefore, a harm reduction 
approach for services would be most appropriate (Lenton & Single, 1998), where people are 
helped to minimize the risks of chemsex behaviours, and are made aware of services to reduce 





Chapter 6: Methodology of qualitative interviews with service users and 
service providers 
 
Rationale and outline 
 
The LGBT+ Sex and Lifestyles survey highlighted a number of interesting and novel 
findings regarding sexualised drug use among LGBT+ people to explore further. Due to the 
larger proportion of MSM reporting sexualised drug use and chemsex, only MSM were 
recruited for qualitative interviews. In relation to Objective 4 of the programme of research 
regarding service provision and service development for LGBT people engaging in sexualised 
drug use, interviews were also conducted with sexual health workers regarding sexualised drug 
use and chemsex among MSM. This enabled both service user and service provider perspectives 
regarding service provision to be obtained. This chapter will outline the rationale, recruitment, 
and analysis method for the interviews. 
The LGBT+ Sex and Lifestyles Survey found that MSM who engaged in chemsex were 
more likely to report doing so because of the intense sexual experience and to have sex for 
longer, compared to those who reported engaging in other sexualised drug use. Those who 
reported engaging in other sexualised drug use were more likely to report doing so because of 
the intense sexual experience and to have sex for longer, compared to those who reported 
engaging in sex under the influence of alcohol. MSM engaging in chemsex were also more 
likely to report doing so because of pressure from friends compared to those engaging in other 
sexualised drug use and sex under the influence of alcohol. Previous qualitative interviews 
among MSM engaging in chemsex found the intense sexual experience to be a motivation, in 
addition to HIV stigma and internalised homophobia (Weatherburn et al., 2017). Chemsex has 
also been described as a normalised behaviour among MSM in London, with those engaging in 
chemsex setting boundaries for themselves in terms of drug and sex practices (Ahmed et al., 
2016). Whilst no association between internalised homophobia and sexualised drug use or 
chemsex was found in The LGBT+ Sex and Lifestyles Survey among MSM, it would be 
interesting to explore these motivations and social norms further in comparison to other forms 
of sexualised drug use. MSM who engaged in sexualised drug use generally reported a lower 
life satisfaction than those who did not engage in sexualised drug use, but this did not differ 
between those engaging in chemsex and those engaging in other forms of sexualised drug use. 
Additionally, previous research regarding chemsex and sexualised drug use has been criticised 




therefore these effects were explored further in the qualitative interviews. Research regarding 
chemsex in the UK has been largely London based, so this research was conducted in other 
regions in the UK where chemsex and sexualised drug use is known to take place (Schmidt et 
al., 2016), to investigate whether the behaviour is similar to findings from the London based 
research. 
The previous survey found that MSM who engaged in sexualised drug use and chemsex 
were more likely to have attended a GUM clinic in the past 12 months, and those who engaged 
in chemsex were more likely to have attended than those who engaged in other sexualised drug 
use. It was also found that 17% of those engaging in chemsex reported the behaviour having a 
negative effect on their life. Previous research found that a majority of MSM engaging in 
chemsex in Manchester would prefer to access care at a specialist chemsex support service 
within a sexual health clinic (Tomkins, Vivancos, et al., 2018). The qualitative interviews 
explored this topic further by not only asking MSM who have engaged in sexualised drug use 
and chemsex about the care they have received from sexual health services, but also interviews 
with sexual health staff provided insights into the types of care available for MSM engaging in 
sexualised drug use and chemsex. PrEP was another form of sexual health protection that was 
associated with sexualised drug use and chemsex in bivariate analyses but not in the 
multivariable analyses, possibly due to the association between PrEP and condomless sex. It 
would therefore be interesting to further understand the use of PrEP in the context of sexualised 
drug use and chemsex. 
When observing the effects of chemsex, MSM in the LGBT+ Sex and Lifestyles Survey 
reported they were more likely to have sex without a condom and do things they would not do 
sober, compared to those engaging in other sexualised drug use and sex under the influence of 
alcohol. The Theory of Planned Behaviour (Ajzen, 1991) states that a person’s attitude towards 
a behaviour, subjective norms, and perceived behavioural control influence a person’s intention 
to carry out that behaviour, and intention and perceived behavioural control influence whether 
someone conducts that behaviour. This has been applied to condom use among MSM with 
intention explaining some of the variance in behaviour, although an intention-behaviour gap 
remains (Andrew et al., 2016). The intention-behaviour gap is a term used to explain when a 
person’s intention to conduct a particular behaviour does not translate into action (Sniehotta, 
Scholz, & Schwarzer, 2005). The previous study found MSM engaging in sexualised drug use 
were more likely to engage in condomless sex, and those engaging in chemsex were more likely 
to engage in condomless sex compared to those who engaged in other forms of sexualised drug 




lower sexual self-efficacy, which suggests there may be an intention for condom use, but a lack 
of confidence in carrying out condom use behaviour. This research will examine the Theory of 
Planned Behaviour (Ajzen, 1991) in relation to sexualised drug use and chemsex, particularly 
focusing on intention and behaviour of condom use during sexualised drug use. This is because 
if there is a discrepancy between sober intentions to use condoms and condom use behaviour 
when engaging in sexualised drug use, then this provides an opportunity for intervention to 
increase condom use behaviour and reduce STI transmission. 
Service providers were included in the qualitative stage to provide a greater 
understanding of sexualised drug use among MSM and the standard of care provided. Including 
service providers not only provided two perspectives regarding sexualised drug use and 
therefore a more holistic understanding, but it can also helped identify any discrepancies in 
service delivery or knowledge that can be used to inform regarding service delivery. 
Additionally, if barriers to care are identified by service users, interviewing service providers 
may provide more context as to why those barriers exist and what can be done to minimise 
these barriers to care.  
Therefore, to build upon the findings from The LGBT+ Sex and Lifestyles Survey, the 
qualitative stage of this mixed methods programme of research had three objectives: 
1. To further investigate the relationship between sexualised drug use and chemsex with 
physical and psychological wellbeing from a service user and service provider 
perspective. 
2. To explore using the Theory of Planned Behaviour (Ajzen, 1991) in relation to intention 
to use condoms and condom use behaviour in the context of sexualised drug use. 
3. To understand the current standard of service provision for MSM engaging in sexualised 
drug use, as well as any barriers to potential service development from both a service 










Recruitment of MSM (service users) 
 
Ethical approval for semi-structured interviews with MSM was obtained from Liverpool 
John Moores University Research Ethics Committee (approval reference:18/PHI/36). The 
information sheet and consent form for the semi-structured interviews can be seen in 
Appendices 6 and 7 respectively. Semi-structured interviews were chosen for both service user 
and service provider interviews, because of the conversational and informal style that was 
deemed appropriate due to the sensitive topics researched (Longhurst, 2003). Additionally, the 
one-on-one nature of semi-structured interviews could protect participants’ anonymity on a 
sensitive and personal issue compared to other techniques, such as focus groups. Three methods 
of participant recruitment were used for MSM: Facebook posts, community organisations, and 
a call for participants sent to those who took part in The LGBT+ Sex and Lifestyles Survey. A 
Facebook post was placed on The LGBT+ Sex and Lifestyles Survey Facebook page. The 
LGBT Foundation in Manchester, which has a chemsex support network, was approached to 
help aid recruitment through mentioning the research at their support network meetings. Other 
LGBT organisations providing chemsex or sexual health support in Merseyside, South 
Yorkshire, and West Midlands were also approached, but recruitment was unsuccessful with 
most organisations not responding to recruitment requests. One organisation did assist but no 
recruitment was gained. Participants from The LGBT+ Sex and Lifestyles Survey were given 
the option to be contacted for future research if they lived in the North West, and a call for 
participants was sent out using this mailing list. To be included, participants had to identify as 
a man who has sex with other men and report the use of one of 10 substances before or during 
sex in the past 12 months (amphetamine, cocaine, crack cocaine, crystal methamphetamine, 
ecstasy, heroin, ketamine, GHB/GBL, mephedrone, poppers). Alcohol and cannabis were not 
included as the aim was to investigate intentional sexualised drug use, as opposed to sex under 
the influence of drugs. 
The semi-structured interview guide for MSM was based on findings from The LGBT+ 
Sex and Lifestyles Survey and previous research (Appendix 8). Questions investigating 
motivations and wellbeing during and after were based on findings relating to differing 
motivations between those engaging in chemsex and those engaging in other sexualised drug 
use from The LGBT+ Sex and Lifestyles Survey, as well as the association between sexualised 




the finding that a higher proportion of MSM engaging in sexualised drug use and chemsex 
reported more male condomless anal intercourse partners and PrEP use, as well as a specific 
question investigating motivations based upon the Theory of Planned Behaviour (Ajzen, 1991). 
Questions regarding sexual health clinic services were added in relation to Objective 4 of the 
programme of research to assess support needs for MSM engaging in sexualised drug use and 
chemsex. 
The interview guide was piloted on one participant and a small modification was made, 
which was adding a question to ease the transition to talking about sex (i.e. did you use Grindr 
at the weekend). No changes to the interview guide were made once interviews commenced. 
Interviews were conducted at LJMU private offices, at public locations with the required level 
of privacy, over the phone, and via Skype between January and June 2019. It was intended that 
interviews would be conducted until data saturation was reached. Thirteen MSM service users 
were recruited, and whilst data saturation was achieved as no new information emerged in the 
later interviews, ideally a small number of additional interviews would have confirmed data 
saturation. Participants were given a £20 Amazon voucher for their time.  
 
 
Recruitment of NHS sexual health workers (service providers) 
 
 The recruitment of service providers was combined with another sexual health project 
regarding PrEP provision (Hillis, Germain, Hibbert, Hope, & Van Hout, in press) to aid 
recruitment and reduce time taken out of work for the service providers. The interviews were 
divided into PrEP questions and chemsex/sexualised drug use questions and three quarters of 
NHS interviews were conducted by the researcher (n=12/16), with the remaining conducted by 
other researchers on the PrEP project. Ethical approval for semi-structured interviews with NHS 
staff was obtained from the NHS Health Research Authority (REC reference:19/HRA/0443). 
The information sheet and consent form for the semi-structured interviews can be seen in 
Appendices 8 and 9 respectively. Questions were designed in relation to Objective 4 to assess 
the current services available for MSM engaging in sexualised drug use and chemsex and what 
service development is needed. Six NHS Trusts based in the North or Midlands of England 
were approached for recruitment, five of which agreed to take part (two from Merseyside, and 
one each from Greater Manchester, South Yorkshire and the West Midlands). Names of 
potential service provider participants at the NHS Trusts were gained through a research contact 




conducted between June and December 2019. Interviews were conducted until multiple 
researchers (n=3) believed data saturation had been achieved and there was good geographical 
representation from the four locations in England. The semi-structured interview guide can be 
seen in Appendix 10. The interview guide was initially developed for face-to-face interviews, 
but due to constraints placed on the project from the NHS Health Research Authority, 
interviews had to be conducted via telephone. Therefore, some of the questions had to be 
adapted for this change (i.e. draw a referral pathway was changed to describe a referral 
pathway). Due to NHS time constraints, questions could not be piloted before use, but no 






Generic qualitative research is an approach to conducting qualitative research that is not 
guided by specific philosophical assumptions (Caelli et al., 2003) and is used for topics unsuited 
to traditional qualitative methods (e.g. case study, ethnographic, grounded theory, 
phenomenology) (Percy, Kostere, & Kostere, 2015). It has been suggested that a generic 
qualitative research approach is suitable for research topics regarding attitudes towards an issue 
and is well suited to mixed methods research (Percy et al., 2015). The aim of this qualitative 
research is to investigate attitudes towards sexualised drug use and chemsex among MSM and 
service providers, as well as investigating service provision for MSM engaging in these 
behaviours, and therefore using a generic qualitative approach was deemed appropriate. The 
generic qualitative research approach lends itself to semi-structured interviews for data 
collection, and the use of thematic data analysis (Braun & Clarke, 2006). Thematic analysis 
(Braun & Clarke, 2006) was chosen to analyse the data because it is not limited to a single 
theoretical approach, is widely used in health and wellbeing research, and has a systematic 
coding framework which is useful for those new to qualitative analysis (Braun & Clarke, 2014). 
It has also been used previously when researching chemsex among MSM (Ahmed et al., 2016; 
Weatherburn et al., 2017). Other analysis techniques, such as Interpretative Phenomenological 
Analysis (IPA), were considered but not chosen due to the role of the researcher’s subjective 
experiences (Peat, Rodriguez, & Smith, 2019) that may have led to a misinterpretation of 
participants’ lived experiences on a sensitive issue. Additionally, IPA would not have been 
appropriate for interviews with NHS sexual health workers, as participants were discussing 




The six phase guide to thematic analysis, as outlined in Braun and Clarke (2006), was 
followed to analyse the data. Interview transcripts were coded and analysed in NVivo 12 (QSR 
International 2018).  
 
Phase 1: Familiarising yourself with your data 
Interviews were transcribed verbatim and then checked for accuracy against the audio. Five 
service provider interviews were transcribed using a transcription service; otherwise all 
interviews were transcribed by this researcher. The transcription of all service user interviews 
and most service provider interviews enabled familiarisation with the data. The transcripts were 
grouped into two datasets (service users and service providers). The transcripts were then read 
multiple times for the researcher to further familiarise themselves with the data. During this 
phase, any initial ideas for coding were made note of.  
 
Phase 2: Generating initial codes 
Two researchers independently generated initial codes on three service user and three service 
provider transcripts. The coding of these transcripts were then compared for accuracy and 
relevance to the research questions. The coding of the rest of the two datasets was then 
completed. Most of the coding was data-driven, with codes depending on the data and relevance 
to the research questions. However, due to the use of Theory of Planned Behaviour (Ajzen, 
1991) as a model for condom use in the context of sexualised drug use, there were some specific 
themes related to the Theory of Planned Behaviour (Ajzen, 1991) that the researchers coded to. 
Therefore, the majority of coding was done inductively, but deductive coding was done with 
regards to the Theory of Planned Behaviour (Ajzen, 1991) and intention to use condoms and 
condom use behaviour. Because the service provider interviews were combined with questions 
regarding PrEP, the coding of these transcripts was specific to anything with relevance to 
sexualised drug use and chemsex only. A screenshot of the coding framework at this stage can 
be seen in Appendix 12 for service users and Appendix 13 for service providers. 
 
Phase 3: Searching for themes 
Once all data had been coded, codes that were similar or overlapping were condensed. Codes 




this grouping stage. Codes that did not appear to fit into any initial themes were grouped as 
miscellaneous. This category was then reviewed at the end of phase 3 and were coded into 
existing themes if applicable. 
 
Phase 4: Reviewing themes 
The first part of this phase involved reading the data extracts within themes to assess if the data 
extracts formed a coherent pattern within themes. Data extracts that did not fit within the theme 
or sub-theme were either recoded to a more suitable theme or removed. Overlapping themes 
were condensed into one theme. The miscellaneous category was reviewed again, this time 
removing any data extracts that did not coherently fit into a theme or sub-theme. A candidate 
thematic map was then created. After this, the entire datasets were read, considering if the 
themes were an appropriate representation of the dataset and research questions, as well as 
coding any additional data to themes that was previously missed. Data were coded and themes 
were generated until it was deemed that no substantial value was being added by additional 
coding.  
 
Phase 5: Defining and naming the themes 
Once satisfactory thematic maps had been created, themes and sub-themes were then defined 
and refined by identifying the fundamental quality of a theme, using this to inform the theme’s 
name, as well as identifying and naming sub-themes. Figure 12 and 13 displays the final 
thematic maps for service users and service providers respectively. 
 
Trustworthiness of qualitative research 
 
 To ensure rigour and trustworthiness in the qualitative research section of this 
programme of research, the framework developed by Shenton (2004) was used to demonstrate 
the methods undertaken to ensure reliability, validity, and objectivity of the research. Shenton’s 
(2004) criteria was based upon the four criteria for trustworthiness outlined by Guba (1981), 
which are: credibility, transferability, dependability, and confirmability. Table 14 outlines how 




 The next chapter will provide the results from the qualitative interviews, discussing the 





















Table 14. Shenton’s (2004) criteria for trustworthiness in qualitative research. 
Quality criterion Provisions made in the research 
Credibility Adoption of appropriate and established methods: Semi-structured 
interviews are a well-established research method within the context of the 
generic qualitative approach and thematic analysis is one of the most widely 
used qualitative analysis techniques. 
 
Use of reflective commentary: Personal reflections were made and noted 
throughout the qualitative research stage and these reflections are provided at 
the end of Chapter 7. 
 
Peer scrutiny: Supervisors provided feedback at all stages of the qualitative 
research project, from design, analysis, interpretation, and write-up. 
Presentations at conferences allowed for external peer scrutiny. Additionally, 
stakeholders at LGBT Foundation provided constructive feedback on the 
project, as they wanted to ensure anonymity and appropriate ethical 
considerations were in place for participants recruited via this organisation. 
 
Transferability Provision of background data to establish context of the study: The rationale 
and outline section at the beginning of this chapter provides the context of the 
research in relation to how the findings from the LGBT+ Sex and Lifestyles 
Survey were used, in addition to previous research that was used to guide the 
qualitative research. 
Dependability In-depth methodological description: This chapter provided a detailed 
description of the methods used for the qualitative section of this programme of 
research in sufficient detail so that the project could be repeated. 
Confirmability Triangulation to reduce investigator bias: Findings from the qualitative stage 
were triangulated with findings from the systematic review and The LGBT+ Sex 
and Lifestyles survey using Farmer et al.’s (2006) method, which can be seen in 
Chapter 9 alongside the protocol for the triangulation process. 
 
Recognition of shortcomings: In Chapter 8, a strengths and limitations section 
is provided where limitations to the qualitative methodology are outlined and 
how these may have impacted the results are discussed. 
 
Use of diagrams to demonstrate an audit trail: Appendices 12 and 13 provide 
images of the coding after phase 2 of thematic analysis, and Figures 12 and 13 










Thirteen participants took part in semi-structured interviews. The majority of 
interviews (n=7) were conducted face-to-face (4 Skype, 2 phone call). Most participants (n=9) 
were recruited through the mailing list to the previous survey, and four participants were 
recruited through the community organisation. Interviews were on average 43 minutes in length 
and ranged from 20-70 minutes long. Demographics of participants can be seen in Table 15. 
The majority of participants identified as gay, were white British, and had a median age of 34 
years (range 23-66). Two participants were living with HIV and three participants were 
currently taking PrEP, all of whom self-reported engaging in chemsex. The most common 
sexualised drugs used were mephedrone and poppers, followed by cocaine and crystal 
methamphetamine. Five out of the thirteen participants (38%) reported engaging in chemsex 
when defining chemsex as the use of crystal methamphetamine, GHB/GBL, ketamine, or 
mephedrone immediately before or during sex. Two other participants self-identified as 
engaging in chemsex, both using cocaine before sex. One of these participants was in an 
exclusive relationship, the other discussed using cocaine at group sex parties. For clarity in the 
analysis, any referral to chemsex is referring to the use of crystal methamphetamine, GHB/GBL, 
ketamine, or mephedrone immediately before or during sex. 
Analysis of data identified five themes. These were: motivations for sexualised drug 
use; sexual risk management; the impact of sexualised drug use; care and support, and 
perceptions of sexualised drug use.  
 
Theme 1: motivations for sexualised drug use 
 
Participants discussed their motivations for engagement in sexualised drug use. Motivations 
were organised into three sub-themes: sexual motivations, psychological motivations, and 
social motivations. The primary motivation for engagement appeared to be sexual, which were 
seen as positive motivations by participants. Psychological and social motivations on the other 
hand appeared to hold a mixture of positive and negative value, depending on the motivation 




Table 15. Service user demographics. 
 
No. of participants 
(N=13) % 
Sexuality   
Gay 11 85% 
Bisexual 1 8% 
Queer 1 8% 
Ethnicity   
White British 10 77% 
White Irish 1 8% 
White Australian 1 8% 
Latino 1 8% 
Work Status   
Full-time 10 77% 
Student 3 23% 
Relationship status   
In a relationship 6 46% 
Single 7 54% 
Location   
Lancashire 1 8% 
Liverpool 1 8% 
Manchester 9 69% 
Stockport 1 8% 
Warrington 1 8% 
Sexualised drugs used   
Cocaine 3 23% 
Crystal methamphetamine 4 31% 
GHB/GBL 4 31% 
LSD 1 8% 
Mephedrone 5 38% 
Poppers 5 38% 




Sub theme: sexual motivations 
All but one participant noted a sexual motivation for sexualised drug use and this was primarily 
to enhance the sexual experience. This was a key motivation regardless of the substance used, 
although the specifics of how it enhanced the experience appeared difficult to articulate. 
Sexualised drug use was described as “intense”, “euphoric” and “enhancing”, with a number 
of participants noting how it creates an intense focus on sexual pleasure, creating a “little 





That’s the thing that I wanted, was to carry on using chems [GHB/GBL, mephedrone] and 
having sex, coz of the like how much of a more intense experience it was. – 31, Gay 
 
I think it [poppers] lends itself to a kind of subservient role, a kind of nothing else matters, it 
creates almost like a single focus, single focus in terms of like eroticism and sexual pleasure 
really. – 52, Gay 
 
A number of participants did specifically describe how the sexual experience is enhanced, 
because certain drugs helped them to prolong the sexual experience. One participant described 
how the use of crystal methamphetamine amplified their “sexual stamina, so you can fuck like 
mad hung for hours and hours” (41, Queer), and another described using cocaine to “stretch it 
out, make sure you don’t come as quickly” (24, Gay). Another way in which the sexual 
experience was enhanced was that sexualised drug use lent itself to sexual experimentation 
because of reduced inhibitions, whereby sexualised drug use facilitated enacting sexual 
fantasies or trying new sexual practices. One participant described how engaging in chemsex 
helped him recreate sexual desires he had seen in porn or being more willing to try fetishes that 
are not acknowledged by the conscious mind. Another participant described how poppers were 
used between him and his partner when trying out a new sex toy that helped facilitate the 
experience practically and psychologically.  
 
If you were sober, you might be less willing to experiment, but actually you’d be more willing 
to experiment [during chemsex], so you actually play out your fantasies, and a lot of those 
fantasies are then driven around what you experience there in terms of what you watch on 
porn online, so what you see on porn, then you then want to recreate it…so you might 
actually watch a bit of porn and think ‘actually, aw yeah’ you know, you quite like that fetish 
or something like that, but you wouldn’t necessarily do it, because actually you understand 
that actually it’s a porn, and it’s a porno movie, and it’s fictitious, and it’s not real, it’s made 
up, but actually when you’re doing chems, you then you seek to recreate those fantasies that 
are sometimes ingrained really, really deep – 42, Gay 
 
but whenever we do use them [poppers], it’s more that we’re trying to introduce something 
new into the bedroom, therefore we both or me be more relaxed in what we’re trying…so for 
example we got some new sex toys. We got an inflatable butt plug, so we just wanted to kind 
of make sure that I was fully confident but also relaxed with it, so for example we’d get 





Sub-theme: psychological motivations 
Several participants identified self-esteem as a psychological motivation for engaging in 
sexualised drug use and how using drugs for sex helped them feel more confident. One 
participant outlined how chemsex helped them moderate their own drug use due to the 
confidence boost from chemsex, and therefore only took drugs when in that environment. This 
increase in self-esteem was related to feeling more attractive, because of being invited to more 
sex parties. Another participant identified the validation he received from others at chemsex 
parties from his sexual behaviour was a motivation that was secondary to sexual fulfilment.  
 
For me it’s been a really good thing [engaging in chemsex], like it’s massively helped my 
confidence even though I have that confidence on the drugs and then I don’t have it as much 
when I’m not, in myself I feel like, I feel more attractive because people want to invite me to 
these things, like someone’s boyfriend messaged me because his boyfriend had met me and 
like that is a really strange thing for boyfriends to do but it made me feel really nice, and it’s 
made me feel better about my drug use, because I really enjoy taking drugs, but I know it’s 
not a good thing to do all the time, so the fact I can go to these parties just like you know, 
once a couple of weeks or once a couple of months and still take those drugs in an 
environment where no one is judging you, and come away from it and be confident in myself 
that I’m not gonna continue that on my own, that’s really helped me as well. – 26, Gay 
 
I then go and get the gratification to validate myself, and that’s what I go to chemsex parties 
for as well as being horny. That’s maybe what I see as see as the surface driving me to go 
and have chemsex, those chemsex parties is because I’m horny and I want sex and I’m 
probably, I dunno what you want to call it, I can still cum when I’m high, so when everyone 
else is just sat there and they’re not really able to like get to that point where they do, for me 
like I know I can and it’s almost like that drives me, but also it’s that validation from other 
people – 31, Gay 
 
Three participants mentioned negative psychological motivations for engaging in sexualised 
drug use, such as loneliness and mental health. All of those who mentioned a negative 
psychological motivation had been engaging in chemsex and had stopped engaging, either 
because of the harm it was doing to them or due to a very small period in time where they did 
engage in this behaviour. One participant reflected on how they were previously using drugs 
to “self-destruct” by engaging in a number of risk behaviours that could have had a potentially 
negative effect on their health. Another participant described how the breakdown of a long-
term relationship had left him “grief-stricken”, and how the drugs contributed to the worsening 




loneliness. One participant described how recently receiving a mental health diagnosis had led 
to a situation where they tried mephedrone, because they had stopped caring about life and 
their wellbeing. 
 
Motivations [for chemsex]? Loneliness, I had been for seven years in what I considered a 
totally loving relationship and unfortunately my partner met someone else, fell in love with 
him and it was handled very, very carefully and very delicately, and we’re still friends to this 
day and I’m friends with his partner, but I was grief-stricken, totally and utterly grief-
stricken. I couldn’t face the future on my own. I’d mentally and physically, I’d set myself a 
whole target of where I was going, he was 14 years younger than me, and I just couldn’t face 
the future, and I used to say to everyone I haven’t got anything to live for anymore, and that’s 
that mental side that eventually I had to come to terms with and sort out, but taking the 
combinations of MKAT [mephedrone] and G [GHB/GBL] and then eventually doing a lot of 
Tina [crystal methamphetamine] did not help that mental state at all, it was trying to get 
someone round the whole time to fill the void. – 66, Bisexual 
 
It was a really, really tough time for me in general. Just before that I’d quit my job, been 
diagnosed with PTSD and depression and severe anxiety disorders all in the same go, after 
probably six or seven years of struggling with various different things and not really 
understanding why and kept hitting this point. So I quit my job, so there was just this quite 
long period where I didn’t have a clue what my future would be, how I was going to get 
sorted again, how I was going to get back on my feet, what was going to happen. I was single 
at the time so any experience that happened I just thought it could be my last, so it just didn’t 
matter to me whether or not it went bad or not, and it sounds awful, I distinctly remember 
snorting something [mephedrone] and at the moment of snorting thinking ‘that could be the 
last thing I ever do’ and I didn’t care at all – 34, Gay 
 
Sub-theme: social motivations 
For one participant, the psychological motivation of their mental state had lent itself to 
circumstantial chance, a social motivation combined with a ‘YOLO’ (you only live once) type 
attitude, describing his thinking beforehand as “fuck it”. This circumstantial chance arose from 
a dating app hook-up, whereby the participant met someone who he knew was going to use 
mephedrone and used mephedrone themselves without pressure from his sexual partner, which 
then lead to the participant using mephedrone three times after that with the same sexual 
partner. 
 
I had no plan to do anything. There was three times I took MKAT [mephedrone], it was all 
with the same guy. The first time I had no intentions of taking anything at all, it was just I had 




knew he did and it was one of those situations I never really gave a shit and I just thought 
fuck it…It was just like I said it was just there. He had said before that he would use it 
occasionally and that night that I arrived, it was already on the table. So it was more a case 
of, I think from his perspective it was like ‘I’m gonna do it, it’s there if you want it’. There 
was never any pressure, or you should, or persuasion, and from me it was genuinely just a 
‘fuck it’. – 34, Gay 
 
One participant who reported using cocaine for sex discussed how a social queue would trigger 
positive memories about drug use and sex and motivate them to want to engage again. This 
participant likened the circumstances of engaging in sexualised drug use to that of seeing an 
advert, whereby something would trigger a positive memory of sexualised drug use that would 
then be motivation to engage. The ‘advert’ could be something seen on social media or a 
conversation about drugs. 
 
It’s difficult to…erm…do you know what it is? It’s like if someone brings it up or someone 
says something, and you go…it’s like seeing and advert on TV for McDonald’s, you didn’t 
ever want the McDonald’s and think I don’t want that it’s full of shit, then you watch the 
advert and you think could really do with it, then someone brings it up and you go ‘aw god do 
you know that time we did this’ or ‘oh god I would love to go out and do this’ and you think 
‘oh god I’d love one too’, I would love that buzz again [from cocaine and sex] and you just 
kind of forget all the bad stuff because all you’re focusing on is it makes me feel really 
buzzed, it makes me feel really good. – 24, Gay 
 
A small number of participants (n=3) discussed how pressure to adhere to or rebel against 
certain stereotypes were a motivation for engaging in sexualised drug use. These were either 
stereotypes of gay men, such as having an active sex life, which also included media depictions 
of gay men having active sex lives and using drugs, or stereotypes surrounding relationships, 
such as married couples having a conservative sex life. One participant who previously 
engaged in chemsex described how he felt he needed to conform to the stereotype of a gay man 
having sex with multiple partners and conformed to this stereotype by engaging in chemsex. 
Another participant described how the stereotype of marriage being a sexless relationship made 
him want to use poppers during sex to rebel against this stereotype.  
 
Is it because you’re a gay man and it’s available, do you think you actually need to be part of 
that stereotype? That you actually need to go out and have it [sex] two or three times just so 
you’re exactly the same as everyone else in the gay scene, and that’s I think where it came 




my God given right, and I could go and do it [chemsex] coz it was so easy, but then also, the 
other side of that coin is that it filled the loneliness and it filled the void. – 66, Bisexual 
 
So the expects[sic] about a married couple is they are going to be having sex just with 
themselves, just in their beds, in a really quite conservative practice. I think that’s what 
makes me go away from that idea. I don’t want to become one of them really boring couples. 
– 28, Gay, discussing poppers use and sex 
 
Pressure from a partner was not common among participants stating they had engaged in 
sexualised drug use within a relationship, but one participant mentioned how social pressure 
from his partner was his motivation for engaging in sexualised drug use, specifically LSD. This 
participant later regretted his behaviour, because he did it to please his partner, despite it going 
against his own beliefs. 
 
I think I did deliberately take LSD to have sex with him [my partner], but it was only the one 
time and then after that it wasn’t…because I took it out like not of my own choice, because it 
was genuinely he wanted me to take it, after I felt like I betrayed what I kind of go against 
when it comes to any kind of drug recreation, and after I did kind of feel like I’d kind of 
betrayed myself – 23, Gay 
 
Theme 2: sexual risk management 
 
Participants discussed their methods for managing sexual risk in relation to engaging in 
sexualised drug use. For those who were living with HIV or taking PrEP, service users 
discussed how they would manage adherence to their medication whilst engaging in sexualised 
drug use. For other participants, they discussed their intention and behaviour in relation to 
condom use, and for the majority of participants, they practiced consistent intention and 
behaviour, but this was no intention to use condoms, and therefore did not use condoms. 
 
Sub-theme: adherence to HIV medication and PrEP 
The two participants who were living with HIV and engaging in chemsex mentioned how 
engaging in chemsex for long durations did not affect their adherence to their medication. One 




another highlighted that an adherence strategy of carrying ART medication in a keyring, which 
was used before engaging in chemsex, helped him adhere to their medication in chemsex 
situations. 
 
There were a couple of times when I might have missed during the, I always took everything 
within a 12 hour period, so I was safe. In fact quite honestly [laughs] the number of times 
totally sober and in a way, I mean I woke up this morning, pottered around, I normally take 
mine at eight o’clock and I went into the kitchen at midday today and suddenly realised I 
hadn’t taken them, so in fact, in rather a perverse way, I was probably better at taking my 
meds [when engaging in chemsex] then than I am sober. – 66, Bisexual 
 
No, I would say that’s more so…I mean I’ve had HIV for four and half, five years now, so 
I’ve been on meds for four and a half so I would say that was a lot earlier on like in my, in 
having HIV, like I’m very good now at taking ‘em. 
Interviewer: So would you take your meds to the [chemsex] party as well? 
Yep. Yeah, I have like keyrings full of ‘em, I take ‘em everywhere with me. – 26, Gay 
 
This was true for participants taking PrEP and engaging in chemsex as well (n=3). Two of 
these participants mentioned how engaging in chemsex did not affect their adherence by having 
a set routine of adherence and taking PrEP daily, so that even if they did miss a dose, this would 
not reduce the overall effectiveness. One participant mentioned how if he did not have any 
PrEP with him, people at the party were likely to share, suggesting PrEP is common among 
those engaging in chemsex, and there is a community that are protecting each other.  
 
There has been incidences where if I had been there [at a chemsex party] for several days, 
then somebody who has got PrEP, I’d ask them if I could have a tablet from them. – 31, Gay 
 
Sub-theme: intention and behaviour towards condom use 
Regarding intention around using condoms, most participants reported consistent intention and 
behaviour regardless of the effect of a substance, with most stating intention not to use 
condoms. Besides those who were in an exclusive relationship, and therefore reported not using 
condoms, participants who were single also commonly reported not using condoms, with four 




the social norm of not using condoms at a chemsex party, one stating it did not influence them 
using a condom, because of their deeply held attitude towards consistent condom use. Another 
participant stated how the social norm of not using condoms influenced their condom use over 
time after initially wanting to use condoms in chemsex situations.  
 
And I’ve come across a lot of guys, where I’ve said I’ve wanted to use one [a condom], and 
they’ve almost said it in a way where like, they’ll make an allowance for me. Like, it’s odd 
that I want to use one. 
Interviewer: But that never impacts on your sexual safety? 
No, I’m a little bit obsessive about condoms really. – 43, Gay, discussing cocaine use and sex 
 
I’ve got into a belief in my head where I think it’s unprotected, like bareback sex is, I never 
would think oh I’m going to bring condoms [to a chemsex party], because, I mean, I did 
actually to begin with, going back years ago, I remember now, I would put my trackie 
bottoms on, I would bring some lube, bring some condoms and I would use them, but then it 
very quickly developed, because of being in a chemsex environment, like condoms just 
weren’t used or people didn’t want to use them, and then when PrEP came about I then 
maybe in my head it was almost like we don’t need the condoms and I know PrEP is not 
100% safe at all because of all the other things you can get – 31, Gay 
 
Theme 3: the impact of sexualised drug use 
 
Participants discussed how engaging in sexualised drug use had impacted them. The impacts 
of engagement were grouped into four sub-themes: association of drugs and sex; the comedown; 
negative effects, and social connections. 
 
Sub-theme: association of drugs and sex 
Over half of participants (n=8) discussed how they had formed a strong association between 
the use of drugs and sex. One participant discussed how he had taken mephedrone in a non-
sexual context and this triggered a desire for sex, like “a switch was flipped”, and then 
subsequently went to a chemsex party. Another participant described how poppers were needed 





It was almost like a, like a switch is flicked, coz that could happen if I was out clubbing with 
friends and I’d like be I’d be having some MKAT [mephedrone] and I’d go to the toilet and 
create a profile whilst I was there and then be messaging in between cigarettes going outside 
and then like would maybe go straight from the club to a sex party, so it’s almost like a 
switch was flipped and like I want sex now, like I’m horny – 31, Gay 
 
I must admit, it’s [the use of poppers] probably the only thing that ensures my husband cums 
as well. He needs the rush, I think he’s used them for so long – 35, Gay 
 
Sub-theme: the comedown 
The impact of the comedown was outlined in terms of how it felt and how some participants 
would manage their comedown. The length of the comedown was specific to the particular 
drug used, with a comedown associated with poppers lasting a few hours, but a comedown 
associated with chemsex drugs was described as lasting a couple of days. Two participants who 
engaged in chemsex stated how they would use other substances, such as prescription drugs or 
cannabis, to help mitigate some of the negative effects of the drugs used and to facilitate sleep. 
 
Zolpidem would be my like go to for a comedown, 48 hours say into a session, you know 
when the body is naturally sort of tired anyway, then it’s kind of, it works quite well, just to 
short circuit the Tina [crystal methamphetamine] for 5-6 hours maybe. It’s enough for the 
body to get rest for that period - 41, Queer 
 
Interviewer: What’s your motivation for taking weed at the end? 
So to help me like come down, like to start to come down off that level. Like if I wasn’t to 
have a joint it would probably take me about 2 days to fall asleep after taking [GHB/GBL] 
obviously…to be fair if I do start to feel like a come down and I start to get in to that 
worrying kind of place, it’ll take that away for me as well, so it can help kind of cope with the 
aftermath. – 26, Gay 
 
Four participants talked about a feeling of regret that sometimes came with the comedown. 
This tended to be associated with a fear about what may have been said whilst engaging in 
sexualised drug use. Two participants who had taken cocaine for sex described how they both 
regretted what had been said, with one participant regretting potentially upsetting his partner 
but avoided talking about it, whilst another participant feared that they had given too much 





I always always always always say afterwards, the morning after ‘never doing it again’ 
[cocaine and sex], it’s not worth it, it’s not worth the money, it’s not worth the hangover, you 
think, you know you call yourself stupid for doing it and you think do you know what, you 
think all the sex and stuff was really good but is it really worth it? Is it worth feeling like 
this? You might have said something that was, that might make your partner uncomfortable. 
You don’t know coz you’re not fully aware of what you’re saying, it might be offending 
someone or not, but because I don’t want to bring it up, you just don’t know, because you 
don’t ask the next day. – 24, Gay 
 
You just tell people things you wouldn’t really tell people, like your fantasies or stuff [on 
cocaine] you’ve done or things you want to do, things you wouldn’t really tell your friends or 
partner sometimes. 
Interviewer: And how does that feel being able to express that? 
Yeah it feels amazing at the time, and then sometimes you think ‘oh I shouldn’t have said that 
now’ and that’s one of the reasons you don’t want to see the people again. Especially in most 
cases, in this situation anyway, there’s a chance that everyone knows everyone or at least 
they know someone that knows, do you know what I mean, it’s that you might say something 
and they know your friend or your friend’s friend and it’s a bit…things like that and then the 
paranoia of the come down, that doesn’t make a good combination. – 43, Gay 
 
A number of participants (n=5) discussed how the comedown influenced their mental health. 
One participant who had not previously been diagnosed with a mental health condition, 
described how they were using drugs to manage their mental health and this resulted in two 
separate suicide attempts, both of which were attempted whilst on a comedown from chemsex 
drugs. 
 
So that you know there’s no doubt in my mind now that looking back, the reason I was doing 
more and more drugs [crystal methamphetamine, GHB/GBL, mephedrone] is because I was 
trying to cope with my mental health. I committed suicide, I tried to commit suicide twice in 
that time period…and on both occasions, I was very lucky to survive. One was I overdosed on 
30mls of GHB, I had a flatmate at that time, and it was such bad, I actually walked into the 
kitchen, picked up, poured out myself 30mls, came into here, stood there and necked it. I was 
on the comedown. It was the depression. The depression was so bad that just didn’t want to 






Sub-theme: negative effects 
Other negative effects of sexualised drug use identified were the risk of overdosing and 
psychosis. One participant discussed his experience of someone making him overdose on 
GHB/GBL and then try to have sex with him. He went on to say this is the behaviour of a 
minority of people engaging in chemsex, and noted that there is a community that will look out 
for one another if someone does come into harm.  
 
I went there with a fuckbuddy, but there were a lot of cute guys there and there was a lot of 
guys there who were sort of like gym bunny, white gym bunny guys that I wasn’t into at all, 
and one of them was really into me and I was just like nah, I was just like trying to like kinda 
sherk him off all the time, then he asked me if ‘oh do you want a hit of G[GHB/GBL]?’ and 
obviously he gave me a fucking huge dose so I went under, and somehow I just managed to 
come round enough to realise he was starting to fuck me, so I kicked him in the face and like 
pushed him and said ‘Don’t fucking touch me or I’ll cut your fucking cock off’, very 
aggressively…I heavily emphasise this to guys all the time, just because somebody has come 
to your chill out doesn’t mean they have to have sex with you…I actually think there’s a lot of 
decent people out there that don’t want to engage in non-consensual sex and look after each 
other if somebody goes under and you know, want the conversation as well as the sex, not 
just in it for the drugs – 41, Queer 
 
One participant discussed his experience of psychosis whilst engaging in chemsex. The 
participant described this psychosis, which involved being unable to scream for help and being 
locked in their bedroom. This psychosis triggered the participant to seek help for their chemsex 
usage.  
 
I had this episode [after crystal methamphetamine use] where actually it’s probably very 
similar to a K-hole. I was lay just in like my underwear, on the rug on the living room floor, 
and I could feel the whole world dropping in on me, everything, going like, it’s like, 
sometimes they call it a k-hole, they get it off ketamine, and it took all of my energy to let out 
this scream, and it was the wimpiest little scream that you’ve ever heard, [wimpy scream], 
like that, but it took every single energy, and then suddenly I got light again, and then that 
happened about three or four times, but then I made it up to my bedroom, and got into my 
bed, but I couldn’t get out of me bedroom, because there was broccoli, there was a pile of 
broccoli at the door, and I couldn’t actually get out of my bedroom…and that psychotic 
episode, that at that point, I thought actually no, I need to do something – 42, Gay 
 
Participants who had stopped engaging in chemsex (n=4) described how engaging in chemsex 




financial, having to take time off work, and family. One participant stated how they had “lost 
everything” in terms of their personal assets and financial stability due to the cost of engaging 
in chemsex. Four participants described the professional impact engaging in chemsex was 
having. One participant described injecting a chemsex drug in the toilets whilst at work. 
Another participant described how the exhaustion from long chemsex sessions was impacting 
them at work. Participants who had stopped engaging in chemsex would compare the impact 
of engaging in chemsex with their personal goals and aspirations. 
 
I’ve lost everything, you know, I’ve lost houses, I’ve lost money, you know, because that’s 
from my drug usage, my assets, coz I live in a furnished house, so everything in my house is 
actually a landlord’s. My assets are what I’m stood up in, other than a computer at home, 
that’s it, I’ve got no assets whatsoever. All me savings gone, everything, so you know, you’ve 
got to really think, well actually, but you still aspire to actually having a nice house and a 
nice car, and doing nice things, but you can’t do any of that until you actually sort out your 
mental health and move away from drugs, and it’s a hard journey, and you’re never going to 
stop on that recovery, it’s going to be all my life. – 42, Gay 
 
I was having huge difficulties at work. I think dealing with the realisation of some the 
behaviour in the more recent like weeks since February and the exhaustion from obviously 
missing a day’s sleep every other week, I had to, I was actually off of work with stress, I got 
signed off for four weeks by the doctor, but I took only a week off work and I’ve gone back to 
work now, but I had to kind of just say to them look there’s issues with my mental health 
outside of work that I’m also dealing with at the moment and again that was a big, big thing 
for coz I’ve never wanted it to ever affect my work – 31, Gay 
 
One participant then elaborated how engaging in sexualised drug use had changed their risk 
behaviour beyond associated sexual risks, and how this conflicted with their sober behaviour. 
They described themselves as a “risk averse” person normally, but then discussed a time after 
taking cocaine, where they then drove to go to a sex party and then did more drugs, and how 
this conflicts with their attitude towards alcohol and driving.  
 
but it’s the strange thing is how risk averse I am in my normal day-to-day life, I’m quite risk 
averse. When I’m high [cocaine, GHB/GBL, mephedrone] it’s the complete polar opposite 
version of me. It’s like those risks aren’t even a consideration. 
Interviewer: What sort of risk adverse things do you do when you’re sober? 
So I mean I wouldn’t even consider getting in my car even if I had a glass of wine, I only 




wanna, don’t wanna play with that, but then for some reason the last two occasions I got 
high, I thought it was acceptable to get in a car and drive, which I just don’t understand how 
in my head I can think that’s right – 31, Gay 
 
Sub-theme: social connections 
Beyond the positive reasons for engaging in sexualised drug use, such as enhancing the sexual 
experience and boosting self-esteem, a positive impact noted by participants was the social 
element and the connections made from engaging in chemsex. One participant mentioned how 
they enjoyed the personal conversations that happen at chemsex parties (“chillout”), and 
another described the friends they made from engaging in chemsex, and later described how 
they would meet up with these friends outside a sexual context as well. 
 
So a lot of what happens at a chemsex chillout isn’t either chems or sex, it’s actually 
conversation, it’s a bunch of men sitting around really comfortable, naked together, talking 
about their experience of you know many things, what they do, what they’re passionate about 
– 41, Queer 
 
Like I’ve made loads of friends at chemsex parties and stuff, like I dunno you just, I just feel 
like, you only mainly you only remember the bad stories you hear. It’s just a fun thing, do you 
know what I mean? I dunno it’s just, I really enjoy it. – 26, Gay 
 
Theme 4: care and support 
 
Participants were asked about sources of support for sexual health and drug use. Participants 
identified a range of sources and methods for support regarding sexualised drug use, which was 
coded into five sub themes: sexual health clinics; self-help; peer support; family and 
relationships, and identifying barriers to support. 
 
Sub-theme: sexual health clinics 
Some participants spoke of using sexual health clinics as a source of support for their sexualised 
drug use. One participant described how using a specific chemsex clinic helped him manage 
his usage. It provided an opportunity to vent and receive reinforcement and generate ideas of 




helped him get the care needed to stop his usage, because this started the chain of events that 
led to him receiving help and support. 
 
It’s like things get quite heavy and it can be a nice kind of release valve, just to go up and 
have a word with the, and you know talk about some of the things that happen and like I’ve 
gone up sometimes when things are going really well, like I’m looking really well and they’re 
saying aw it’s really good, I’m still doing chems but you know I’m putting all these things in 
place. It’s not that I need it every week, but there’s certain times where I just feel aw I’ll give 
them a call, and just book in an appointment and just talk to them coz I think I need it at the 
moment, for both positive reinforcement and for possibly like advice really or kind of 
exchange of ideas, what do you think of this, do you think if I start doing this. I mean, sitting 
there in that space with them, sometimes I come up with the realisation just by being there. – 
41, Queer 
 
I was backwards and forwards so much to the clinic during that time period [when having 
chemsex], and my consultant and the whole of the team at [sexual health clinic] were so 
concerned about me, to the point where letters were being written to my GP, and my GP 
eventually said to me isn’t it about time you started getting some help for this, put me in 
touch with the [community organisation chemsex support group] – 66, Bisexual 
 
Beyond seeking specialist sexual health and drug care, most participants found engaging in 
sexual health services a positive experience, complimenting the staff for their friendliness and 
making them feel comfortable, with one participant saying he found them “really friendly” 
and it was “completely fine, very comfortable” (29, Gay). Another participant stated: “they’re 
really friendly, really nice, make you feel really comfortable, they’re very good at answering 
questions if you’ve got any worries, really good at referrals and things” (26, Gay). However, 
a number of participants (n=7) complained about waiting times and accessibility of sexual 
health clinics, with one participant referring to them as “sausage machines” and stating 
“They’re overrun. The difficulty of getting an appointment” (66, Bisexual). Two participants 
acknowledged that this was not the fault of staff, but rather due to funding and current 
constraints on sexual health clinics. For example, one participant said: “I still don’t think the 
governments and that are taking sexual health serious. I think they think they put out this 
message ‘use a condom’ and that’s enough and people just aren’t” (43, Gay). Another 
participant felt austerity had impacted sexual health and recognised that staff were doing the 





They’re at a strain, austerity has hit them really hard and they’re trying to run a complex 
service, dealing with a very sensitive issue, on a very limited budget, with very limited staff, 
and all they get all the time is criticism including from me like, but it’s all like ‘ aww they’re 
shit, can’t get an appointment, blablabla, it’s shit,’ but they are doing the best in a very 
fucking difficult environment. – 41, Queer 
Sub-themes: self-help, peer support, and family and relationships 
Other sources of support for participants included self-help, peer support, and family and 
relationships. For those using self-help, this involved participants setting rules for themselves, 
such as abstinence or limiting drug use to specific occasions. Participants who had sought peer 
support from community organisations mentioned how useful it was to discuss things with 
people from similar experiences, and some participants stated how their family and partners 
reactions helped them to control or stop their usage.  
 
and by actually sorting my mental health out then that in a way meant I could actually take a 
proper look at why I was doing so many drugs [crystal methamphetamine, GHB/GBL, 
mephedrone], which is exactly what happened, I sorted that out and then went ‘why am I 
doing all this? I don’t need to’, and coz then I found a purpose in life I didn’t then find this 
need to actually be sitting there doing a lot of chem, and quite frankly I came to the 
conclusion that I didn’t really need at the age of 64 at that point, you know, I’d had a bloody 
good innings in terms of sex, and I actually stopped having sex, I didn’t feel the need to have 
actually sex anymore, so I actually stopped doing drugs because I stopped having sex, is how 
I actually dealt with it. – 66, Bisexual 
 
you get peer support groups, so there’s lots of peer support groups [for chemsex], you’re 
talking to other people who are actually going through the same shit, because you’re using 
and you’re thinking it’s only you, you know, you think it’s only you that’s got a problem, 
where actually that problem’s actually all over, so talking to other people, I’ve learnt so 
much from it. I’m only getting to the point where I’m not dependent on it – 42, Gay 
 
But my mum said to me how her and my brothers had been speaking and they could see I me 
getting better [from drug use unrelated to sex] and that was my motivation, coz I was like oh 
shit people are actually noticing, coz I was really trying for a couple of weeks but in myself 
still feeling you know, like urgh I don’t think I’m getting anywhere. Once I’d heard that kind 
of affirmation from my mum, I would say that really helped as well. – 26, Gay 
 
Sub-theme: barriers to support 




attitudes of the practitioner, and the person seeking support as well. One participant discussed 
how after they attempted suicide during a comedown from chemsex drugs they received no 
after care, because no care was available in the near future. Another revealed how their GP 
referred them to an organisation that no longer existed, suggesting both a lack of knowledge 
and a lack of services for MSM engaging in chemsex, as well as more generally for mental 
health support.  
 
When I tried to commit suicide the first time in 2015, there was nothing. There was absolutely 
nothing available. I wanted counselling at that time and there was an 18-month waiting 
period – 66, Bisexual 
 
When I reported to my own GP and said actually, I’ve tried to kill myself because I’m a drug 
user, me GP gave me a telephone number for this team, he said ring this local drug team, he 
gave me a telephone number, that team had ceased existence five years ago, you know, and 
my GP at that particular point was a GP in the suburb, never even heard of it, never even 
know, didn’t know anything about it, didn’t even know the types of drugs I was talking about. 
He’s a GP, he’s a medical professional, coz he was thinking it’s a criminal matter, you know 
what I mean, so that whole mind-set. – 42, Gay 
 
Related to this, two participants identified their practitioner as a barrier to care. One participant 
detailed how he was rejected from private counselling whilst seeking help for chemsex. They 
were given the analogy that they were trapped inside a car that was on fire and the counsellor 
could not help. Another participant described an experience of receiving drug support unrelated 
to sexualised drug use from an HIV clinic, and how the practitioner’s expectation that gay men 
who used drugs did so because of trauma related to their sexuality made him question his 
validity for help. 
 
he just stopped me at half way through and was like look, you know, you need extra support 
[for chemsex] coz he said, he gave the analogy, it’s like you’re sat in a burning car and I’m 
stood outside asking you how it is in there and he’s like we need to put the fire out first. – 31, 
Gay 
 
He was like really surprised that I was still in touch with my family and they were accepting 
of me being gay and I’d come from an OK family, like he was just really shocked that I 
needed help. So that made me feel like, do I actually need this help? Am I kind of valid for it 




sit there for days and be like do I actually, or am I just being an idiot you know? Are they just 
going to ask me the same questions and then tell me that I don’t fit into that box so I don’t 
need that help – 26, Gay 
 
Another barrier to care participants identified was themselves. One participant described how 
they perceived themselves as a barrier if they were in a situation where they needed support, 
because their anxiety would talk them out of seeking help. One participant identified a gender 
norm specific to men seeking healthcare, describing themselves as a “typical bloke”, and that 
their fear of the unknown was a barrier to healthcare, regardless of the problem. 
 
The only barrier in my life would be me, I’m my own worst enemy, but no yeah other than 
that. 
Interviewer: Can you expand on that a bit more? 
Erm so just like if I am going through a bad patch I get really bad anxiety so I’ll know the 
right thing to do is to go and seek these services and get this help, but then sometimes I’ll 
manage to talk myself out of it – 26, Gay 
 
but the thing is I’m very much a coward, I’m a typical bloke, I put my head in the sand and I 
don’t always want to know about my health coz I’ve got no one to confine in, I’ve no support, 
coz I live on my own and I’ve a very small network of friends who I don’t think really fully 
appreciate or understand circumstance and there’s things I wouldn’t want to share with 
them, so consequently I tend to neglect that part of my wellbeing really, my health be it orally 
or sexually or whatever. – 52, Gay 
 
Theme 5: Perceptions of sexualised drug use 
 
How men who engage in sexualised drug use, in particular chemsex, are perceived by the 
general public became a topic among some participants. Other participants discussed the 
narratives surrounding chemsex, such as the parallels drawn with the AIDS epidemic of the 
early 1980s.  
 
Sub-theme: public perceptions 
Participants commented on what they see as the public’s perception of chemsex. They 




have negative perceptions in society. Therefore, this implies that the combination of drugs and 
sex will exacerbate these negative attitudes. This was the opinion of both those that engaged in 
chemsex and those that engaged in other forms of sexualised drug use. 
 
In public opinion, chemsex has a really bad image and it’s something that is for morally 
wrong people and underground subcultures and just people who is not in charge of their 
lives. They don’t behave properly to what is expected, and I think that’s not the truth. I mean, 
it can be chemsex, it can be drugs by themselves, it can be just unprotected sex and a lot of 
another practices can be, can reflect something wrong with your life, but chemsex doesn’t 
mean necessarily you have something wrong in your life. – 28, Gay 
 
People just think drugs are bad, and people think people who have lots of sex are bad. I think 
society in the past is to blame in regards to religion and things, you know, we are taught, I 
mean I grew up Catholic, so you’re taught that unless you are just one man and one woman 
having children together that’s the only valid sex kinda thing. You know so then everyone 
around you just thinks anyone who doesn’t have that is bad, and especially when you throw 
drugs into the mix. You know, you think of drugs and you just think of smack heads on the 
street or people in prison, you don’t ever hear about the positives. – 26, Gay 
 
Sub-theme: comparisons with AIDS 
Two participants discussed the parallels drawn between chemsex and the AIDS crisis in the 
early years of the epidemic, where gay men were losing friends at an alarmingly rapid rate. 
One participant rejected this narrative and other narratives around chemsex, such as people 
engaging in chemsex are doing so because of internalised homophobia. On the other hand, one 
participant compared their experience of engaging in chemsex with that of the AIDS crisis, 
discussing how there has been a shift from friends dying from natural causes to friends dying 
from overdoses or suicides, and how this compared to life before the development of effective 
HIV treatment.  
 
this notion that chemsex is just gay tragedy on a par with the AIDS crisis, that it’s this 
meaningless interaction inhabited by desperate people living at the edges of society, or 
fiercely addicted but unwilling to admit it because of this innate self-loathing, they’re 
infantile, and they don’t understand themselves so they have to deal with it by filling 
themselves full of meaningless sex and pumping drugs until they crash and it’s just a 
nightmarish, ghoulish scenario. It’s a description of an extreme end of chemsex and it’s kind 




experience some of that stuff, whereas it’s not true of every experience of chemsex. – 41, 
Queer 
 
It’s a little bit telling, that out of those ten people, six of them are no longer with us anymore, 
they’ve either overdosed or they’ve committed suicide, six out of the ten…We know that we’re 
losing people. Prior to 2012, I didn’t hear of any of my friends dying other than from natural 
causes, cancers, heart attacks, the things that effect everyone else in the community, but since 
2012, it’s did you hear about so-and-so. It’s like pre 1996 the comments are exactly the same 
‘did you hear about X’ or on Facebook, people, deaths are being reported all the time. The 









 Sixteen NHS staff were recruited for semi-structured interviews. Nine of these worked 
in Merseyside, four in Greater Manchester, two in the West Midlands, and one in South 
Yorkshire. Seven of the staff recruited were consultants, four were speciality doctors, two were 
health advisors/psychotherapists, two had an administrative role, and one was a nurse 
practitioner. Interviews took on average 30 minutes and ranged from 15-45 minutes.  
 Three themes were identified from the interviews: the service user, service provision, 
and service evaluation. Participants discussed the service user and the possible psychological 
reasons as to why someone might engage in chemsex, as well as the variation seen among 
MSM who use drugs and engage in sexualised drug use. Service provision and how to reduce 
risk was discussed, and service providers evaluated their service provision, identifying both 
positives and barriers to care.  
 
Theme 1: the service user 
 
 Discussion regarding the service user was grouped into two sub-themes: psychological 
reasons for engaging in chemsex, and variation among people who use drugs. Variation among 
people who use drugs was discussed in the context of variation between those who engage in 
chemsex and those who engage in other types of drugs, as well as variation among those 
engaging in chemsex in terms of their diversity. 
 
Sub-theme: psychological reasons for engaging in chemsex 
Service providers mentioned possible psychological reasons for engaging in chemsex, which 
usually involved mental health and self-esteem, but acknowledged that this was not true for all 
MSM who engage in chemsex. One participant discussed how a particular patient would 
engage in chemsex every time they had a mental health relapse. Another participant mentioned 
the stereotype of being a gay man may influence engagement, whereby a metaphor of a merry-






I had a lad the other day who has mental health relapses and every time he has a mental 
health relapse he goes into chemsex. He'd come in for PEP because he'd had a relapse and 
just had unprotected sex. – Nurse practitioner 
 
 
but sometimes I find that, after having time to have a discussion of someone’s history and 
what their goals are, the lifestyle choices that they’re making are related to having low self-
esteem, and they’re also related to the fact they see this type of lifestyle as a kind of merry-
go-round, they can’t get off, and it’s almost an expectation as a gay man that they should be 
part of a scene, when actually, I’d take the fact that they’re having sex with other men out of 
the equation, and look at the fact they’re a human being with various of needs and some of 
that might be intimacy, and they can get that however best they see fit. It doesn’t have to fit in 
with the stereotype, so explore some of those things, lifestyle, stereotypes, self-esteem. – 
Health Advisor/Psychotherapist 
 
Sub-theme: variation among people who use drugs 
Participants also discussed variation among people who use drugs. For variation among 
chemsex users, service providers recognised it as a broad group of people with different 
impacts for different people. The complexities of referring to MSM who engage in chemsex as 
one group were discussed, due to the wide ranging behaviours and experiences among MSM 
engaging in chemsex. One participant stated from their experience, it was not a behaviour 
solely associated with MSM, identifying that a woman had come seeking support for using 
GHB.  
 
It’s still probably about a quarter of the people that I see who are using chems at some 
degree, but it also varies very much from the occasional use of G to people who are 
completely out of control and who are using all kinds of drugs like Tina and mephedrone and 
cocaine and all kinds of other things so it’s very variable. I think it’s difficult to lump 
together chems users as a whole because they actually encompass a very wide wide range of 
behaviours. – Consultant 
 
We have had a request for it [chemsex support] for non-MSM people recently, a young lady 
who had a real problem with GHB, which that service isn’t commissioned to provide. 
Clearly, maybe chemsex isn’t just all about gay men, maybe that’s just the bit that we know 
about. Clearly this young lady had gone to her GP with that as an issue for her, which was 






Participants also discussed variation between those who engage in chemsex and other people 
who use drugs, defining drug use as a spectrum, which made comparisons between groups of 
people who use drugs potentially problematic. This was seen as potentially problematic due to 
the diversity within drug users and the overlap between those who use drugs and then have sex, 
as opposed to intentional sexualised drug use, and how the use of these drugs is common among 
other groups beyond MSM.  
 
No, it’s not only one social group actually, I think that would be wrong to say, but certainly 
from kind of traditional IV drug users, I guess that would vary quite a bit between 
sociodemographic groups and chems, I would say chems is probably more diverse, yeah, 
yeah I think that’s probably it, a greater spectrum. – Speciality Doctor 
 
I feel like that’s caricaturing people a little bit. I think there is a whole complexity to drug 
use. That includes MSMs as well as people who aren’t MSM. The use of class A drugs is 
quite common in general, I think, among students and lots of people. There is going to be an 
overlap there between taking cocaine at parties and then engaging in chemsex. – Consultant 
 
Theme 2: service provision 
 
Service provision for MSM engaging in sexualised drug use was discussed in terms of routine 
screening, further care, and risk reduction. Service providers discussed how these methods 
were utilised to provide a high level of care to MSM engaging in sexualised drug use and 
chemsex. 
 
Sub-theme: routine screening 
Service providers mentioned routinely screening for both drug use and non-consensual sex. For 
non-consensual sex, the screening question was used as an opportunity to raise awareness of 
consent, particularly among those who engage in chemsex, and participants’ main concern was 
around someone’s ability to maintain consent when using any drugs for sex. In reference to 
routine screening for drug use, one service provider described how they adapted their 
questioning method for drug use based upon the trend they had noticed regarding steroid use 




“gym drugs”, because men using these drugs would see them more as health supplements 
rather than a drug. 
 
Generally we ask people routinely actually in the clinic about non-consensual sex, so I will 
then specifically ask about do people feel that they have ever been kind of forced into doing 
things they didn’t want to do or not be aware of what they’ve done, and just kind of make 
people aware that there is this kind of, I feel there is this grey area between kind of 
maintaining consent and do they actually definitely know everything that’s happened because 
of being under the influence of chems. It’s just really, I would say, raising awareness – 
Speciality Doctor 
 
So I think we are definitely seeing an increase in steroid use. I would say that’s not just in 
MSM though, I’m seeing that in heterosexual patients as well, and actually when I ask about 
drugs, I’m now saying do you use recreational drugs, chems, or gym drugs, because I’ve 
started, I was finding that patients were not counting steroids as a recreational drug, and 
therefore weren’t disclosing them, so I think we’re definitely seeing an increase in steroid use 
via gyms. – Consultant 
 
Sub-theme: risk reduction 
Reducing risk was a common practice when discussing service provision to MSM engaging in 
chemsex. Risk was considered in terms of both sexual health and drug use. Adherence to HIV 
medication and PrEP among those who engage in chemsex was not perceived to be a significant 
concern among service providers. This was because of the effectiveness of PrEP, and that if 
people were not taking PrEP during long chemsex parties, the drug would still provide a high 
level of protection if taken daily outside of these parties. Even if adherence was a concern 
among those engaging in chemsex, participants suggested finding alternative methods to 
provide the same level of care. 
 
There’s a concern if people are having long parties, where it’s sort of running into days, then 
the advice would be that if they’re taking as much as possible, if they were to take four days 
in the week, but miss it for three days, they’re probably still going to be protected. I think 
chaotic lifestyles obviously do lead to challenges with drug adherence, in every aspect of 
medicine, not just in HIV and PrEP. So, I still think it’s worth people signing up to it, and 
being on it for the protection. Because there are different ways that people can take PrEP, 
and they might decide that they only need it for their chemsex parties, and do it as event-





My experience of people taking it is that they just tend to get on with it, and I don’t think that 
any drug use, at all, is a barrier to effective medical care. For HIV treatment and care, you 
find ways around that and strategies to help people adhere to treatments. It’s the same 
skillset, really, that you use for this. It’s the same for any medicines really. – Consultant 
 
Consultations with MSM engaging in chemsex were also seen as an opportunity to reduce 
sexual risk through a variety of methods. Participants described using consultations as 
opportunities to discuss risk and aim to reduce sexual risk by as many methods as possible, 
such as vaccinations, PrEP, regular testing, and condom use.  
 
So I think vaccination is a really important, you know, Hep B, Hep A, HPV, that’s a really 
important step, and then with PrEP they’re coming for regular testing anyway, but again it’s 
important, you know, it gives us an important opportunity to reiterate the importance of 
regular screening. I think it is a good opportunity to discuss kind of risk taking, and if there 
are other ways to mitigate risk-taking behaviour, so you know condoms, thinking about other, 
you know, other measures to reduce risk as well. – Consultant 
 
Reducing harms related to drug use was discussed in the context of safer drug use, as well as 
consent and chemsex. In terms of safer drug use, one participant described how they would 
give advice around safety, and how this knowledge is spread among the community, as well as 
giving patients chemsex packs that contained tools for reducing both sexual and drug risk, such 
as sterile spoons, gloves, and syringes appropriate for GHB/GBL measurements due to the 
small dosing required by GHB/GBL. This participant also highlighted how he believed MSM 
engaging in chemsex were looking out for each other with regards to drug safety. 
 
In all groups we give advice about safe use, drug interactions with other things, but 
particularly around injecting, and we’ve got the chemsex packs that we can give out as well. 
We give a lot of safety information about GHB and GHL, and kind of the, coz that’s where if 
people are going to come to harm it’s coz the GHB, they overdose on GHB and have a 
respiratory arrest, so a lot of safety information around that, about generally being safe, 
about the infection risks which are mainly about kind of snorting drug use kind of and mostly 
intravenous drug use, so it’s more a safety about if this happens do this and just increasing 
the awareness of the, coz some people have no idea quite how fine line the toxicity of 
something like GHB can be. One drop can make a difference between a good night and a 
cardiac arrest, so it’s just getting the safety message across, and we’re seeing people kind of 
doing it in networks, so quite often some more experienced users tend to look after the less 
experienced users until…it’s just general safety information would be the extra bit. 




When discussing non-consensual sex and chemsex, service providers said they raised 
awareness and increased knowledge by discussing this issue with the service user to reduce 
both physical and mental harms that can come to someone in a chemsex situation. One 
participant outlined how this applies to both those who experience non-consensual sex as well 
as unintended perpetrators, and how raising the issue of non-consensual sex would hopefully 
deter people from acting in a way that was not intended. 
 
We’ve discussed how someone can be very vulnerable, and it might be my client, it might be 
that so vulnerable that, you know, they’re so out of it that things happen, and either that they 
are unable and not fit to say no, they don’t want to engage in that activity, or actually don’t 
remember what’s happened and you know, will explain that the consequences of that might 
be not just physical and contracted disease or any rips or tears to their body or damage, it 
might also be psychological, and you know obviously I see it in other instances, I see people 
who are victims of sexual assault, because if someone doesn’t consent to something, it is 
sexual assault, and then I flip it over and say well you know, hypothetically you can be in a 
position where you’re almost unable to remember your behaviours, or so out of it you can’t 
pick up on the signs that are telling you that this person does not want to consent to this 
activity, and that would basically cost you, committing a sexual assault, and the 
consequences of that which involve, you know, obviously, the criminal justice system, the 
psychological effect on you who will have committed a sexual assault, and maybe not have 
set out with the intention of doing that, so you know, we’d obviously spend some time about 
looking at the consequences on both sides, whether someone is a victim or a perpetrator, and 
how the rules of consent state someone cannot give their consent if they’re under the 
influence, and the absence of no does not imply yes. – Health Advisor/Psychotherapist 
 
Sub-theme: further care 
Signposting to community organisations was used for both non-consensual sex and chemsex. 
Service providers tended to describe signposting all patients to available services, whether they 
were seeking help or not, to raise awareness that support is there if it was ever needed. This 
was seen as giving the patient the information needed to make an informed choice if they ever 
wanted to seek help. However, one participant mentioned that both internal and external 
services had long waiting lists for services. 
 
So I would ask specifically about chems, and if they disclose any risk at all, I would discuss 
[community organisation] with them, I think it’s, you know it’s good for them to know about 
that service even if they don’t want to engage with it. I think it’s helpful that they know it 
exists and then they’ve got that choice really, so any kind of chem use in the past year or so I 





We may or may not involve the sexual assault referral centre depending on the detail of 
what’s happened. We usually offer people self-referral to [community organisation], who 
I’ve found to be really helpful. Unfortunately, they have a bit of a waiting list. Our sexual 
assault referral centre has got a really long waiting list, longer than [community 
organisation’s] so I’d always mention that for counselling – Consultant 
 
When the service user wanted further care, service providers mentioned making both internal 
referrals to health advisors, drug workers, psychologists, as well as external community 
organisations who were sometimes onsite. Some service providers mentioned their clinic 
running specific chemsex clinics. One participant highlighted how it helped having a service 
within the sexual health clinic, so they could make an immediate referral if needed, and how 
that helps with continuation of care. 
 
We do have a psychologist onsite, but that’s mainly for our HIV patients. We have used that 
as a referral pathway once or twice previously. The relationship that we had with 
[community organisation] onsite and that’s immediate, you know, so they could touch base, 
make that face to face contact and arrange their next meet with them. If that’s done face to 
face it’s real time and people are more likely to make an effort for that continuation. – Health 
Advisor/Psychotherapist 
 
We have a weekly clinic that has a drug worker, and GU consultant, and sexual health 
nurses. So, some booked appointments, and some walk-in slots; so people can come in and 
get support around their chemsex use. - Consultant 
 
Theme 3: service evaluation 
 
Participants evaluated their current service provision with regards to MSM engaging in 
sexualised drug use. The evaluation of services was grouped into three sub-themes: 
understanding local need; positives, and barriers to care.  
 
Sub-theme: understanding local need 
When evaluating current service provision to MSM engaging in chemsex, some service 




in chemsex. Before setting up a specific service for MSM engaging in chemsex, they were of 
the opinion that there needed to be a clear demand for the service so it would be cost effective. 
 
So I think before we were to set up a specific service, we would need to know what the 
demand was for it, so I think we would have to get an idea of how prevalent chem use was in 
our area, because it has to be cost effective. I do think the team we have working, the 
outreach team we have working the [name removed] clinic have a lot of skills to discuss this, 
so I do think that drop in service for that specific MSM group with the option of talking to 
somebody for support is probably adequate for our needs at present – Speciality Doctor 
 
I think it could be improved but I don’t know what our cohort is to be honest. I’m not, yeah I 
don’t know how many people we’re seeing that are engaging in chemsex so I don’t know 
what whether there would be enough demand for a specific clinic. – Speciality Doctor 
 
Sub-theme: positives 
When evaluating their service, two service providers highlighted positives with the services 
they are currently providing. One participant showed pride in their service provision and 
running a specific service for MSM engaging in chemsex, stating “I think we provide a really 
good service, actually, I’m really proud of it”, and that it is “great to have it within our service” 
(Consultant). One participant stated that although the service they currently provide is good, 
there are still ways it could be improved. 
 
We’ve done a lot of training, and with chems, and kind of, you know, managing high-risk 
MSM. I think I would say yes, overall it is a good service, but as with anything it can always 
be improved. – Speciality Doctor 
 
Sub-theme: barriers to care 
Barriers to providing optimum care for MSM who engage in chemsex and sexualised drug use 
were identified by a majority of participants (n=12). These included access to services, capacity 
to provide services, and funding for service development. Some participants discussed whether 
the clinic was accessible as it should be, and one participant suggested possibly utilising online 





Well not everyone conforms to the nine to five or the nine to seven screening, you know, 
working hours that we offer, so if people could access things at a time that was convenient to 
them, so perhaps more online engagement, so we weren’t trying to get people to fit in with 
what we already, when we’re open, but they can access services through other means, so 
online, perhaps receive help and support that way. More use of social media I think, I don’t 
know about other services, but I know [clinic] we don’t have really any kind of social media 
profile and I think, you know, we’re behind the times. – Speciality Doctor 
 
Capacity was identified as another barrier to providing optimum care for MSM who engage in 
chemsex. Clinicians expressed a desire to improve services, but a lack of capacity was cited in 
terms of competing resources, staffing, and time. Two consultants discussed constraints the 
current PrEP trial was having on sexual health clinics and how this was limiting their capacity 
to deliver services not just to MSM, but a lot of groups that were competing for limited 
resources. 
 
I think it’s [chemsex services] far from ideal, I think we’re doing the best we can within 
limited resources and within the conditions imposed upon us by the IMPACT study is being 
rolled out. – Consultant 
 
I think we probably need to bolster, because of PrEP, we need to bolster maybe increase our 
MSM dedicated provision and the chemsex provision will kind of follow that really. Like 
anything, all the sexual health services are really under stress, and this is just one kind of 
high-risk group that we kind of have to assess and look after really and we have a lot of 
sexual exploitation in younger people. We have a lot of trafficking. All these groups are kind 
of competing for intensive kinda health advisor and clinician time. There’s just not enough 
people to go around, so services for all our kind of high-risk groups could be definitely 
increased. – Consultant 
 
Funding was seen as a barrier to providing optimum care for MSM engaging in chemsex. A 
lack of funding was noted as underpinning all other barriers to providing optimum care. This 
was identified as a national problem across sexual health generally, due to funding for sexual 
health services now falling under local authorities, and whether funding would remain in place 
for current services was a concern.  
 
I mean sexual health services around the country have seen major cuts in budgets. We’re no 




on year budget cuts which are actually bigger than they seem because those budget cuts 
come on top of the fact there’s inflation of wage and other inflation so I’m not talking 
specifically about [region], it’s known that that’s a national issue. – Consultant 
 
I don’t know if it’s still going now coz the time, we, [community organisation] were providing 
chemsex support, but I know a while ago their funding was questionable, it was questionable 





Chapter 8: Discussion and reflection of semi-structured interviews with 
service users and service providers 
 
 Qualitative semi-structured interviews with both service users and service providers 
allowed a more detailed investigation into some of the topics from the online survey, as well as 
providing a different perspective of the topic from sexual health service providers. A number 
of themes were identified from service users and service providers, with some of these 
overlapping between the two groups. Themes were identified that supported the research aims 
of investigating health and wellbeing in relation to sexualised drug use, sexual risk behaviour 
whilst engaging in sexualised drug use, and service provision to MSM engaging in sexualised 
drug use. This chapter will discuss the significance of these findings in reference to previous 
research and the objectives for this stage of the programme of research. A conclusion and 
personal reflection on this stage of the programme of research will then be provided. 
 
The relationship between sexualised drug use and chemsex with physical and 
psychological wellbeing 
 
 Both positive and negative impacts on wellbeing were highlighted from service users. 
Positive effects of engaging in sexualised drug use were seen as motivations to engage, such as 
the sexual experience and boosting self-esteem, which has been observed by other research into 
chemsex among MSM (Weatherburn et al., 2017). Additionally, the current study observed 
these motivations in other forms of sexualised drug use among MSM, and service users’ 
motivations for engagement appeared to be primarily sexual regardless of the sexualised drug 
used, with only one service user participant not reporting a sexual motivation. Another positive 
impact noted by service users was the social experience of chemsex, which included the 
conversations had during these experiences and gaining new social connections. Although, two 
participants did report regret over possibly disclosing more information than they would have 
liked to whilst under the influence of drugs.  
 Self-esteem was seen as a positive effect of engagement in chemsex for one service 
user, but a service provider mentioned this as a negative reason for engagement. However, this 
service provider did state that, as a psychotherapist, they would not be seeing these patients 
unless they were experiencing negative psychological effects and wanting to stop. Interestingly, 
this service provider mentioned how they would discuss someone’s life goals in relation to their 




and life goals, and saw how their engagement in chemsex was inhibiting these goals. Some 
participants also stated how their chemsex behaviour was having the unintended consequence 
of negatively affecting their personal relationships and work life, which is consistent with 
previous research regarding MSM and chemsex (Bourne et al., 2015). Therefore, it could be 
that these negative motivations and effects of engaging in sexualised drug use are only negative 
when they are conflicting with someone’s ambitions. It may be that in these instances where 
chemsex is inhibiting someone’s goals and ambitions that service users want to manage or stop 
their sexualised drug use. Service providers should therefore investigate a service user’s 
motivation for engagement and if this appears to be harmful (e.g. loneliness) or contradictory 
to the service user’s goals and ambitions, this may identify a service user who would like further 
care and support. 
 Service providers noted that engaging in sexualised drug use was a variable behaviour, 
ranging from non-problematic use to witnessing service users experiencing negative effects on 
wellbeing. Negative effects tended to be associated with chemsex drug use as opposed to other 
types of sexualised drug use. Although, service providers found the concept of a difference 
between chemsex and other sexualised drug use potentially problematic, possibly due to 
witnessing a wide spectrum of sexualised drug use with wide ranging effects on patients’ health. 
From a service user perspective, for those expressing negative effects on wellbeing, these 
tended to be particularly adverse, with two participants stating they had attempted suicide, both 
of whom were engaging in chemsex. One participant stated his suicide attempt was related to 
his drug use, and another specifically mentioned that both his suicide attempts were during 
comedowns from chemsex drugs. Research that was published after the current study had been 
conducted found that MSM chemsex users recruited from an LGBT drug and alcohol support 
service were less likely to report previous suicidal ideation than those attending for other 
substances (Stevens, Moncrieff, & Gafos, 2020). However, among chemsex users, using 
GHB/GBL or crystal methamphetamine was associated with an increased likelihood of 
previous suicidal ideation, but not for chemsex users using mephedrone (Stevens et al., 2020). 
Additionally, it could be that all MSM seeking help for drug support are at an increased risk of 
suicidal isolation compared to the general population, but further research is needed to 
understand the associations between chemsex, sexualised drug use, and suicidal ideation or 
suicide attempts. 
 A number of participants mentioned overdosing, particularly on GHB/GBL, and one 
participant reported an experience of non-consensual sex whilst unconscious. Some service 




whilst engaging in chemsex, and expressed concern for patients’ ability to maintain consent in 
this situation. Overdosing and sexual assault have been identified as effects of engaging in 
chemsex previously (Bourne et al., 2015), and this supports the finding from The LGBT+ Sex 
and Lifestyles Survey that a higher proportion of MSM engaging in chemsex had experienced 
or were unsure they had experienced non-consensual sexual contact. No participants engaging 
in other sexualised drug use referred to non-consensual sex, which may be due to most people 
engaging in other forms of sexualised drug use with their partner, or because there is a lower 
risk of overdose using these drugs allowing for greater control over maintaining consent. This 
study provides further evidence that service providers need to be aware of the potential for non-
consensual contact among MSM engaging in chemsex. It is positive that service providers in 
this study were aware of this issue and would discuss the issue with service users engaging in 
chemsex.  
 The stigma of living with HIV has been suggested as a motivation for engaging in 
chemsex previously (Weatherburn et al., 2017), and living with HIV was associated with 
engaging in chemsex in bivariate analyses in the previous study. Two out of the thirteen service 
user participants were living with HIV, both of whom were engaging in chemsex and neither 
of these suggested that their HIV status influenced their sexualised drug use. Service users 
discussed ways they managed their sexual risk, and for those who were living with HIV and on 
ART medication as well as those taking PrEP, engaging in chemsex did not influence adherence. 
Service providers were also confident in the effectiveness of PrEP and how engagement in 
chemsex would not influence adherence. Previous research has found that injecting drug use 
among MSM living with HIV was associated with poorer ART medication adherence 
(Daskalopoulou et al., 2014); however, the service users living with HIV in the current study 
appeared to have routines and strategies to manage their adherence whilst engaging in chemsex. 
Service providers also discussed even if there were concerns with regarding adherence whilst 
engaging in chemsex, they would attempt to find strategies to improve this. Similar to service 
users’ self-reported adherence to PrEP whilst engaging in chemsex in this study, research that 
was published after the current study was conducted found no difference in adherence to PrEP 
between MSM engaging in chemsex and those not (O'Halloran et al., 2019).  
 Multiple findings suggested there was a social coercion and social capital among MSM 
(Kawachi & Berkman, 2000). This was evident from service users discussing the sharing of 
PrEP and protecting MSM who overdose from sexual assault, as well as from service providers 
suggesting MSM were sharing knowledge of how to protect each other and looking after one 




HIV prevention, and PrEP (Grover et al., 2016; Zarwell, Ransome, Barak, Gruber, & Robinson, 
2019), and was utilised by service providers in this study in disseminating knowledge about 
drug harms and safer drug use. However, further research is needed to understand how social 
coercion and social capital exists in the context of chemsex, and how this can be used to develop 
health promotion and harm reduction strategies.  
 Service users discussed the public perception of chemsex and how these perceptions are 
often negative due to negative opinions of gay sex and drug users. The joining of two 
stigmatised behaviours was suggested to compound the stigma surrounding chemsex in society. 
Two participants discussed the narrative that the effects of chemsex is on a par with the AIDS 
epidemic in the 1980s, in relation to lots of the MSM community dying due to a pandemic 
where there was little knowledge or understanding. One participant objected to this narrative, 
discussing how harmful this narrative could be, while another participant stated this was 
reflective of their experiences of losing friends to chemsex related overdoses and suicides. 
When considering sexualised drug use and specifically chemsex as a spectrum, it may be that 
both participants have these opinions due to different experiences and positions on this 
spectrum. Previous research has suggested that chemsex is a highly variable experience (Bourne 
et al., 2015), which was also suggested by service providers in this research. Although stigma 
around certain behaviours can be a barrier to care for some (Wakeman & Rich, 2018), service 
providers did not appear to hold stigmatising opinions, and instead offered a non-judgemental, 
harm reduction approach (Lenton & Single, 1998), which should be utilised by all service 
providers engaging with this group. 
 
The Theory of Planned Behaviour (Ajzen, 1991) in relation to condom use intentions and 
behaviour in relation to sexualised drug use 
 
 The Theory of Planned Behaviour (Ajzen, 1991) was used to investigate whether an 
intention-behaviour gap existed between intention to use condoms when not under the influence 
of drugs and condom use behaviour whilst engaging in sexualised drug use. However, due to 
most participants reporting consistent condom use intention and behaviour, with the majority 
of these participants not intending to use condoms, this investigation was not possible. Two 
participants did mention social norms related to condom use at chemsex parties, with one 
service user suggesting that the social norm of not using condoms may have influenced their 
condom use behaviour over time. Alternatively, another service user stated the social norm did 




condom use. Therefore, similar to previous research regarding condom use among MSM 
generally (Andrew et al., 2016), the Theory of Planned Behaviour (Ajzen, 1991) may help 
explain condom use behaviour among MSM whilst engaging in sexualised drug use, but a larger 
quantitative study would be needed. It may be that attitudes, subjective norms, and perceived 
behavioural control influence intention with regards to condom use, and therefore this is more 
influential than a potential gap between intention and behaviour. Because service users’ 
intentions to not use condoms appeared cemented, it may be that by addressing attitudes, 
subjective norms, and perceived behavioural control, this can influence intention and behaviour 
regarding condom use. Service users who were not using condoms appeared to have strong 
attitudes towards not using condoms and the service user who reported using condom use during 
group sex had strong attitudes and perceived behavioural control towards using condoms. This 
gives some support towards the Theory of Planned Behaviour (Ajzen, 1991) with regards to 
explaining condom use among MSM engaging in sexualised drug use, but components of the 
theory beyond intention and behaviour need to be explored. 
 Service users who engaged in other types of sexualised drug use (cocaine, poppers) and 
were in an exclusive relationship did not intend to use condoms. This is understandable in 
relation to the reduced sexual risk compared to those engaging in condomless anal intercourse 
with multiple partners whilst engaging in chemsex. It therefore appears that those engaging in 
chemsex were at greater sexual risk due to an intention not to use condoms with a much larger 
number of sexual partners. Whilst there may be some level of sexual risk with regards to the 
potential for infidelity and therefore transmission of STIs, it may be ethically questionable to 
try to change this specific attitude towards condom use, as it involves implying that a person 
should question their partner’s sexual commitment. Therefore, if the Theory of Planned 
Behaviour (Ajzen, 1991) is to be explored further with regards to other types of sexualised drug 
use in addition to chemsex, researching this behaviour specifically among single MSM or those 
in a non-monogamous relationship may be more appropriate. This will allow for a greater 
investigation into different attitudes that may influence condom use intention in relation to 
sexualised drug use. Although the Theory of Planned Behaviour (Ajzen, 1991) has been 
demonstrated to best explain condom use compared to the Socio-Cognitive model (Bandura, 
1994) and Information-Motivation-Behavioural skills model (Fisher, Fisher, Misovich, Kimble, 
& Malloy, 1996) among young people (Espada, Morales, Guillén-Riquelme, Ballester, & 
Orgilés, 2016), these models may better explain condom use in relation to sexualised drug use 
among MSM, but further research would be needed to determine this. However, the usefulness 




are available for HIV prevention. Additionally, The LGBT+ Sex and Lifestyles survey found 
that MSM engaging in sexualised drug use were more likely to attend for sexual health care, 
which would reduce onward transmission of STIs. Therefore, attempting to change condom 
behaviour may be less effective as a health promotion strategy, compared to encouraging the 
use of PrEP and PEP, as well as regular STI screening in this population. 
 Condoms were seen as just one sexual health protection tool to be utilised and service 
providers discussed utilising all methods available to reduce sexual risk among MSM engaging 
in chemsex, such as vaccinations, PrEP, regular screening, and condoms. This approach 
therefore provides the patient with the best possible level of care. Research has been conducted 
with regards to intentions to these other methods of reducing sexual risk among MSM, such as 
PrEP (Goedel, Mayer, Mimiaga, & Duncan, 2019; Jaspal, Lopes, Bayley, & Papaloukas, 2019), 
HPV vaccination (Marra et al., 2016), and sexual health screening behaviour (Horvath, 
Lammert, Danh, & Mitchell, 2019). Therefore, understanding intentions towards sexual health 
behaviours among MSM remains an important research consideration when attempting to 
understand and influence sexual health behaviour in this group, and should continue to be 
investigated in the context of sexualised drug use. 
 
Service provision for MSM engaging in sexualised drug use 
  
  Research has previously suggested that MSM who engage in chemsex would prefer 
drug services within sexual health clinics as opposed to traditional drug services (Deimel et al., 
2016; Glynn et al., 2018). All sexual health services in this study mentioned providing MSM 
clinics as an opportunity to discuss sexualised drug use and chemsex, with some services 
running specific chemsex clinics. When deliberating the need for a specific chemsex service, 
service providers considered whether there would be a local need. When a desire to expand 
services was expressed, numerous barriers such as finances, competing resources, and capacity 
were commonly reported. One service user mentioned using a specific chemsex clinic and how 
they found the service useful, in terms of moderating and supporting their chemsex behaviour 
when needed.  
 Most service users had positive experiences of sexual health services generally, 
complementing staff and the treatment they received. The most common complaint among 
service users was access and service providers also noted accessibility as a barrier to care. One 




research has found that MSM who have used HIV self-testing services reported it reduced 
barriers relating to convenience (Witzel et al., 2019). Therefore, more modern means of testing 
may help reduce this accessibility barrier, although further research is needed (Wellings, Mehl, 
& Free, 2017). Additionally, both service users and service providers noted funding strains on 
sexual health services, which may hinder any potential service development. It was interesting 
that service users were aware of issues regarding funding of sexual health services, suggesting 
that service users may be feeling the impact of these funding constraints, or these service users 
may have been aware of the funding issues because they were reported on by the media.  
 Some service users mentioned seeking support from community organisations and 
highlighted a lack of access to appropriate healthcare services, particularly mental health 
services. Poor access to NHS mental health services has been reported across the UK (Care 
Quality Commission, 2019). Therefore, the findings from the current study are likely to be 
reflective of a lack of access generally, rather than being specific to those seeking support for 
sexualised drug use. To help those that may have experienced more negative impacts of 
sexualised drug use, service providers mentioned signposting participants to available services, 
offering the opportunity to discuss and give advice during consultations, and referring into both 
internal and external services. Both service users and service providers noted some internal and 
external services as having long waiting lists, which is a barrier to care at a time when people 
may be particularly vulnerable. Therefore, existing services may need to be expanded to cope 
with demand, but this may not be possible due to the existing funding constraints on sexual 
health services (BASHH/BHIVA, 2018). 
 Whilst a definition of what drugs constitute chemsex is needed for quantitative research, 
specifying particular drugs in a clinical setting may be a barrier to services for MSM not using 
the ‘four chems’ (crystal methamphetamine, GHB/GBL, ketamine, mephedrone) (Schmidt et 
al., 2016). Service providers highlighted issues with visualising chemsex users as a 
homogenous group. Additionally, two service users stated using cocaine for sex and self-
identified as engaging in chemsex, one of whom stated going to chemsex parties and having 
sex with multiple partners, but would not have been included in the ‘four chems’ definition 
despite engaging in some of the risk behaviours associated with chemsex (e.g. group sex). One 
service provider highlighted a potential problem of defining chemsex as a behaviour exclusive 
to MSM, as they recalled a heterosexual woman with problems related to GHB/GBL use but 
could not access support because these are specific to MSM. This highlights that, even if 
chemsex is more prevalent among the MSM community, other groups may engage in this 




in a clinical setting may need to be more loosely defined, so that it is not a barrier to those 
engaging in other forms of sexualised drug use with a similar level of sexual risk. 
 Whilst the service providers in this study, as well as previous research with MSM 
(Weatherburn et al., 2017), has highlighted internalised homophobia as a possible motivation 
for engagement in chemsex for some, service providers would often contextualise this statement 
by discussing the variability of chemsex, and how from their experience, sexualised drug use 
does appear to be a wide-ranging spectrum of behaviour. One participant discussed the narrative 
around chemsex being related to internalised homophobia, and argued against this being the 
reason that people engage. It was highlighted how relating chemsex to internalised homophobia 
could potentially be a barrier to seeking care for some, as people who do not identify as 
experiencing internalised homophobia but engage in chemsex may question their validity for 
such help. One service user stated they had a negative experience of seeking help for drug use 
unrelated to sexualised drug use through sexual health services, where the practitioner’s 
expectations of MSM with ‘problematic’ drug use was off-putting. The practitioner’s 
expectation that MSM experiencing problematic drug use must have experienced problems 
relating to their sexuality was enough to make this particular service user question his validity 
for help in this instance. The service user then discussed how this could be a barrier for him 
seeking help in the future, after describing himself as a possible barrier to future help due to 
talking himself out of needing support. This service user then went on to discuss other stigmas 
surrounding chemsex, including the combination of drug stigma and gay sex stigma. It is 
possible that other stigmas, such as the stigma surrounding polygamy and non-monogamy 
(Frank, 2019; Moors, 2019), which is in itself linked to same-sex sexual stigma for men (Herek, 
2004), and the stigma and marginalisation of people who use drugs (Room, 2005), all interact 
in the case of chemsex and sexualised drug use resulting in a highly stigmatised behaviour by 
different means. Ensuring service providers have the perception that sexualised drug use and 
chemsex is a variable behaviour, with variable motivations for engagement, could avoid 
potentially stigmatising patients resulting in avoidance of future care. 
 
Strengths and limitations 
 
 To the author’s knowledge, this is the first attempt to understand and compare both 
service users’ and service providers’ perspectives on sexualised drug use and chemsex. 




holistic understanding that contextualised some of the issues raised by service users. As the 
majority of research regarding chemsex among MSM has been conducted in London (Bourne 
et al., 2014; Ottaway, Finnerty, Amlani, et al., 2017), it is a strength to have a regional 
comparison within the UK, given the lack of generalisability in qualitative research. However, 
due to issues with service user recruitment, it was not possible to completely match 
geographical locations of service providers and service users. Additionally, most service user 
participants were recruited via the online survey, which had a sample that was majority white 
ethnicity, and therefore this may reflect the qualitative service user participants being mostly 
white as well (n=12/13). Although it was assumed data from service users was approaching 
saturation, it is unclear how much additional information could have been gained by recruiting 
service users from all locations where service providers were recruited from.  
 In principle, involving community organisations to aid with recruitment was a good idea 
but proved difficult in practice for this study. The Liverpool-based chemsex organisation that 
was involved in The LGBT+ Sex and Lifestyles Survey had been integrated into a sexual health 
clinic, meaning they could not be used without NHS ethics for patients. Additionally, the other 
Merseyside-based LGBT organisation also came under the NHS, and was therefore inaccessible 
without NHS ethics. Due to time constraints on the project, it was not deemed realistic to 
attempt to gain NHS ethics for access to patients. Community organisations in the other 
locations that NHS staff were recruited from were contacted to be involved, but this was also 
unsuccessful apart from Manchester, where LGBT Foundation who run a chemsex support 
group agreed to help. Although, the additional recruitment from this organisation was not as 
successful as desired. The majority of service user participants were therefore recruited using 
the call for participants from previous online survey. However, the question regarding interest 
in future research was limited to those based in the North West of England, and in hindsight, 
this should have been national, but at the time it was expected that the qualitative stage would 
only take place locally. 
 Interviews with service user participants were conducted via telephone, Skype, and 
face-to-face. Whilst providing interviews face-to-face would have been optimal to minimize 
any technical or communication difficulties, utilising other methods allowed interviews to be 
conducted more conveniently to participants and provide an extra layer of confidentiality to 
service user participants. There were some moments that were inaudible when conducting 
telephone and skype interviews, but equally there were inaudible moments when conducting 
interviews face-to-face. Therefore, it is unlikely that the utilisation of different interview 




face-to-face, but this was not possible due to NHS Health Research Authority guidelines. 
Although some questions had to be modified due to this change in interview methods, this may 
have actually aided recruitment, as it increased accessibility for service providers who were 
experiencing heavy workloads.  
 As with other research, it cannot be overlooked that the findings may reflect a self-
selection bias. Both service users who were currently engaging in sexualised drug use and 
service users who had stopped engaging in sexualised drug use were recruited in an attempt to 
provide multiple narratives and experiences. It is still possible that those that wanted to voice 
positive or negative experiences were more likely to volunteer for recruitment, but as with all 
qualitative research, the aim was to explore people’s experiences of sexualised drug use and 
chemsex, rather than focusing on the representativeness of these viewpoints. Self-selection bias 
is a possibility for service provider responses, but due to participants discussing their day-to-
day work life, which is not necessarily a personal topic, this may reduce this risk somewhat. 
Service provider interviews were combined with another project regarding PrEP to potentially 
aid recruitment and reduce time taken away from work for potential service provider 
participants. However, discussing PrEP first may have framed some of the responses for 
sexualised drug use and chemsex, with service providers potentially overlooking experiences 
of MSM living with HIV and engaging in chemsex. Although, having two topics of discussion 
may have aided recruitment, as this could have resulted in participants who were more 
interested in the PrEP part of the interview, but still provided a perspective on sexualised drug 




 Sexualised drug use and chemsex among MSM is a wide-ranging behaviour, as 
demonstrated by MSM service users, and this was also the opinion held by service providers. 
Sexual health providers appeared to be delivering a high-level of care for MSM engaging in 
sexualised drug use under the current constraints placed upon them. Although it can be seen as 
a positive that community organisations were being utilised when needed, certain barriers to 
care still remained and service providers expressed a desire to improve services. For service 
users who were engaging in sexualised drug use and were content with their drug use, sexual 
health services provided an opportunity to reduce possible harms associated with this 




not necessarily reflective of sexual health services, but possibly reflective of poorer quality of 
care across other health disciplines such as mental health. To improve the quality of care for 
MSM engaging in sexualised drug use, not only does funding for current services need to be 
maintained and possibly increased in places, but funding for health services where these MSM 
may come into contact, such as A&E departments and mental health services, may also need to 




 The lack of anonymity between the researcher and the participant in qualitative research 
was something I had not yet experienced when conducting research, and it is natural that 
personal opinions formed. This meant that during analysis, whilst I had committed to setting 
aside my own bias and opinions, these thoughts were apparent when taking what participants 
stated at face value. For example, one participant reported engaging in chemsex had boosted 
his self-esteem, and whilst I questioned the positivity of this notion myself (using drugs and sex 
to develop self-esteem), the participant’s point of view and interpretation was maintained 
during the analysis and reporting of findings. One participant in particular had stated his 
pseudonym associated with a fictitious career when taking part in research to protect his 
anonymity. However, the participant would refer to this fictitious career in relation to some of 
his responses. This left me wondering how much truth I could ultimately take from these 
experiences. Therefore, I decided to not include any information with regards to his career in 
the analyses, and it is highly likely this information would not have been included anyway due 
to confidentiality.  
 Negativity bias is a bias in all human experiences where negative events, feelings, and 
traits are given more weight than their positive equivalents (Rozin & Royzman, 2001). I found 
my own negativity bias present when analysing and writing up my research, because two 
participants stated attempting suicide and that drew more focus than those discussing the 
positive elements of sexualised drug use. To overcome this, it was important that those 
expressing positive aspects of sexualised drug use had their experiences heard also, and I had 
to make a conscious effort to make sure an equal platform was given to both of these 
perspectives.  
 Combining the service provider questions with another project appeared to be successful 




responses to the chemsex and sexualised drug use questions somewhat, because starting with 
questions regarding PrEP first potentially narrowed the frame for discussing sexualised drug 
use and chemsex to men who were not living with HIV. In addition, service provider 
participants who maybe agreed to take part more to give opinions on PrEP kept referring to 
back to previous PrEP questions during the chemsex and sexualised drug use questions, which 
was frustrating. Whilst I tried to keep participants on track by referring back to the chemsex 
questions, some participants kept adding information with regards to PrEP. That being said 
some participants did discuss MSM living with HIV engaging in chemsex and sexualised drug 
use, and therefore this may be more reflective of my frustration in the moment, rather than a 
true reflection of the data collected.  
 As stated in my personal reflection on The LGBT+ Sex and Lifestyles Survey, before 
starting this research I was of the opinion that MSM engaging in chemsex were doing so 
because of internalised homophobia and were unhappy doing so. The LGBT+ Sex and 
Lifestyles Survey did not find any evidence of this association between chemsex and 
internalised homophobia, and this investigation contextualised how harmful this narrative can 
actually be, given that one participant reported how a practitioner who expressed this opinion 
made him question his validity for help. Therefore, this research has made me question the 
assumptions I make and how trying to pigeonhole an experience into a narrative can be harmful 
to those needing help and support. That being said, although this was a narrative I believed 
before conducting this research, I have been able to reject this narrative when finding 
contrasting evidence. 
 Due to the sensitive nature of this topic, it was expected that emotional topics would be 
discussed that may be distressing to the participant. Whilst appropriate ethical approval was 
gained and participants were referred to support organisations if needed, it took me by surprise 
that the only time a participant displayed distress was when they were discussing how they felt 
lonely and isolated in general. When this happened, I highlighted the appropriate organisations 
available that this person may contact for further help and support. Reflecting on this experience 
made me realise the role of the researcher is to be a bystander while participants are discussing 
these issues, and just talking about these feelings could have been cathartic for the participant. 
It was not my job to counsel or provide emotional support to this participant, but to simply refer 
to an appropriate place they can get that support if needed. I was therefore confident my ethical 




Chapter 9: Discussion and triangulation of findings 
 
This programme of research has made several novel contributions to research and 
knowledge on the subject of sexualised drug use among LGBT people. In this chapter, the 
findings from all three studies (systematic review (Study 1), cross-sectional online survey 
(Study 2), semi-structured qualitative interviews (Study 3)) will be triangulated and discussed 
in relation to the research aims and objectives. This chapter will also outline the strengths and 
limitations of the programme of research as a whole and discuss the novel contributions this 
programme of research has made. Recommendations for future research will be highlighted and 
personal reflection on the programme of research will be provided. Finally, overall conclusions 
and a summary of this programme of research will be given. 
 
Triangulation of findings 
 
 Triangulation is the method of combining findings from numerous data sets that utilise 
different methods to answer research questions that were underpinning the programme of 
research (Flick, 2018). Triangulation was historically used for combining different qualitative 
studies, but has also been used to combine mixed methods research (Denzin, 2012). Whilst it 
has been questioned whether the ‘languages’ of both quantitative and qualitative studies can be 
effectively combined (Creswell, 2011), and although the combination of mixed methods 
findings can be difficult and time consuming, this process can add greater breadth and 
understanding to a particular research topic (Almalki, 2016). To effectively triangulate the 
findings from the three studies, it is important to contextualise this process with the aims and 
objectives of this programme of research, and consider which studies relate to each particular 
objective. The aim of this programme of research was to investigate sexualised drug use among 
LGBT people, with a particular focus on reasons for engagement, as well as the potential impact 
on physical health and psychological wellbeing. 
 
The objectives for this programme of research were:  
 
1. To investigate the occurrence of general sexualised drug use in the context of chemsex 




2. To measure quantitatively the psychological reasons as to why some MSM engage in 
chemsex and/or sexualised drug use, and also investigate possible reasons for 
engagement in the wider LGBT community (Study 2).  
3. To understand what potential impact engaging in sexualised drug use has in terms of 
sexual and physical health, and psychological wellbeing (Study 1, 2, and 3).  
4. To investigate what services are currently available for LGBT people engaging in 
sexualised drug use and what service development is needed. (Study 3). 
 
 The third objective was the only objective to span across all three studies in this 
programme of research. Nevertheless, due to the QUAN→qual design of this programme of 
research, the triangulation of findings across the three studies in the context of all the objectives 
may reveal findings that were not expected and support additional objectives. A criticism of the 
triangulation process is that it has been previously conducted with a lack of transparency 
(Farmer et al., 2006). Therefore, in the interest of transparency, a triangulation protocol using 
Farmer et al.’s (2006) method was created before the process began and can be seen in Table 
16. The triangulation protocol by Farmer et al. (2006) was designed for different types of 
qualitative research with multiple researchers. Therefore, this protocol was adapted for the 
current programme of research to combine quantitative and qualitative research by one 
researcher (i.e. removal of the researcher comparison and feedback stages). Initially, each study 
was reviewed in sequence for key themes. Each discussion section was systematically analysed 
for findings and these findings were then noted. Where themes of findings appeared to be 
similar across studies, an appropriate title was given to the theme that encompassed the findings. 
Table 17 describes each theme across the three studies, which studies the theme is present in, 
and the degree of convergence coding within the theme. An assessment of convergence across 
all themes was outlined, and how each theme relates to the research objectives will be discussed. 
 The majority of themes identified had agreement with another study (n=8/15), meaning 
the findings from each study were consistent in relation to the theme. Additionally, four themes 
had partial agreement across study findings, implying that there was some agreement on 
findings between the studies but some components of the findings did not agree. Three themes 
were coded as silence, indicating these findings were only present in one study. This is not 
surprising as some objectives were specific to one study in the programme of research, and due 
to the differences in design of the studies, some objectives could not translate across studies 
(i.e. an international systematic review was possible in Study 1, but Study 2 and 3 were national 




agreement (n=12/15). Three themes were unique to one study (silence) and no themes 
demonstrated dissonance. It can therefore be concluded that, globally, there was a high level of 
agreement across studies in relation to themes. Each theme was then grouped in relation to one 
of the four objectives and discussed in relation to that objective, and how this contributed to the 
overall findings from the programme of research. 
 
Table 16. Triangulation protocol adapted from Farmer et al. (2006). 
Step Activity 
1. Sorting Findings from each study in the research programme will be revisited and 
sorted into themes of similar content to determine overlap and divergence. 
Findings that only occurred in one study will also be highlighted.  
2. Convergence 
coding 
The degree of convergence among the findings from the studies will be 
assessed using Fisher et al.’s (2006) criteria: agreement (full agreement 
between findings from studies); partial agreement (agreement on some but 
not all components of findings); silence (where the theme is covered in one 
study but not others); and dissonance (disagreement between the studies on 
all components of the findings). It should be noted that studies were silent 
on some themes due to the design of the study meaning that investigation of 









Assess where studies provide unique findings and how this relates to the 





Table 17. Triangulation matrix for findings themes across the programme of research. 
Theme 
Present in study 
Findings 
Convergence 
coding 1 2 3 
MSM, WSW, and trans 
people engage in 
sexualised drug use 
  
Yes Yes Yes 
Study 1: Only findings from MSM and trans women engaging in sexualised drug use were included in the 
systematic review results; however, the systematic review search found articles that recorded sexualised 
drug use among WSW but they did not meet the inclusion/exclusion criteria. 
Study 2: A proportion of MSM, WSW, and trans people reported engaging in sexualised drug use (41%, 
17% and 21% respectively) and chemsex (6%, 0.6%, and 1% respectively). 
Study 3: MSM engaging in sexualised drug use were recruited to take part in semi-structured interviews 
but no WSW or trans people were recruited. 
Partial 
agreement 
Sexualised drug use and 
chemsex among MSM 
and trans women has been 
researched internationally 
Yes No No 
Study 1: Sexualised drug use had been measured in 53 countries among studies including MSM and trans 
women. 
Silence 
Defining what constitutes 
chemsex is difficult 
Yes Yes Yes 
Study 1: The definition of chemsex varied across studies, but crystal methamphetamine and GHB/GBL 
were common to all definitions of chemsex. 
Study 2: There was a high level of poly-drug use among MSM engaging in chemsex, making a clear 
definition difficult. 
Study 3: Two service user participants who took cocaine before sex self-identified as engaging in 
chemsex, and clinicians noted variability in the drugs used for chemsex.  
Agreement 
Sexualised drug use and 
chemsex is associated 
with sexual risk among 
MSM 
Yes Yes Yes 
Study 1: In meta-analyses, sexualised drug use (poppers/chemsex) was associated with STIs and 
condomless anal intercourse. 
Study 2: Engaging in sexualised drug use was associated with recent STI diagnosis and a higher number 
of condomless anal intercourse partners in the multivariable analysis, and engaging in chemsex was 
associated with a greater likelihood of recent STI diagnosis and a higher number of condomless anal 
intercourse partners in multivariable analyses. 
Study 3: The majority of service user participants, all of whom engaged in sexualised drug use, did not 
intend to use condoms and this was consistent with their behaviour. 
Agreement 
Chemsex may be 
associated with greater 
sexual risk than other 
forms of sexualised drug 
use 
 
Yes Yes Yes 
Study 1: In meta-analyses, chemsex drug use was generally associated with greater odds of living with 
HIV, having an STI, and engaging in condomless anal intercourse than other drugs used. 
Study 2: Engaging in chemsex was associated with a greater likelihood of recent STI diagnosis and a 
higher number of condomless anal intercourse partners in multivariable analyses. 
Study 3: When service users discussed condom use, those engaging in other types of sexualised drug use 
(i.e. poppers/cocaine) were either engaging in condomless sex in exclusive relationships or using condoms, 





Sexualised drug use and 
chemsex among MSM is 
associated with living 
with HIV 
Yes Yes Yes 
Study 1: Meta-analyses revealed a consistent association between (sexualised) drug use and living with 
HIV among MSM, regardless of the drug used. 
Study 2: MSM who engaged in sexualised drug use were more likely to be living with HIV than those 
who did not (8% vs 2%). MSM who engaged in chemsex were more likely to be living with HIV than 
those who engaged in other sexualised drug use (20% vs. 6%). 
Study 3: Two of the thirteen service user participants (15%) were living with HIV, both of whom had 
engaged in chemsex (n=2/5, 40%). 
Agreement 
Engaging in sexualised 
drug use and chemsex 
may be associated with 
taking PrEP among MSM 
No Yes Yes 
Study 2: Those engaging in chemsex were significantly more likely to report currently taking PrEP than 
those who engaged in other types of sexualised drug use (21% vs. 9%) in bivariate analyses, and taking 
PrEP was significantly associated with event-level condom use. Event-level condom use was associated 
with taking PrEP for MSM engaging in sex under the influence of alcohol or cannabis, as well as taking 
poppers or EDD immediately before or during sex. 
Study 3: Three service user participants reported taking PrEP, all of whom engaged in chemsex, and 
service providers mentioned discussing PrEP to anyone who was engaging in chemsex. 
Agreement 
People engage in 
sexualised drug use to 
help facilitate the sexual 
experience 
No Yes Yes 
Study 2: MSM who engaged in chemsex and other sexualised drug use were more likely to report doing 
so to have sex for longer and because of the intense experience than MSM who had sex under the influence 
of alcohol. WSW and trans people who engaged in intentional sexualised drug use were more likely to 
report doing so to have sex for longer and the intense sexual experience compared to those who had sex 
under the influence of cannabis or alcohol. 
Study 3: The main motivation for engaging in sexualised drug use among MSM service user participants 
(n=12/13) was to facilitate the sexual experience, which included enhancement, prolonging the experience, 
and sexual experimentation.  
Agreement 
Internalised homophobia 
is not a motivation for 
engaging in sexualised 
drug use 
No Yes Yes 
Study 2: Internalised homophobia was not associated with engagement in sexualised drug use or chemsex 
among MSM, and was not associated with sexualised drug use among WSW. 
Study 3: Service users did not express internalised homophobia as a motivation for sexualised drug use 
or chemsex, with one participant expressing frustration that this is an assumption of MSM who engage in 
chemsex. Some service providers did note that they had witnessed MSM engaging in chemsex who did 
have internalised homophobia, but this was often contextualised with an understanding that a wide 
spectrum of MSM engage in chemsex. 
Partial 
agreement 
There can be negative 
psychological associations 
with chemsex and 
sexualised drug use 
No Yes Yes 
Study 2: Engaging in sexualised drug use among MSM was associated with lower life satisfaction 
compared those who did not engage in sexualised drug use. Among WSW, engaging in sexualised drug 
use was associated with very high psychological distress at the bivariate level 
Study 3: Two MSM engaging in chemsex reported having attempted suicide in relation to their drug use. 
Other MSM acknowledged psychological impacts of engaging in sexualised drug use. Service providers 





Poorer perceived health 
may be associated with 
sexualised drug use 
No Yes Yes 
Study 2: Engaging in sexualised drug use among MSM was associated with poorer perceived health, 
which could relate to mental, sexual, or physical health. Poorer perceived health was associated with 
sexualised drug use among WSW compared to those engaging in drug use, and poorer perceived health 
was significantly associated with sexualised drug use compared to drug use in the multivariable analysis 
among trans people. 
Study 3: Some service user participants discussed the impact sexualised drug use, in particular chemsex, 
had on their sexual and their mental health. 
Partial 
agreement 
People engaging in drug 
use and sexualised drug 
use may experience 
sexual contact without 
consent 
No Yes Yes 
Study 2: 53% of MSM and 56% of WSW who experienced sexual contact without consent in the past 12 
months had engaged in sexualised drug use, which was significant in bivariate analyses. Trans people who 
had engaged in drug use were more likely to report experiencing sexual contact without consent than those 
who had not engaged in drug use. 
Study 3: One service user participant described their experience of sexual contact without consent whilst 
engaging in chemsex. Service providers mentioned concern about someone’s ability to maintain consent 
when engaging in chemsex, and described consultations where they had observed this among MSM 
patients engaging in chemsex. 
Partial 
agreement 
Sexual health clinics can 
play a role in service 
provision for people 
engaging in sexualised 
drug use 
No Yes Yes 
Study 2: Attending a GUM clinic in the past 12 months was significantly associated with sexualised drug 
use among MSM and trans people in multivariable analyses. Attending a GUM clinic was significantly 
associated with sexualised drug use at the bivariate level among WSW.  
Study 3: Service user participants mentioned using sexual health clinics as a source of support for 
sexualised drug use, and service providers discussed running specialised clinics for MSM engaging in 
chemsex. 
Agreement 
Engaging in chemsex did 
not affect MSM’s 
adherence to PrEP or 
ART medication 
No No Yes 
Study 3: Service users who were taking PrEP or on ART medication stated they adhered to their 
medication when engaging in chemsex, and some service providers mentioned whilst this may be a concern 
among MSM taking PrEP and engaging in chemsex, the effectiveness of PrEP could allow for a couple of 
treatments being missed if taken daily. 
Silence 
Barriers to effective care 
exist for MSM engaging 
in sexualised drug use 
No No Yes 
Study 3: Both service users and service providers highlighted a number of barriers to care for sexualised 
drug use, which included barriers to sexual health clinics, but also barriers to other aspects of healthcare 







Objective 1: To investigate the occurrence of general sexualised drug use in the context of 
chemsex among MSM and the wider LGBT community 
 
Previous research regarding sexualised drug use among LGBT people has mostly 
focused on MSM (Halkitis et al., 2001; Schmidt et al., 2016; Stall & Purcell, 2000), which is 
understandable in terms of associated sexual risks. However, sexualised drug use had also been 
previously observed among WSW (Mooney-Somers et al., 2018), and trans women (Hoffman, 
2014; Reback & Fletcher, 2014), but much less is known among these populations with regards 
to associations with sexualised drug use compared to MSM. The themes related to Objective 1 
and the level of agreement across studies can be seen in Table 18.  
 
Table 18. Triangulation themes related to Objective 1 and level of agreement, partial agreement, 
dissonance and silence across the studies. 
Theme Study 1 Study 2 Study 3 
MSM, WSW, and trans people engage in 
sexualised drug use Agreement Agreement 
Partial 
agreement 
Sexualised drug use and chemsex among 
MSM and trans women has been researched 
internationally 
Agreement Silence Silence 
Defining what constitutes chemsex is 
difficult 
Agreement Silence Agreement 
 
Study 1 and 2 found sexualised drug use among MSM, WSW, and trans people. In the 
systematic review, whilst studies investigating MSM and trans women met the inclusion and 
exclusion criteria, studies researching sexualised drug use among WSW found during the search 
strategy did not. The online questionnaire observed sexualised drug use among MSM and WSW, 
in addition to observing sexualised drug use among all trans people, not just trans women. The 
qualitative interviews with service users were only conducted among MSM, and therefore this 
study only partially agreed with the finding that MSM, WSW, and trans people engage in 
sexualised drug use.  
Study 1 found that sexualised drug use was observed internationally among MSM and 
trans women, and because Study 2 and Study 3 were conducted in the UK, the latter two studies 
were coded as silence regarding this theme. However, the national design of Studies 2 and 3 
meant that that this finding could not be addressed. Despite only being observed in Study 1, 




referred to as a behaviour that occurs in and is predominantly researched in Western countries, 
when sexualised drug use and chemsex are behaviours that occur internationally (Bourne, 2012). 
Whilst attempting to understand the possible implications of engaging in sexualised 
drug use and chemsex, it became clear that defining chemsex within sexualised drug use is quite 
difficult. In Study 1, the drugs included in a study’s definition of chemsex varied, with only 
crystal methamphetamine and GHB/GBL included in all definitions. Study 2 found that MSM 
engaging in chemsex were more likely to report polydrug use than those engaging in other 
forms of sexualised drug use, thereby making a clear definition of what substances are more 
associated with chemsex difficult. In Study 3, two service user participants stated using cocaine 
and self-identified as engaging in chemsex, one of whom was engaging in group sex, which has 
also been associated with chemsex. Also, service provider participants acknowledged that there 
is variation within MSM with regards to drug use, and therefore categorising this complex 
behaviour is difficult.  
 
Objective 2: To measure quantitatively the psychological reasons as to why some MSM engage 
in chemsex and/or sexualised drug use, and also investigate possible reasons for engagement 
in the wider LGBT community  
 
 Motivations for engaging in sexualised drug use have emerged from both quantitative 
and qualitative research (Glynn et al., 2018; Weatherburn et al., 2017), with the sexual 
experience being a motivator identified in both types of research. Qualitative interviews have 
suggested more psychological motivations with regards to reasons for engaging in chemsex 
among MSM. Because sexualised drug use research had largely neglected WSW and trans 
people, research regarding any possible psychological associations with engaging in sexualised 
drug use among these groups is relatively unknown. Due to the finding from Study 2 that WSW 
and trans people do engage in sexualised drug use, psychological reasons for engagement could 
be investigated in these groups. The themes related to Objective 2 and the level of agreement 
with these themes across the studies can be seen in Table 19. Study 1 was silent on both themes 
relating to Objective 2, as investigating associated motivations for chemsex and sexualised drug 
use was not the aim of the systematic review.  
 Studies 2 and 3 found that people engage in sexualised drug use to help facilitate the 
sexual experience. In Study 2, this was evident by the high proportion of MSM who stated they 
engaged in chemsex to prolong the sexual experience (72%) and to have sex for longer (58%). 




prolong the sexual experience, and one quarter reported doing so to have sex for longer, which 
were both significantly more than MSM engaging in sex under the influence of alcohol. Whilst 
these motivations had been previously established among MSM engaging in chemsex (Glynn 
et al., 2018; Weatherburn et al., 2017), Study 2 highlighted that these are also motivations for 
other types of sexualised drug use among MSM. Furthermore, motivations for intentional 
sexualised drug use could be investigated among WSW and trans people in Study 2, showing 
similar findings that people engaging in sexualised drug use were more likely to do so because 
of the intense sexual experience and to prolong the sexual experience. The proportion of trans 
people reporting these motivations for intentional sexualised drug use were similar to MSM 
(61% intense experience; 26% sex for longer). A smaller proportion of WSW reported these 
motivations (29% intense experience; 12% sex for longer), but in both trans and WSW analyses 
these motivations were still significantly greater than those who reported sex under the 
influence of alcohol or cannabis. A theme that emerged in Study 3 was the sexual motivation 
for sexualised drug use among service users and revealed that in addition to prolonging and 
enhancing the sexual experience, sexual experimentation was also a motivation for engaging in 
sexualised drug use. All but one participant identified at least one sexual motivation for 
engaging in sexualised drug use, and therefore both Study 2 and 3 collectively suggest that a 
primary motivation for most people engaging in sexualised drug use is a sexual one.  
 
Table 19. Triangulation themes related to Objective 2 and level of agreement, partial agreement, 
dissonance and silence across the studies. 
Theme Study 1 Study 2 Study 3 
People engage in sexualised drug use to help 
facilitate the sexual experience 
Silence Agreement Agreement 
Internalised homophobia is not a motivation 






Previous qualitative interviews with MSM engaging in chemsex had suggested 
internalised homophobia was a motivation for engaging in chemsex (Weatherburn et al., 2017). 
Additionally, internalised homophobia and experiences of discrimination have been used to try 
and explain LGBT health more generally (Meyer, 2003), as well as in relation to drug use 
among LGB people (Lea et al., 2014), and sexual behaviour among gay and bisexual men when 
engaging in drug use (Dentato et al., 2013). Internalised homophobia was not associated with 




MSM in Study 2. In Study 3, no service user participants suggested internalised homophobia 
was a driver for their behaviour, and one participant argued that the narrative that MSM 
engaging in chemsex do so because of internalised homophobia is homophobic and incorrect. 
However, the interviews with service providers in Study 3 revealed that some clinicians had 
seen MSM service users where they perceived that internalised homophobia had been a 
motivation for engaging in chemsex. Therefore, Study 3 only partially agrees with the theme 
that internalised homophobia is not a motivation for sexualised drug use. It may be the case that 
internalised homophobia may motivate some individuals to engage in this behaviour, but people 
who have internalised homophobia are not more likely to engage in sexualised drug use because 
there are many other motivations for sexualised drug use, and sexualised drug use and chemsex 
are highly individual experiences (Bourne et al., 2015).  
 
Objective 3: To understand what potential impact engaging in sexualised drug use has in terms 
of sexual and physical health, and psychological wellbeing 
 
 Previous research into sexualised drug use and chemsex among MSM has found a 
number of associated sexual risks, such as condomless anal intercourse with multiple partners, 
group sex, and STI diagnoses (Bourne et al., 2014; Glynn et al., 2018; Hegazi et al., 2017; 
Mattison et al., 2001). In addition to neglecting WSW and trans people, research regarding 
sexualised drug use and chemsex has been criticised due to its focus on sexual health outcomes 
(Desai et al., 2018; Edmundson et al., 2018), neglecting possible psychological impacts of 
engaging in sexualised drug use or chemsex. The themes related to Objective 3 can be seen in 
Table 20. Study 1 was silent on the majority of themes related to Objective 3, because the scope 
of the systematic review was limited to three specific sexual health and behaviour outcomes 
(HIV status, STI diagnoses, and condomless anal intercourse). 
 There was a consistent finding across the programme of research that engaging in 
sexualised drug use and chemsex was associated with living with HIV, which is similar to 
previous research (Bourne et al., 2014; Hegazi et al., 2017; Ottaway, Finnerty, Amlani, et al., 
2017). Study 1 found an association between HIV status and sexualised drug use across meta-
analyses regardless of the drug used. Study 2 found that the proportion of MSM engaging in 
sexualised drug use that were living with HIV was higher than those not engaging in sexualised 
drug use (8% vs. 2%), and the proportion of MSM engaging in chemsex living with HIV was 




of these findings were significant at the bivariate level, but not in the multivariable analyses, 
possibly due to an association between HIV status and condomless anal intercourse. In Study 
3, the two MSM living with HIV recruited had both engaged in chemsex and acquired their 
HIV before engaging in chemsex. Therefore, the consistent finding across the three studies that 
MSM living with HIV are more likely to engage in sexualised drug use and chemsex may reflect 
this behaviour being common among MSM already living with HIV, as opposed to MSM 
acquiring HIV through engaging in chemsex, and previous research has not found an 
association between chemsex and HIV incidence (Hegazi et al., 2017; Ottaway, Finnerty, 
Amlani, et al., 2017). 
 
Table 20. Triangulation themes related to Objective 3 and level of agreement, partial agreement, 
dissonance and silence across the studies. 
Theme Study 1 Study 2 Study 3 
Sexualised drug use and chemsex among 
MSM is associated with living with HIV 
Agreement Agreement Agreement 
Sexualised drug use and chemsex is 
associated with sexual risk among MSM 
Agreement Agreement Agreement 
Chemsex may be associated with greater 
sexual risk than other forms of sexualised 
drug use 
Agreement Agreement Agreement 
Engaging in chemsex may be associated 
with taking PrEP in MSM 
Silence Agreement Agreement 
Engaging in chemsex did not affect MSM’s 
adherence to PrEP or ART medication 
Silence Silence Agreement 
Poorer perceived health may be associated 




People engaging in drug use and sexualised 





There are negative psychological 
associations with chemsex and sexualised 
drug use 
Silence Agreement Agreement 
 
 
Similar to the previous research on sexualised drug use among MSM, all three studies 
found an association between sexualised drug use and sexual risk. In Study 1, meta-analyses 
revealed that poppers and chemsex was associated with STI diagnosis and having condomless 
anal intercourse. In Study 2, MSM engaging in sexualised drug use were more likely to have 
been diagnosed with an STI and have more condomless anal intercourse partners than those 
who did not. Also in Study 2, MSM who engaged in chemsex were more likely to report an STI 




engaged in other types of sexualised drug use. Interestingly, drug use among WSW and trans 
people was associated with STI diagnoses, but not sexualised drug use in comparison to general 
drug use. This may be due to a low incidence of self-reported STI diagnoses in this group. 
During interviews with service users in Study 3, all of whom engaged in sexualised drug use, 
the majority of MSM reported no intention to use condoms, and this was consistent with their 
behaviour. Therefore, there was a consistent finding across all three studies that sexualised drug 
use and chemsex was associated with increased sexual risks. 
 The results from this programme of research were used to compare chemsex with other 
types of sexualised drug use, as other forms of sexualised drug use had been somewhat 
neglected in the recent literature due to the emergence of chemsex. Study 1 found meta-
analytical associations between engaging in chemsex and HIV status, STI diagnoses, and 
condomless anal intercourse. Additionally, the association between chemsex and HIV status, 
STI diagnoses, and condomless anal intercourse tended to be greater compared to meta analyses 
between other drugs and HIV status, STI diagnoses, and condomless anal intercourse. 
Additionally, Study 2 found that MSM engaging in chemsex were more likely to report an STI 
diagnosis and a greater number of condomless anal intercourse partners than those engaging in 
other types of sexualised drug use. Study 3 provided context for this finding, as MSM engaging 
in other types of sexualised drug use tended to report having condomless anal intercourse within 
an exclusive relationship, compared to MSM who were engaging in chemsex and condomless 
anal intercourse with multiple partners. Whilst further research is needed to justify this 
conclusion, there has been a consistent finding across this programme of research that there 
may be greater sexual risk associated with chemsex.  
PrEP use has been associated with engaging in chemsex among MSM in Amsterdam 
(Druckler et al., 2018), but prior to this programme of research, little was known about PrEP in 
the context of sexualised drug use and chemsex in the UK. Study 2 found that MSM engaging 
in sexualised drug use were more likely to report currently taking PrEP than those who were 
not (11% vs. 3%), and those engaging in chemsex were more likely to report currently taking 
PrEP compared to those who did not (21% vs. 9%). These findings were significant at the 
bivariate level but not in multivariable analyses, possibly due to the association between PrEP 
use and condomless anal intercourse. Additionally, taking PrEP was associated with 
condomless anal intercourse in event-level analyses when engaging in sex under the influence 
of alcohol or cannabis, or taking poppers or EDD medication immediately before or during sex. 
Three service user participants who were taking PrEP and engaging in chemsex were recruited 




Therefore, Study 2 and 3 provided consistent evidence for the association between PrEP and 
sexualised drug use and chemsex. 
Previous research regarding MSM living with HIV and engaging in sexualised drug use 
and chemsex had suggested that engagement may be associated with a lack of adherence to 
medication (Daskalopoulou et al., 2014; Pufall et al., 2018), and prior to this programme of 
research, adherence to PrEP and the influence of sexualised drug use and chemsex had not been 
investigated. Study 3 found that service user participants did not report any problems with 
adherence to ART medication or PrEP whilst engaging in chemsex, and service providers did 
not perceive engaging in chemsex as a barrier to PrEP with regards to adherence, because of 
the effectiveness of PrEP even if a couple of doses are missed per week. Whilst research 
regarding adherence to PrEP and chemsex published after the current research programme had 
been conducted found no difference in PrEP adherence between those engaging in chemsex and 
those not (O'Halloran et al., 2019), interviews with service users gave a more in-depth 
understanding of participants’ strategies to maintain adherence to PrEP or ART medication 
whilst engaging in chemsex. These included taking their medication to parties, building and 
maintaining a routine of adherence, using adherence tools like keychains, and sharing PrEP 
with other members at the party. Due to the fact that adherence was investigated in Study 3 on 
the basis of findings from Study 2 that MSM engaging in sexualised drug use and chemsex 
were more likely to be taking PrEP or living with HIV, this finding is unique to Study 3 and 
makes an interesting contribution to knowledge with regards to adherence and sexualised drug 
use.  
Participants in Study 2 were asked to rate their perceived health and it was found that 
poorer perceived health was associated with sexualised drug use among MSM and trans people, 
as well as drug use among WSW. Although it is unclear whether this is related to sexual, 
physical, and/or mental health, due to the question asking participants how they perceived their 
health generally, MSM service user participants in Study 3 discussed poorer health in terms of 
mental and sexual health, but it is unclear if this was contributing to how they perceived their 
health overall. Therefore, Study 3 only partially supports the finding theme in relation to 
sexualised drug use and perceived health, and further research is needed to investigate the 
implications for overall health in regards to drug use and sexualised drug use.  
 Over half of MSM and WSW who reported experiencing sexual contact without 
consent in the past 12 months had engaged in sexualised drug use in their respective analyses. 
These findings were significant at the bivariate level but not the multivariable level, possibly 




sexual contact without consent was significantly associated with drug use among trans 
participants in multivariable analyses, but this was not significant when comparing sexualised 
drug use with drug use generally, possibly due to the fact that 82% of trans participants who 
had experienced sexual contact without consent had also engaged in drug use. However, the 
direction of this relationship is uncertain; whether engaging in drug use or sexualised drug use 
makes someone more vulnerable to sexual assault, or whether drug use may act as a coping 
mechanism for people who experience sexual assault. It may be that there is variability between 
MSM, WSW, and trans people with regards to the direction of this effect, as well as variability 
within these groups. Previous research among MSM engaging in chemsex has found evidence 
that sexual assaults have taken place during chemsex (Bourne et al., 2015), and one service user 
in Study 3 described an experience of sexual contact without consent in the context of chemsex. 
Service providers also expressed concern about a person’s ability to maintain consent in the 
context of chemsex and described consultations where participants reported experiencing non-
consensual sex in the context of chemsex. Further research is needed to understand the direction 
of effect in regards to sexual assault and drug use or sexualised drug use, particularly among 
WSW and trans people.  
As mentioned previously in relation to Objective 3 of the programme of research, 
research regarding sexualised drug use and chemsex has been criticised for often neglecting 
possible psychological associations (Desai et al., 2018; Edmundson et al., 2018). Study 2 found 
that among MSM engaging in sexualised drug use was associated with lower satisfaction with 
life. In addition to this, bivariate associations were found between having very high 
psychological distress was associated with sexualised drug use among WSW, but this was not 
significant in the multivariable analysis, possibly due to psychological distress being associated 
with drug use generally among WSW. In Study 3, service users noted some negative 
psychological associations with sexualised drug use, particularly chemsex, with one participant 
reporting experiencing psychosis and two participants reporting attempting suicide. Service 
providers also noted that some MSM engaging in sexualised drug use may do for psychological 
reasons, such as low self-esteem and/or mental health problems, and some service providers 
stated some MSM engaging in chemsex may need further psychological support. Whilst not all 
people engaging in sexualised drug use will do so due to negative psychological reasons, or all 
people engaging in chemsex will experience negative psychological associations, both Study 2 
and 3 highlight that caution is needed when engaging in this behaviour. People engaging in 





Objective 4: To investigate what services are currently available for LGBT people engaging in 
sexualised drug use and what service development is needed  
  
Previous research has highlighted that MSM engaging in sexualised drug use and 
chemsex have a preference for integrated sexual health and drug services (Bourne et al., 2014; 
Tomkins, Vivancos, et al., 2018). Objective 4 was designed in specific reference to the 
qualitative interviews stage of this programme of research (Study 3), and the themes related to 
Objective 4 and the level of agreement with these themes across the studies can be seen in Table 
21. Study 1 was silent on the themes related to Objective 4, because the systematic review did 
not aim to investigate sexual health clinic use among those engaging in sexualised drug use and 
chemsex.  
 
Table 21. Triangulation themes related to Objective 4 and level of agreement, partial agreement, 
dissonance and silence across the studies. 
Theme Study 1 Study 2 Study 3 
Sexual health clinics can play a role in 
service provision for people engaging in 
sexualised drug use 
Silence Agreement Agreement 
Barriers to effective care exist for MSM 
engaging in sexualised drug use Silence Silence Agreement 
 
 
 Research regarding sexualised drug use and chemsex among MSM is often conducted 
in sexual health clinics (Edmundson et al., 2018; Hegazi et al., 2017; Ottaway, Finnerty, Amlani, 
et al., 2017). By using a community sample, Study 2 was able to assess whether those engaging 
in sexualised drug use were more likely attend sexual health clinics. Multivariable analyses 
found MSM engaging in sexualised drug use were more likely to have attended a sexual health 
clinic than those who did not (55% vs. 38%), and this was also significant when comparing 
MSM engaging in chemsex with those who engaged in other types of sexualised drug use (84% 
vs 65%). Similarly, bivariate analyses among WSW suggested that engaging in sexualised drug 
use was associated with attending a sexual health clinic compared to drug use generally (35% 
vs. 22%), and was significant in the multivariable analysis when comparing sexual health clinic 
attendance between trans people engaging in sexualised drug use and those engaging in drug 
use generally (62% vs. 26%). Study 2 found that sexual health clinics are a point of contact for 
LGBT people engaging in sexualised drug use and so can be used as a source of support if 




of support for drug use to help someone stop or manage their usage. Some service providers 
described running specialist chemsex clinics, as well as providing both internal and external 
support for MSM engaging in chemsex attending for care, although it is unclear what services 
were available for WSW and trans people. Therefore, Study 2 and 3 were both in agreement 
that sexual health services can play a role in service provision to people engaging in sexualised 
drug use.  
 Despite the opportunity for service provision in sexual health services, Study 3 
highlighted barriers to care for MSM engaging in sexualised drug use. Service users and service 
providers both identified a number of barriers associated with sexual health clinics, such as 
accessibility and funding. However, access to other forms of care (mental health services, 
counselling) were also reported as a barrier among MSM engaging in sexualised drug use and 
chemsex. This barrier was not deemed specific to MSM engaging in sexualised drug use, but 
because of poor access to services generally (Care Quality Commission, 2019). This was a 
unique finding to Study 3, but important in terms of the quality of care received by LGBT 
people engaging in sexualised drug use, and further research that is inclusive of WSW and trans 
people is needed to investigate the level of care received. 
 
Summary of the triangulation of findings 
 
 The triangulation process has highlighted the novel contributions this programme of 
research has made in relation to the four objectives. The aim and objectives of the programme 
of research have been achieved through a combination of the three studies, and the findings 
from these studies can be used to inform recommendations for future research and public health 
practice that will be outlined in the conclusion.  
 
Strengths and limitations  
 
 The strengths and limitations of each individual study have been discussed in their 
respective chapters, and therefore the strengths and limitations of the programme of research as 
a whole and the triangulation process will now be discussed. 
 A limitation of the programme of research is that, unlike Studies 1 and 2, Study 3 was 
not inclusive of WSW and trans people. Although this decision was made due to the higher 




recruitment, including WSW and trans people may have provided supporting or contrasting 
findings regarding sexualised drug use among these groups compared to MSM. It is unclear if 
any WSW or trans participants would have been recruited if included, but any recruitment 
would have provided novel contributions to knowledge with regards to sexualised drug use 
among these groups, as it is uncommon that WSW and trans people are included in sexualised 
drug use research. Therefore, it is recommended that future research investigate sexualised drug 
use among WSW and trans people using qualitative interviews to add to the growing body of 
knowledge regarding this issue. 
As outlined as good practice in Farmer et al. (2006), a triangulation protocol was created 
before the triangulation process began. Whilst this is a strength, Farmer et al. (2006) also 
suggesting using two researchers to assess the level of agreement on finding themes between 
studies. Although this was not possible in this programme of research, the supervisory team did 
play a role in ensuring accurate categorisation of themes. Additionally, a protocol was produced 
to minimise bias in the triangulation process, but the level of agreement may still be biased to 
one researcher’s interpretation of findings from each study. Despite this, the triangulation 
process was useful in understanding the findings from each of the studies from the programme 
of research in the context of the research objectives and providing assessment of how these 
objectives were achieved.  
Using a mixed methods approach allowed for a more comprehensive investigation into 
sexualised drug use. However, Study 2 used self-reported measures and causation could not be 
inferred due to the cross-sectional design. The qualitative interviews in Study 3 allowed for 
further investigation into peoples’ perspectives regarding causation between findings from 
Study 2, but this personal perspective of causation is limited to a small number of participants, 
and it cannot be said with any certainty to be reflective of people’s experiences more generally. 
Additionally, participants self-selected for both Study 2 and 3, which may have resulted in a 
self-selection bias in both datasets, with participants with particular experiences regarding 
sexualised drug use and chemsex being more likely to come forward; therefore, possibly 
missing a section of this target population. Those currently reporting negative associations with 
chemsex and sexualised drug use may be less likely to come forward, but it is equally plausible 
that those that have experienced negative associations may be more likely to come forward so 
they can have their experience heard. Despite this, both positive and negative associations with 
chemsex and sexualised drug use were found across the programme of research, but further 





The PPI group was utilised during Study 2 and their contribution was of significant 
value with regards to the design and accuracy of variables included. The inclusion of a PPI 
group also gave this study an added sense of validity, ensuring that research was inclusive of 
community members, as well as designed and used by community members. An attempt was 
made to have PPI in Study 3, but this was not possible due to capacity within appropriate 
community organisations. Although it is unfortunate that this research approach could not be 
applied to Study 3, the benefits of having the PPI group in Study 2 highlight the success of 




Personal reflection is provided after Studies 2 and 3; therefore, this personal reflection 
will focus on the whole programme of research. Using a mixed methods approach has added a 
greater value and insight into the topic of sexualised drug use, than would have been gained 
from just using either quantitative or qualitative methods. Despite my previous skill set and 
research exposure being mostly quantitative, I did enjoy conducting interviews and collecting 
narratives that are hidden from the quantitative data. I was never a researcher who diminished 
the value or integrity of qualitative research, and in my opinion, I found this portion of the 
programme of research much more difficult. I don’t believe this is because I have more 
experience with quantitative research, I think the data collection, analysis, and reporting of 
qualitative research requires a lot more energy than for quantitative research. That is not to say 
I will shy away from using qualitative research in the future, but I have more of an awareness 
of how much work is required. 
Having a PPI group has meant that this research was conducted in partnership with 
LGBT people and for LGBT people, as opposed to just conducting research on LGBT people. 
The use of community organisations has helped generate impact and dissemination of findings 
that would not have occurred otherwise. Although I had previous experience of conducting 
research with a PPI group, I was part of a large research group, whereas in this programme of 
research I had a lot of autonomy over the research, which then led to me being more involved 
in forming and liaising with the PPI group. Being more involved in the organisation of the PPI 
group allowed me to experience the additional value PPI groups bring to research, and I would 
highly recommend any researcher conducting health or community based research to consider 




My only regret with the PPI group is not including an LGBT group for people of colour. 
Had I known that Facebook advertising for Study 2 would have resulted in a biased sample in 
terms of white ethnicity, I would have definitely included a community organisation for LGBT 
people of colour. This would have helped to overcome the biases that came from using 
Facebook advertising. It is unclear as to whether LGBT people of colour were less likely to be 
shown the advert, or less likely to engage in the advert. Additionally, it is unfortunate that 
community organisations could not be utilised in the same way for Study 3, but funding 
problems for community organisations and integration with NHS services created additional 
barriers to utilising these groups, and seeking NHS Health Research Authority ethics for service 
users was not feasible in the remaining timescale.  
 In relation to Study 3, only MSM were researched from a service user perspective. 
Although this has left some gaps during the triangulation process, there are multiple reasons for 
and against focusing solely on MSM. Firstly, I have issues with trans women being grouped in 
with MSM due to the historic misidentification of trans women as MSM, and if not enough 
trans women were recruited, I would not want these findings to be hidden by or submerged with 
the MSM findings. Even though some interesting findings from The LGBT+ Sex and Lifestyles 
Survey emerged with regards to WSW and thus warranted further research, the findings were 
not homogeneous with MSM, and therefore I see it as two separate studies. Whilst I am proud 
of my inclusion of all LGBT people in Studies 1 and 2, designing a fully inclusive survey was 
not easy, and there are definitely situations that warrant focusing on one subgroup of LGBT 
people, because although there are similarities, LGBT people are not one homogenous group. 
Ideally, three separate qualitative studies would have been conducted (one for MSM, one for 
WSW, and one for trans people), in addition to interviews with service providers; however, this 
was not feasible within the time frame for this programme of research. Additionally, MSM 
reported the most sexualised drug use compared to WSW and trans people in Study 2 and are 
generally forthcoming with regards to sexual health research, due to being a group that sexual 
health research has focused on for some time. Although WSW and trans people engaging in 
sexualised drug use may be harder to recruit, this should not be a reason to neglect this topic, 
but a larger time scale may be needed to recruit these groups. 
During my personal reflection for Studies 2 and 3, I discussed the preconceived notion 
that MSM engaging in chemsex were doing so because they were unhappy and had high levels 
of internalised homophobia. Whilst this may be true for some MSM engaging in this behaviour, 
the current programme of research found very little evidence of this. Additionally, Study 3 




as it may question someone’s validity for help. Although I have admitted this was an opinion I 
held and something I thought I would find when conducting this research, the fact that I have 
been able to change my opinion when analysing the evidence in this programme of research 
demonstrates my integrity as a researcher. All researchers go into their research with the 
expectation to find something, but being able to demonstrate that you can disregard that 
expectation when presented with evidence is key to being an honest and unbiased researcher. 
Because I am conducting research on a community I am also a part of, and therefore may have 
strong personal opinions about certain topics formed outside of research, I think it is important 




The aim of this programme of research was to investigate sexualised drug use among 
LGBT people, with a particular focus on reasons for engagement, and the potential impact on 
physical health and psychological wellbeing. The findings from this programme of research 
have made several novel contributions to knowledge regarding sexualised drug use among 
LGBT people, which are: 
 
 The term chemsex was often used in a Western context and among MSM in previous 
research, but Study 1 found sexualised drug use and chemsex has been researched 
internationally among MSM and trans women. 
 The LGBT+ Sex and Lifestyles Survey included WSW and trans people, and observed 
sexualised drug use among these groups, which had not been researched in the UK and 
had received very little attention internationally. 
 Previous research had often neglected to examine psychological associations with 
sexualised drug use, and psychological associations with sexualised drug use and 
chemsex among MSM were investigated, finding sexualised drug use was associated 
with poorer life satisfaction.  
 Psychological motivations for MSM engaging in sexualised drug use and chemsex, such 
as internalised homophobia, were not found. Both Study 2 and Study 3 highlighted that 





 Whilst previous research had established the association between sexualised drug use, 
chemsex, and sexual risk among MSM, The LGBT+ Sex and Lifestyles Survey found 
that in addition to sexual risk behaviours like more anal intercourse partners, sexualised 
drug use and chemsex was associated with PrEP use, which had not been investigated 
in UK research previously. 
 Despite the finding across all three studies that chemsex may be difficult to define, it 
did appear that chemsex may be associated with greater sexual risk than other types of 
sexualised drug use. 
 Due to the lack of inclusion in sexualised drug use research generally, little was known 
about psychological and physical health associations with drug use and sexualised drug 
use among WSW, and trans people, and a number of potential physical and 
psychological associations were found, such as sexual assault and psychological distress. 
 MSM engaging in sexualised drug use and chemsex appeared to be engaging with and 
receiving a high level of care from sexual health services, but this level of care was 
lacking from other services (e.g. mental health services). This poorer level of care did 
not appear to be specific to MSM engaging in sexualised drug use, but because of a poor 
level of care generally due to a lack of funding for mental health services. 
 
These novel findings contribute to a number of recommendations for both future research and 
public health practice.  
 
Recommendations for future research 
 
Although it became apparent that defining what constitutes chemsex as opposed to other 
sexualised drug use is somewhat difficult, it is interesting that certain drugs, like those 
associated with chemsex, appeared to be associated with greater sexual risk among MSM. It 
would be interesting to explore this further and to assess whether drugs used in certain contexts 
are associated with greater sexual risk taking behaviour, and to further understand what 
influences intention to use condoms and condom use behaviour in the context of sexualised 
drug use. Additionally, the systematic review found that some studies that aimed to investigate 
sexualised drug use were using global associations, which means the drug use is not defined 
and measured in a sexual context. Any future research should utilise situational associations 
and event-level analyses to improve the accuracy of the measurement, as both of these analyses 




This programme of research highlighted a possible association between sexualised drug 
use and psychological wellbeing among MSM that warrants further investigation. The 
qualitative interviews with MSM engaging in chemsex revealed some participants experienced 
negative psychological associations and some did not. The reason as to why some people 
experience negative psychological associations and others do not, may be a result of their 
motivations for engaging, or their psychological wellbeing before engaging in sexualised drug 
use and chemsex. A longitudinal cohort study recording behaviour and wellbeing over a period 
of time may provide an answer to this research question. 
 By including WSW and trans people in Study 2, this programme of research was able 
to make some novel contributions to knowledge regarding sexualised drug use among these 
groups. The association between sexual assault and drug use among WSW and trans people 
requires further investigation, as little is known about the context of these assaults, and research 
regarding this may be able to protect people in the future. Although creating a fully inclusive 
survey regarding sexual health of LGBT people was difficult, research into LGBT health issues 
generally should aim to be inclusive of all LGBT people where appropriate.  
Including a PPI group was a rewarding and worthwhile experience during this 
programme of research, and the group added to the quality of work produced. Therefore, it is 
recommended that researchers consider the inclusion of a PPI group in health related research, 
as well as LGBT research.  
 
Recommendations for public health policy and practice 
 
People who engaged in sexualised drug use and chemsex were identified to be at high risk of 
sexual health and drug harms, and support services need to be available for those engaging in 
this behaviour. The programme of research had identified a number of recommendations for 
public health policy and practice, which are:  
 Sexual health services have been identified as a source of support for those engaging in 
sexualised drug use, but funding and capacity were common barriers to care, and sexual 
health services have had funding cut dramatically since 2013 (BASHH/BHIVA, 2018). 
It cannot be expected that sexual health clinics provide a high level of care on reduced 
funding, and therefore funding for sexual health services should be increased. 
 Additionally, increases in sexual health funding may help reduce accessibility issues, 




 Funding to mental health services should also be increased, as some participants 
reported attempting suicide and receiving no help from health services. 
 This lack of appropriate care resulted in service users relying on community 
organisations for help, and whilst it is positive that participants experiencing negative 
effects have somewhere to go besides sexual health clinics, it was reported community 
organisations also had long waiting lists, and therefore funding for these services should 
also be increased.  
 When this research was conducted, PrEP was currently available on the IMPACT trial 
in England, and whilst this has now been made more widely available (Kirby, 2020), 
this research identified strains on clinic capacity the PrEP trial was having. Therefore, 
it is recommended that future HIV prevention techniques should not be limited in this 
way, as this places increasing pressure on sexual health clinics and raises a number of 
moral and ethical questions. 
 Experiences of sexual assault were common experiences among people using drugs or 
engaging in sexualised drug use. Therefore, training for services coming into contact 
with MSM, WSW and trans people (community organisations, sexual health clinics, 
rape and drug support services) should be provided to raise awareness of these 
potentially compounding issues to provide appropriate help and support. 
 Narratives surrounding chemsex were identified as a potential barrier to care, and one 
participant reported how a practitioner’s expectation of MSM who use drugs deterred 
him from seeking help. Although, service user participants in Study 3 identified that 
drug use was a spectrum of behaviour and training to sexual health staff should adopt 
this harm reduction approach. 
 Additionally, promotion and training regarding of drug use as a spectrum of behaviour 
should be given to services other than sexual health clinics, such as other health services 
like mental health or accident and emergency, as well as private counselling services, 









 This programme of research has achieved the aim of investigating sexualised drug use 
among LGBT people, particularly the reasons for engagement and associations with physical 
and psychological wellbeing. It has been recommended that a harm reduction approach be 
adopted to help minimise any possible barriers to care that those engaging in sexualised drug 
use experience. It was novel to include WSW and trans people in sexualised drug use research, 
and this has resulted in a number of original and interesting findings and recommendations for 
future research and public health policy. Research into LGBT health should aim to be inclusive 
as possible, and although certain topics may affect a higher proportion of a particular subgroup 
within LGBT people, this does not necessarily mean that research regarding the topic on other 
LGBT groups is not needed. Highlighting LGBT health research is not only important for public 
health knowledge and practice, but to raise awareness of issues LGBT people face in society 
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Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions 
at each stage, ideally with a flow diagram.  
32 
Study characteristics  18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) 
and provide the citations.  
33-35 
Risk of bias within studies  19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).  Appendix 2 
Results of individual studies  20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each 
intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.  
38-41 
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and measures of consistency.  38-41 
Risk of bias across studies  22 Present results of any assessment of risk of bias across studies (see Item 15).  Appendix 2 
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).  38-41 
DISCUSSION   
Summary of evidence  24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to 
key groups (e.g., healthcare providers, users, and policy makers).  
42 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of 
identified research, reporting bias).  
44 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and implications for future research.  44-45 
FUNDING   
Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for 
the systematic review.  
n/a 
 
From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. 
doi:10.1371/journal.pmed1000097   
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B: Sample C: Confounders 




F: Analyses Overall 
Men who have sex with men   
Barron-Limon et al. (2012) Strong Moderate Moderate Moderate Strong Moderate Strong 
Bowden-Jones et al. (2017) Strong Moderate Moderate Weak Strong Strong Moderate 
Card et al. (2017) Strong Moderate Weak Weak Weak Moderate Weak 
Daskalopoulou et al. (2014) Strong Weak Strong Moderate Moderate Strong Moderate 
Duan et al. (2017) Strong Moderate Strong Strong Weak Strong Moderate 
Eaton et al. (2015) Strong Moderate Moderate Moderate Moderate Strong Strong 
Eaton et al. (2016) Strong Strong Strong Strong Strong Strong Strong 
M. P. Fisher et al. (2013) Strong Strong Strong Strong Weak Weak Weak 
Frankis et al. (2018) Strong Strong Strong Strong Weak Strong Moderate 
Gilbart et al. (2015) Strong Strong Weak Weak Moderate Strong Weak 
Glynn et al. (2018) Strong Strong Strong Strong Strong Strong Strong 
Goedel and Duncan (2016) Strong Moderate Weak Weak Weak Weak Weak 
González-Baeza et al. (2018) Strong Strong Strong Weak Moderate Strong Moderate 
Halkitis et al. (2012) Strong Weak Weak Weak Weak Weak Weak 
Hammoud et al. (2017) Strong Moderate Strong Weak Strong Strong Moderate 
Hammoud et al. (2018) Strong Moderate Strong Weak Strong Strong Moderate 
Bowring et al. (2014) Strong Weak Weak Weak Weak Strong Weak 
Heinsbroek et al. (2018) Strong Moderate Weak Weak Weak Strong Weak 
Kahler et al. (2015) Strong Moderate Weak Strong Weak Weak Weak 
Kecojevic et al. (2015) Strong Moderate Weak Strong Strong Moderate Moderate 
Kelly et al. (2014) Strong Moderate Weak Strong Strong Weak Weak 
Kelly et al. (2016) Strong Strong Weak Strong Strong Strong Moderate 
Kramer et al. (2016) Strong Moderate Strong Strong Weak Moderate Moderate 
Kupprat et al. (2017) Strong Weak Weak Strong Strong Strong Weak 
Lachowsky et al. (2016) Strong Strong Strong Strong Strong Weak Moderate 
Li & McDavid (2014)  Strong Moderate Moderate Strong Moderate Strong Moderate 
Li et al. (2014)  Strong Strong Strong Strong Moderate Strong Strong 
Lim et al. (2015) Strong Moderate Moderate Strong Weak Weak Weak 
Martinez et al. (2017) Strong Moderate Weak Weak Weak Strong Weak 
Melendez-Torres et al. (2016) Strong Weak Strong Strong Weak Weak Weak 
Melendez-Torres et al. (2017) Strong Weak Strong Strong Weak Moderate Weak 
Mitchell et al. (2016) Strong Moderate Moderate Strong Weak Moderate Moderate 
Morgan et al. (2016) Strong Weak Strong Strong Weak Strong Weak 
Pylli et al. (2014) Strong Moderate Weak Weak Strong Strong Weak 
Rendina et al. (2015) Strong Weak Weak Strong Strong Strong Weak 
Sewell et al. (2017) Strong Strong Strong Strong Strong Strong Strong 
Theodore et al. (2014) Strong Moderate Weak Strong Weak Weak Weak 
Tieu et al. (2014) Strong Moderate Strong Strong Weak Strong Moderate 
Tomkins, Ahmad, et al. 
(2018) 
Strong Weak Strong Strong Weak Strong Weak 
Wei et al. (2012) Strong Strong Strong Strong Moderate Strong Strong 
Wu et al. (2018) Strong Moderate Strong Strong Moderate Strong Strong 
Zhang et al. (2016) Strong Strong Strong Strong Strong Strong Strong 
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Trans women        
Benotsch et al. (2016) Strong Moderate Weak Strong Strong Moderate Moderate 
Colby et al. (2016) Strong Moderate Moderate Strong Weak Strong Moderate 
Grinsztejn et al. (2017) Moderate Weak Weak Weak Strong Strong Weak 
Santos et al. (2014) Strong Weak Strong Strong Strong Weak Weak 




Appendix 3. Facebook adverts for participant recruitment 













Figure 2. Men who have sex with men adverts 




























Figure 3. Women who have sex with women adverts 















Figure 4. Trans people adverts 




Figure 5. LGBT+ advert. 
 
 






Men who have sex with men advert 
The advert ran from 12/04/18 – 8/05/18 (26 days) with a maximum budget set of £6.67 
per day. The advert was targeted at men living in the UK, aged 18 and above, and had 
showed interest in one of the following topics on Facebook: 
 Advocate (gay press) 
 Andrew Christian (underwear brand) 
 Attitude (magazine) 
 AussieBum (underwear brand) 
 Buzzfeed LGBT 
 Daddyhunt 
 Gay bar 
 Gay Love 
 Gay News 
 Gay Rights 
 Gay Star News 
 Gay Times 
 Gay Times Magazine 
 Gay village 
 Gay-friendly 





 LGBT adoption 
 LGBT community 
 LGBT Equality World Wide 
 LGBT history 
 LGBT music 
 LGBT parenting 
 LGBTQ Nation 
 Manhunt.net 
 Out (magazine) 
 Pink (LGBT magazine) 
 Pink News 
 Pride in London 
 Pride parade 
 Queerty 
 Same-sex marriage 
 Same-sex relationship 
 Scruff 
 The Advocate 




Adverts appeared in Facebook and Instagram feeds, Facebook instant articles, and in 
Facebook Messenger Inbox. After 5 days, the advert was modified slightly to contain the 
inclusion criteria of being 18 and above, due to the number of participants getting excluded 
because of their age. Additionally, after 17 days, the advert was modified to target people 
aged 25+ to recruit older MSM. The total cost of the advert was £172.72 with 602 unique link 
clicks. 
 Two additional MSM adverts were ran targeting MSM aged 21 and above living in 
either London, or Manchester and Brighton and Hove. The advert for London ran from 23rd-
26th May and the advert for Manchester and Brighton and Hove ran from 29th-31st May. 
Manchester and Brighton and Hove were grouped due to a smaller population size than 
London. Each advert cost £50 and were shown in Facebook and Instagram news feeds only. 
Potential participants were shown the advert if they showed an interest in one of the topics 
mentioned above. Data regarding the number of link clicks were not available for this types 
of advert. 
Women who have sex with women advert 
The advert ran from 12/04/18 – 8/05/18 (26 days) with a maximum budget set of £6.67 
per day. The advert was targeted at women living in the UK, aged 18 and above, and had 
showed interest in one of the following topics on Facebook: 
 Buzzfeed LGBT 
 Gay bar 
 Gay Life 
 Gay Love 
 Gay News 
 Gay pride 
 Gay Times 
 Gay Times Magazine 
 Gay, Lesbian, Bisexual, Transgender, Straight Alliance 
 Homosexuality 
 International Lesbian, Gay, Bisexual, Trans and Intersex Association 
 Lesbian Connection 
 Lesbian Pride 
 Lesbian Romance 
 Lesbian, Gay, Bisexual & Transgender Community Centre 
 LGBT adoption 
 LGBT community 
 LGBT community centre 
 LGBT culture 
 LGBT Equality World Wide 
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 LGBT history 
 LGBT music 
 LGBT parenting 
 LGBT social movements 
 LGBT tourism 
 LGBTQ Nation 
 Love of Lesbian 
 National Center for Lesbian Rights 
 Pink (LGBT magazine) 
 Pride parade 
 Rainbow flag (LGBT movement) 
 Same-sex marriage 
 Same- sex relationship 
 The Lesbian, Gay, Bisexual & Transgender Community Center 
 
Adverts appeared in Facebook and Instagram feeds, Facebook instant articles, and in 
Facebook Messenger Inbox. After 5 days, the advert was modified slightly to contain the 
inclusion criteria of being 18 and above, due to the number of participants getting excluded 
because of their age. Additionally, after 17 days, the advert was modified to target people 
aged 25+ to recruit older WSW. The total advert cost was £172.83 with 361 unique link 
clicks. 
Trans advert 
The advert ran from 12/04/18 – 8/05/18 (26 days) with a maximum budget set of £6.67 
per day. The advert was targeted at anyone living in the UK, aged 18 and above, and had 
showed interest in one of the following topics on Facebook: 
 Gender-specific and gender-neutral pronouns 
 Genderqueer 
 National Center for Transgender Equality 
 Transgender activism 
 Transgender Day of Rememberance 




Adverts appeared in Facebook and Instagram feeds, Facebook instant articles, and in 
Facebook Messenger Inbox. After 5 days, the advert was modified slightly to contain the 
inclusion criteria of being 18 and above, due to the number of participants getting excluded 
because of their age. Additionally, after 17 days, the advert was modified to target people 
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aged 25+ to recruit older trans people. The total advert cost was £172.83 with 508 unique link 
clicks. 
LGBT+ Advert 
The LGBT+ advert was repeated three times, each for seven days and costing £100 at 
each repetition: from 18/04/18 – 25/04/18 the advert was targeted at people aged 18 and 
above; from 25/04/18 – 02/05/18 the advert was targeted at people aged 25 and above; and 
from 16/05/18 – 23/05/18 the advert was targeted at people aged 30 and above. Participants 
were identified as LGBT+ from a predetermined Facebook group, which was determined by 
potential participants showing an interest in one of the following topics on Facebook: 
 Rainbow flag (LGBT movement) 
 Gay pride 
 LGBT history 
 LGBT culture 
 LGBT social movements 
 Buzzfeed LGBT 
Adverts appeared in Facebook and Instagram news feeds only. Data regarding the number 




Appendix 4. The LGBT+ Sex and Lifestyles Survey (online survey for 
Study 2) 
 
LIVERPOOL JOHN MOORES 
UNIVERSITY PARTICIPANT 
INFORMATION SHEET. 
Title of Project: LGBT+ Sex and Lifestyles Survey. 
 
Matthew Hibbert – PhD Student. Public Health Institute. 
Liverpool John Moores University, UK. 
You are being invited to take part in a research study. Please read the following information and take time to 
decide if you want to take part or not. If you have any questions, you can contact the researcher at 
m.p.hibbert@2017.ljmu.ac.uk.  
  
1. What is the purpose of the study? 
This study is part of PhD research degree. The aim of the study is to explore the sexual behaviour and lifestyles 
of anyone who has had a sexual partner of the same gender, or identifies as trans. We are inviting people who 
live in the UK and are aged 18 or over to take part. If you are under 18 or do not currently live in the UK, you 
are not eligible for this study. 
  
2. Do I have to take part? 
No. It is up to you to decide whether you want to take part. If you would like to take part, after you have read 
this information, click next at the bottom of the page. You can stop the survey at any time. Incomplete surveys 
will not be included in the analysis. After you finish the survey we will not be able to remove you from the 
analysis as no personal identifying information is collected. Most of the questions will have a "prefer not to say" 
option or will allow you to skip the question.  
  
3. What will happen to me if I take part? 
If you decide to take part, you will be taken to an anonymous survey hosted by Qualtrics. The survey is split into 
3 sections: About you (demographics); Sex and lifestyle (drug use and sexual health); and Thoughts and feelings 
(body image, experiences of discrimination, and wellbeing). Some of the questions are personal and ask about 
your sexual behaviour but you are free to skip these questions if you would like. 
  
The survey will take approximately 15 minutes to complete and can be done on a smartphone, tablet or 
computer. There is the opportunity to enter a prize draw at the end of the survey, where there will be the chance 
to win £50 worth of shopping vouchers, or one of two runner up prizes of £25 worth of shopping vouchers. The 
prize draw will be open until the survey closes which will be before 31st September 2018, and winners will be 
notified by email within one month of the survey closing.  
  
This is the first part of a bigger project and the researcher is hoping to conduct interviews to explore the issues 
further. The interviews are likely to happen towards the end of 2018. If you would like to receive more 
information about these interviews then the link at the end of the survey will allow you to enter your email 
address. Your email address will not be linked to your survey answers. 
  
4. Are there any risks/benefits to being involved? 
There are no direct benefits to taking part, however, the information gathered will be used to improve health 
promotion and help service provision. Some of the questions are quite personal and you might want to fill out 
the questionnaire in privacy. There are links during and at the end of the survey, to organisations that can 
provide further information and support if needed. 
  
5. Will my taking part in the study be kept confidential? 
Yes. All answers you give us will be anonymous and confidential. The survey does not contain any questions 
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which could be used to identify you and you will not be asked for your name and address. After the survey is 
complete, you have the option to go to another page to enter your email address to enter the prize draw and/or be 
contacted for future research. Your email address is not linked to any of your answers, and will only be used to 
contact you if you win a prize or to take part in future research. Only the lead researcher will have access to your 
email address. 
  
This participant information sheet is available on our Facebook page: fb.me/SexAndLifestylesUK.  
  
This study has received ethical approval from LJMU's Research Ethics Committee. If you would like to make a 
complaint, then please contact one of the following: 
  
Contact Details of Researcher: 
Matthew Hibbert, Public Health institute, Liverpool John Moores University, Henry Cotton Building, 15-21 
Webster Street, Liverpool, L3 2ET, UK. 0151 231 4088, m.p.hibbert@2017.ljmu.ac.uk.  
Contact Details of Academic Supervisor: 
Vivian Hope, Public Health institute, Liverpool John Moores University, Henry Cotton Building, 15-21 Webster 
Street, Liverpool, L3 2ET, UK. 0151 231 4332, v.d.hope@ljmu.ac.uk.  
 
Your involvement is greatly appreciated.  
 
By continuing you are confirming you have read the information provided and are happy to participate. You 
understand that by completing this questionnaire you are consenting to be part of this research study and for 





Do you currently live in the U.K.? (Forced response) 
o Yes  
o No  
 
Skip To: End of Survey If Do you currently live in the U.K.? = No 
 
 
Are you aged 18 or over? (Forced response) 
o Yes  
o No  
 
Skip To: End of Survey If Are you aged 18 or over? = No 
 
 
Where did you hear about this survey? 
o A community organisation post on social media (Facebook, Twitter, Instagram)  
o A shared post on social media (Facebook, Twitter, Instagram)  
o Sponsored Facebook or Instagram advertising  
o At a community event  
o Word of mouth  









Which of the following best describes how you think of yourself? (Forced response) 
o Male (including trans man)  
o Female (including trans woman)  
o Non-binary  
o In another way, please specify: ________________________________________________ 




Is this the same gender you were assigned at birth? (Forced response) 
o Yes  
o No  




What is your age? 






Which of the following best describes your ethnic group? (Forced response) 
 
 White 
o British  
o Irish  
o Any other White background  
Mixed 
o White and Black African  
o White and Black Caribbean  
o White and Asian  
o Any other mixed background  
Asian or Asian British 
o Indian  
o Pakistani  
o Bangladeshi  
o Any other Asian background  
Black or Black British 
o African  
o Caribbean  
o Any other Black Background  
Other ethnic groups 
o Chinese  
o Arab  
o Hispanic/Latino  
o Other ethnic group, please specify: 
________________________________________________ 




What is your country of birth? 






What is the highest level of education that you have completed? 
o Primary School (or less)  
o Qualifications at age 16 (GSCE, NVQ, O-Levels)  
o Qualifications at age 17/18 (A-levels, AS-levels, high school diploma, Scottish highers)  
o University/First/Undergraduate degree  
o Postgraduate degree  
o Other (please specify) ________________________________________________ 
 
 
What is your current work situation? (please select all that apply) 
▢  Full time employment (at least 30 hours per week)  
▢  Part time employment (less than 30 hours per week)  
▢  Self-employed  
▢  Full time student/education  
▢  Unemployed  
▢  Long-term sickness or disability (for 3 months or more)  
▢  Temporary sickness or disability (for less than 3 months)  
▢  Carer  
▢  Retired  




What is your current relationship status? (please select all that apply) 
o Living with a spouse or partner  
o In a relationship with a partner not living together  
o In relationships with more than one partner  






Which region of the UK do you currently live in? 
o East Midlands  
o East of England  
o London  
o North East  
o North West  
o South East  
o South West  
o West Midlands  
o Yorkshire and Humber  
o Northern Ireland  
o Scotland  
o Wales  
o Prefer not to say  
 
 
Display This Question: 
If Which region of the UK do you currently live in? = East Midlands 
 
Please select where you live: 
▼ Amber Valley ... West Lindsey 
 
 
Display This Question: 
If Which region of the UK do you currently live in? = East of England 
 
Please select where you live: 





Display This Question: 
If Which region of the UK do you currently live in? = London 
 
Please select where you live: 
▼ Barking and Dagenham ... Westminster 
 
 
Display This Question: 
If Which region of the UK do you currently live in? = North East 
 
Please select where you live: 
▼ County Durham ... Sunderland 
 
 
Display This Question: 
If Which region of the UK do you currently live in? = North West 
 
Please select where you live: 
▼ Allerdale ... Wyre 
 
 
Display This Question: 
If Which region of the UK do you currently live in? = South East 
 
Please select where you live: 
▼ Adur ... Wycombe 
 
 
Display This Question: 
If Which region of the UK do you currently live in? = South West 
 
Please select where you live: 





Display This Question: 
If Which region of the UK do you currently live in? = West Midlands 
 
Please select where you live: 
▼ Birmingham ... Wyre Forest 
 
 
Display This Question: 
If Which region of the UK do you currently live in? = Yorkshire and Humber 
 
Please select where you live: 
▼ Barnsley ... York 
 
 
Display This Question: 
If Which region of the UK do you currently live in? = Northern Ireland 
 
Please select where you live: 
▼ Antrim and Newtownabbey ... Newry, Mourne and Down 
 
 
Display This Question: 
If Which region of the UK do you currently live in? = Scotland 
 
Please select where you live: 
▼ Aberdeen City ... West Lothian 
 
 
Display This Question: 
If Which region of the UK do you currently live in? = Wales 
 
Please select where you live: 




How would you describe your sexual orientation? (Forced response) 
o Gay/Lesbian/Homosexual  
o Bisexual  
o Straight/Heterosexual  
o Queer 
o Asexual  
o In another way, please specify: ________________________________________________ 









I have sex with (please select all that apply): (Forced response) 
▢  Men  
▢  Women  
▢  Non-binary people  
▢  Other, please specify: ________________________________________________ 
▢  Prefer not to say  
 
In the past 12 months have you taken any of the following (please select all that apply): 
▢  Alcohol  
▢  Amphetamine (speed)  
▢  Cannabis (weed/pot)  
▢  Cocaine  
▢  Crack cocaine  
▢  Ecstasy  
▢  Heroin  
▢  Ketamine (Vitamin K, K, Special K)  
▢  GHB/GBL (Gina, Liquid Ecstasy, Liquid G)  
▢  Mephedrone (Drone, MCAT, meow meow)  
▢  Meth Amphetamine (Crystal meth, ice/glass, Tina)  
▢  Viagra or other erectile dysfunction drug  
▢  Poppers (Amyl or other nitrite inhalants)  
▢  Other illicit drug or drugs, please specify: ________________________________________________ 





Display This Question: 
If In the past 12 months have you taken any of the following (please select all that apply): = Alcohol 
Or Cannabis (weed/pot) 
 
In the past 12 months have you been under the influence of any of the following during sex (please select all 
that apply): 
▢  Alcohol  
▢  Cannabis (weed/pot)  
▢  None of the above  
 
 
Display This Question: 
If In the past 12 months have you been under the influence of any of the following during sex = Alcohol Or Cannabis 
(weed/pot) 
AND are a man who has sex with men or a trans woman who has sex with men  
 
Thinking of the last time you were under the influence of any of the following during anal intercourse, did you 
use a condom? 
 
Yes, all of the 
time 
Yes, some of 
the time 
No, none of 
the time 
Not sure 
I did not have 
anal intercourse 
Alcohol  o  o  o  o  o  






Display This Question: 
If In the past 12 months have you taken any of the following (please select all that apply): = Amphetamine (speed), Or 
Cocaine, Or Ketamine (Vitamin K, K, Special K) Or GHB/GBL (Gine, Liquid Ecstasy, Liquid G), Mephedrone (Drone, MCAT, 
meow meow), Or Meth Amphetamine (Crystal meth, ice/glass, Tina), Or Poppers (Amyl or other nitrite inhalants), Or Ecstasy, 
Or Crack cocaine, Or Heroin, Or Viagra or other erectile dysfunction drug, Or Other illicit drug or drugs, please specify: 
 
In the past 12 months have you taken any of the following just before or during sex (please select all that 
apply): 
▢  Amphetamine (speed)  
▢  Cocaine  
▢  Crack cocaine  
▢  Ecstasy  
▢  Heroin  
▢  Ketamine (Vitamin K, K, Special K)  
▢  GHB/GBL (Gine, Liquid Ecstasy, Liquid G)  
▢  Mephedrone (Drone, MCAT, meow meow)  
▢  Meth Amphetamine (Crystal meth, ice/glass, Tina)  
▢  Viagra or other erectile dysfunction drug  
▢  Poppers (Amyl or other nitrite inhalants)  
▢  Free text entry option 






Display This Question: 
If In the past 12 months have you taken any of the following just before or during sex (please tick... = Amphetamine 
(speed), Or Cocaine, Or Ketamine (Vitamin K, K, Special K) Or GHB/GBL (Gine, Liquid Ecstasy, Liquid G), Mephedrone 
(Drone, MCAT, meow meow), Or Meth Amphetamine (Crystal meth, ice/glass, Tina), Or Poppers (Amyl or other nitrite 
nhalants), Or Ecstasy, Or Crack cocaine, Or Heroin, Or Viagra or other erectile dysfunction drug, Or Other illicit drug or drugs, 
please specify: 
AND are a man who has sex with men, or a trans woman who has sex with men 






of the time 
No, none 
of the time 
Not sure 
I did not have 
anal intercourse 
Amphetamine (speed)  o  o  o  o  o  
Cocaine  o  o  o  o  o  
Crack cocaine  o  o  o  o  o  
Ecstasy  o  o  o  o  o  
Heroin  o  o  o  o  o  
Ketamine (Vitamin K, K, Special K)  o  o  o  o  o  
GHB/GBL (Gine, Liquid Ecstasy, Liquid G)  o  o  o  o  o  
Mephedrone (Drone, MCAT, meow meow)  o  o  o  o  o  
Meth Amphetamine (Crystal meth, 
ice/glass, Tina)  o  o  o  o  o  
Viagra or other erectile dysfunction drug  o  o  o  o  o  
Poppers (Amyl or other nitrite inhalants)  o  o  o  o  o  




Display This Question: 
If In the past 12 months have you taken any of the following just before or during sex (please tick... = Amphetamine 
(speed), Or Cocaine, Or Ketamine (Vitamin K, K, Special K) Or GHB/GBL (Gine, Liquid Ecstasy, Liquid G), Mephedrone 
(Drone, MCAT, meow meow), Or Meth Amphetamine (Crystal meth, ice/glass, Tina), Or Poppers (Amyl or other nitrite 
 
217 
inhalants), Or Ecstasy, Or Crack cocaine, Or Heroin, Or Viagra or other erectile dysfunction drug, Or Other illicit drug or drugs, 
please specify: 
Thinking of the last time you had drugs just before or during sex, how many different drugs did you take? 
▼ 1 ... 10+ 
 
Display this Question: 
If If In the past 12 months have you been under the influence of any of the following during sex = Cannabis (weed/pot) 
OR 
If In the past 12 months have you taken any of the following just before or during sex (please tick... = Amphetamine 
(speed), Or Cocaine, Or Ketamine (Vitamin K, K, Special K) Or GHB/GBL (Gine, Liquid Ecstasy, Liquid G), Mephedrone 
(Drone, MCAT, meow meow), Or Meth Amphetamine (Crystal meth, ice/glass, Tina), Or Poppers (Amyl or other nitrite 
inhalants), Or Ecstasy, Or Crack cocaine, Or Heroin, Or Viagra or other erectile dysfunction drug, Or Other illicit drug or drugs, 
please specify: 
We are interested in how you feel about the following statements. Read each statement carefully. Indicate how 










I use drugs for sex because 
they give a more intense 
sexual experience. o  o  o  o  o  
I am more likely to have sex 
without a condom when I 
have used drugs for sex. o  o  o  o  o  
When I use drugs I do 
things sexually that I would 
not do sober. o  o  o  o  o  
Using drugs for sex is 
having a negative effect on 
my life. o  o  o  o  o  
I enjoy my sex life and am 
in control of my actions. o  o  o  o  o  
I use drugs for sex because 
they allow me to have sex 
for longer. o  o  o  o  o  
I feel pressured by my 
friends / social circle to use 
drugs for sex. o  o  o  o  o  
I feel pressured by my 
partner to use drugs for 




Display This Question: 
If In the past 12 months have you been under the influence of any of the following during sex = Alcohol 
 
We are interested in how you feel about the following statements. Read each statement carefully. Indicate how 










I have alcohol before sex 
because it give a more 
intense sexual experience. o  o  o  o  o  
I am more likely to have sex 
without a condom when I 
have alcohol before sex. o  o  o  o  o  
When I have alcohol I do 
things sexually that I would 
not do sober. o  o  o  o  o  
Using alcohol for sex is 
having a negative effect on 
my life. o  o  o  o  o  
I enjoy my sex life and am 
in control of my actions. o  o  o  o  o  
I use alcohol for sex 
because it allows me to 
have sex for longer. o  o  o  o  o  
I feel pressured by my 
friends / social circle to 
have alcohol before sex. o  o  o  o  o  
I feel pressured by my 
partner to have alcohol 
before sex. o  o  o  o  o  
 
 
Have you attended a sexual health / GUM clinic in the past 12 months? 
o Yes  
o No  
o Not sure  






In the last 12 months have you been diagnosed with any of the following (tick all that apply): 
▢  Chlamydia  
▢  Gonorrhoea  
▢  Genital warts 
▢  Herpes 
▢  LGV (Lymphogranuloma venereum) 
▢  Shigella  
▢  Syphilis  
▢  Hepatitis C  




What is your HIV status? 
o Negative  
o Positive  
o Don't know  
 
 
Display This Question: 
If What is your HIV status? = Positive 
 
Are you currently on antiretroviral medication? 
o Yes  






Display This Question: 
If Are you currently on antiretroviral medication? = Yes 
 
Your last viral load was: 
o Undetectable  
o Detectable  
o Don't know  
 
Display This Question: 
If What is your HIV status? = Negative Or Don't know 
 
When did you last have an HIV test? 
o In the last 3 months  
o Between 3 and 12 months  
o More than a year ago  
o Over 5 years ago  
o Never had an HIV test  
o  
Display This Question: 
If I have sex with (tick all that apply): = Men 
 
How many men have you had anal intercourse with in the last 12 months? 
▼ 0 ... 100+ 
 
 
Display This Question: 
If How many men have you had anal intercourse with in the last 12 months? > 0 
 
How many of these were without a condom? 
▼ 0 ... 100+ 
 
Display This Question: 




How many women have you had sex with in the last 12 months? 
▼ 0 ... 100+ 
 
Display This Question: 
If I have sex with (tick all that apply): = Men  
And If 
What is your HIV status? Does not = Positive 
 
Are you currently taking PrEP (Pre-exposure Prophylaxis)? 
o Yes  
o No  
 
 
In the past 12 months has a person(s) done sexual things to you or make you do sexual things without your 
consent? 
o Yes  
o No  
o Not sure  
o Prefer not to say  
 
If you would like help and support on this issue please contact one of the following organisations: 
Galop, the leading LGBTQ+ anti-violence organisation, runs a Sexual Violence Casework and Support Service 
for all LGBTQ+ people aged 13+ who have experienced sexual assault, violence or abuse, however or whenever 
it happened. Galop’s services are independent, confidential and free and open to those living in London or going 
through the criminal justice process in London. Galop is one of the leading organisations working with those 
who experience sexual assault in a chemsex context.  
Online: www.galop.org.uk  
Email: referrals@galop.org.uk  
Telephone: 020 7704 2040  
Survivors Manchester offers confidential support, information, practical and emotional support for boys and 
men affected by sexual violence, experienced in the past or present. 
Online: www.survivorsmanchester.org.uk 
Email: support@survivormanchester.org.uk  







Survivors’ Network and LGBT Switchboard run a dedicated helpline which offers support to trans people 
including those who are non-binary or questioning who have experienced sexual violence at any point in their 
lifetime. 
Online: http://www.switchboard.org.uk/projects/trans-survivors-switchboard/ 
Email: info@switchboard.org.uk (please put TSS in the subject). 
Telephone: 01273 204050 (Sundays 1pm - 5pm).  
 
Rape Crisis Centres are women-led and offer a range of support, advocacy, counselling and information in 
women-only safe space for women and girls who have experienced sexual violence.  
Online: https://rapecrisis.org.uk/centres.php 





Display This Question: 
If I have sex with (tick all that apply): = Men  
 
We are interested in how you feel about the following statements. Read each statement carefully. Indicate how 







Agree Strongly agree 
I can choose safer 
sex with a man I 
have sex with 
regularly.  
o  o  o  o  o  
I am able to avoid 
behaviour that may 
put me at risk of HIV 
infection.  
o  o  o  o  o  
When I am drunk or 
high, I can avoid 
situations that I 
consider sexually 
risky.  
o  o  o  o  o  
If I ever did 
something risky, I am 
confident that I would 
go back to having 
safer sex right away.  
o  o  o  o  o  
I am confident that I 
can have safer sex 
even if my partner 
really doesn’t want 
to.  
o  o  o  o  o  
I never lose sight of 
what I consider safer 
sex, no matter what I 
am feeling or if I am 
drunk or high.  
o  o  o  o  o  
When I am drunk or 
high, I can choose 
safer sex with a man 
I have never had sex 
with before.  






If you have had sex with more than one person in the past 12 months, in the following questions, please think of 
"the person I am having sex with" as overall, rather than one person. 
 
In the past 12 months, how satisfied have you been with the following: 
 










The quality of my 
orgasms  o  o  o  o  o  
My ‘‘letting go’’ and 
surrender to sexual 
pleasure during sex  o  o  o  o  o  
The way I sexually react 
to the person I am having 
sex with  o  o  o  o  o  
My body’s sexual 
functioning  o  o  o  o  o  
My mood after sexual 
activity  o  o  o  o  o  
The pleasure I provide to 
the person I am having 
sex with  o  o  o  o  o  
The balance between 
what I give and receive in 
sex  o  o  o  o  o  
The person I am having 
sex with's emotional 
opening up during sex  o  o  o  o  o  
The person I am having 
sex with's ability to 
orgasm  o  o  o  o  o  
The person I am having 
sex with's sexual 
creativity  o  o  o  o  o  
The variety of my sexual 
activities  o  o  o  o  o  
The frequency of my 







Section C: Thoughts and feelings 
Display This Question: 
If identifies as female (including trans female) and has sex with women 
Or If 
Identifies as Female (including trans female) and Gay/Lesbian/Homosexual 
Or If 
Identifies as Female (including trans female) and Bisexual 
We are interested in how you feel about the following statements. Read each statement carefully. Indicate how 










I often feel it best to avoid personal 
or social involvement with 
lesbian/bisexual women.  o  o  o  o  o  
I have tried to stop being attracted 
to women in general.  o  o  o  o  o  
If someone offered me the chance 
to be completely heterosexual, I 
would accept the chance.  o  o  o  o  o  
I wish I weren’t attracted to women.  o  o  o  o  o  
I feel alienated from myself 
because of being attracted to 
women.  o  o  o  o  o  
I wish that I could develop more 
erotic feelings about men.  o  o  o  o  o  
I feel that being attracted to women 
is a personal shortcoming for me.  o  o  o  o  o  
I would like to get professional help 
in order to change my sexual 
orientation from being attracted to 
women to straight.  
o  o  o  o  o  
I have tried to become more 





Display This Question: 
If identifies as Male (including trans male) and Gay/Lesbian/Homosexual 
Or If 
 Identifies as Male (including trans male) has sex with Men 
Or If 
Identifies as Male (including trans male) and Bisexual 
We are interested in how you feel about the following statements. Read each statement carefully. Indicate how 







Agree Strongly agree 
I often feel it best to avoid 
personal or social involvement 
with gay/bisexual men.  o  o  o  o  o  
I have tried to stop being 
attracted to men in general.  o  o  o  o  o  
If someone offered me the 
chance to be completely 
heterosexual, I would accept the 
chance.  
o  o  o  o  o  
I wish I weren’t attracted to men.  o  o  o  o  o  
I feel alienated from myself 
because attracted to men.  o  o  o  o  o  
I wish that I could develop more 
erotic feelings about women.  o  o  o  o  o  
I feel that being attracted to men 
is a personal shortcoming for 
me.  o  o  o  o  o  
I would like to get professional 
help in order to change my 
sexual orientation from being 
attracted to men to straight.  
o  o  o  o  o  
I have tried to become more 




Display This Question: 
If Is this the same gender you were assigned at birth? = No 
And Which of the following best describes how you think of yourself? Is not Prefer not to say 
The term trans will be used in the following questions, but please think of this term in whatever way you feel is 
the best fit (i.e. non-binary, gender variant, gender non-conforming etc). Please rate the following items using 







Being around trans people makes me uncomfortable.      
Life would be easier if I wasn't trans.      
Most of my friends are trans.      
I feel comfortable in bars with trans people.      
I don't like thinking about being trans.      
I don't like socialising with trans people.      
When I think of being trans, I think mainly of positive 
things.   
 
  
I feel comfortable in public.      
I feel comfortable discussing being trans in public.      
It is important to me to control who knows about my 
trans identity.   
 
  
Most people have negative reactions to trans people.      
Society punishes people who are trans.      
I worry about being unattractive.      
I worry about aging as a trans person.      
I would prefer not to be trans.      
Most people don't discriminate against trans people.      
I feel comfortable being trans.      
I am not worried about anyone finding out that I am 
trans.   
 
  
Discrimination against trans people is still common.      




We are interested in how you feel about the following statements. Read each statement carefully. Indicate how 


















I often compare how 
I look with how other 
people look.  o  o  o  o  o  o  o  o  
During the day, I 
think about how I 
look many times.  o  o  o  o  o  o  o  o  
I often worry about 
whether the clothes I 
am wearing make 
me look good.  
o  o  o  o  o  o  o  o  
I often worry about 
how I look to other 
people.  o  o  o  o  o  o  o  o  
I feel ashamed of 
myself when I 
haven’t made an 
effort to look my 
best.  
o  o  o  o  o  o  o  o  
I feel like I must be a 
bad person when I 
don’t look as good as 
I could.  
o  o  o  o  o  o  o  o  
I would be ashamed 
for people to know 
what I really weigh.  o  o  o  o  o  o  o  o  
When I’m not 
exercising enough, I 
question whether I 
am a good person.  
o  o  o  o  o  o  o  o  
When I’m not the 
size I think I should 







Have you taken any image or performance enhancing drugs in the last 12 months (e.g. anabolic steroids, growth 
hormone, hCG, Melanotan, non-prescribed diet pills)? 
o Yes  
o No  
o Prefer not to say  
 
Display This Question: 
If How would you describe your sexual orientation? = Gay/Lesbian/Homosexual Or Bisexual 
Or In another way, please specify: Or Asexual Or Queer 
 
In the last 12 months, have you experienced discrimination, been prevented from doing something, or been 
hassled or made to feel inferior in any of the following situations because of your sexuality (please select all that 
apply)?  
▢  At school or in education 
▢  Getting hired or getting a job  
▢  At work  
▢  Getting housing  
▢  Getting medical care  
▢  Getting service in a store or restaurant  
▢  Getting credit, bank loans, or a mortgage  
▢  On the street or in a public setting  
▢  From the police or in the courts  
▢  Other (please specify) ________________________________________________ 





Display This Question: 
If Is this the same gender you were assigned at birth? = No 
And Which of the following best describes how you think of yourself? Is not Prefer not to say 
 
In the last 12 months, have you experienced discrimination, been prevented from doing something, or been 
hassled or made to feel inferior in any of the following situations because of your gender (please select all that 
apply)?  
▢  At school or in education 
▢  Getting hired or getting a job  
▢  At work  
▢  Getting housing  
▢  Getting medical care  
▢  Getting service in a store or restaurant  
▢  Getting credit, bank loans, or a mortgage  
▢  On the street or in a public setting  
▢  From the police or in the courts  
▢  Other (please specify) ________________________________________________ 
▢  None of the above  
 
 
 The next questions are about how you feel about different aspects of your life. For each one, tell me how often 
you feel that way. 
 Hardly ever Some of the time Always 
How often do you feel 
that you lack 
companionship?  o  o  o  
How often do you feel left 
out?  o  o  o  
How often do you feel 






How would you rate your health at this present time? 
o Very poor  
o Poor  
o Fair  
o Good  
o Very good 
 
 
We are interested in how you feel about the following statements. Read each statement carefully. Indicate how 
you feel about each statement.  
In the past 30 days how often.... 
 None of the time 
A little of the 
time 
Some of the 
time 
Most of the 
time 
All of the 
time 
Did you feel tired out for 
no good reason  o  o  o  o  o  
Did you feel nervous  o  o  o  o  o  
Did you feel so nervous 
that nothing could calm 
you down  o  o  o  o  o  
Did you feel hopeless  o  o  o  o  o  
Did you feel restless or 
fidgety  o  o  o  o  o  
Did you feel so restless 
that you could not sit still  o  o  o  o  o  
Did you feel depressed  o  o  o  o  o  
Did you feel that 
everything was an effort  o  o  o  o  o  
Did you feel so sad that 
nothing could cheer you 
up  o  o  o  o  o  






We are interested in how you feel about the following statements. Read each statement carefully. Indicate how 















In most ways my 
life is close to my 
ideal.  o  o  o  o  o  o  o  
The conditions of 
my life are 
excellent.  o  o  o  o  o  o  o  
I am satisfied with 
my life.  o  o  o  o  o  o  o  
So far I have 
gotten the 
important things I 
want in life.  
o  o  o  o  o  o  o  
If I could live my 
life over, I would 
change almost 
nothing.  
o  o  o  o  o  o  o  
 
 
If you have any additional comments in relation to any of the answers you have given throughout the 







Thank you for completing the survey.  
 
The aim of this survey is to understand why certain LGBT people engage in sex and drugs, as well as how this 
impacts on wellbeing. We have described this survey as looking into the sex and lifestyles of LGBT people, 
because we want to include everyone in our study, not just individuals who engage in sex and drugs, and 
because we also want to understand a wide range of peoples’ experiences. This is the first fully inclusive LGBT 
research in the UK attempting to understand sex and drug use among LGBT people. The findings of this survey 
will be distributed through academic articles and the community organisations involved with recruitment.  
 
If you would like to enter the prize draw for the chance to win £50 worth of shopping vouchers, or one of two 
runner up prizes of £25 worth of shopping vouchers, please click on the link below. Your email address will not 
be linked to the answers you have given. The prize draw will be open until the survey closes, which will be 
before 31st September 2018, and winners will be notified by email within one month of the survey closing. 




If you would like more information about this research, you can contact the researcher at:  
Matthew Hibbert, Public Health institute, Liverpool John Moores University, Henry Cotton Building, 15-21 
Webster Street, Liverpool, L3 2ET, UK. 0151 231 4088, m.p.hibbert@2017.ljmu.ac.uk.  
 
If you would like further help and support please contact one of the following organisations:  
London Friend offer counselling and support around issues such as same-sex relationships, sexual and gender 
identity and promoting personal growth and self-confidence. London Friend are also home to Antidote - the 
UK's only LGB&T drug and alcohol service. Our social groups provide a safe space to meet and socialise as an 
alternative to the bar and club scene.  
Online: londonfriend.org.uk/  
Antidote helpline: 020 7833 1674 (10am-6pm, Monday to Friday). Ask for one of the Antidote Team.  
COAST (Chemsex Open Access Support Team) provides an open-minded, confidential drug, alcohol and 
wellbeing support for men who like men in Liverpool. They run drop-in clinics Monday 5pm-7pm at the 
Armistead and Thursday 3pm-6.30pm at the GUM clinic, Royal Liverpool Hospital.  
Online: www.addaction.org.uk  
Telephone: 07790560085 (Sam), 07790560039 (Peter), 01512 476560 (Armistead)  
Email: coast@addaction.org.uk  
 
LGBT Foundation is part of Manchester Integrated Drug and Alcohol Service and offers support to LGBT 
individuals affected by drugs, alcohol and chemsex. They offer one to one support, chemsex support, telephone 
and online support, referral for specialist GBL/GHB and alcohol detox and rehab, and access to mutual aid and 
peer support groups.  
Online: http://lgbt.foundation/how-we-can-help-you/drug-and-alcohol-support  
Telephone: 0345 3 303030  






If you would like to be entered into the prize draw for the chance to win £50 worth of shopping vouchers, or one 
of two runner up prizes of £25 worth of shopping vouchers, please enter your email address below: 
________________________________________________________________ 
 
The prize draw will be open until the survey closes, which will be before 31st September 2018, and winners will 
be notified by email within one month of the survey closing. 





Appendix 5: Recruitment Log 
 
Advert Cost Duration Start End Likes, shares, retweets Ad location 










MSM paid ad £6.67/day 26 days 12/04/2018 08/05/2018 2 likes 2 comments X X X X  
Trans paid ad £6.67/day 26 days 12/04/2018 08/05/2018 2 likes X X X X  
WSW paid ad £6.67/day 26 days 12/04/2018 08/05/2018 19 likes, one comment X X X X  
Boost 1 - paid ad £100 7 days 18/04/2018 25/04/2018 136 likes, 54 
comments, 113 shares 
X  X   
Boost 2 - paid ad £100 7 days 25/04/2018 02/05/2018 X  X   
London friend n/a n/a 25/04/2018 n/a 11 retweets 5 likes     X 
LGB&T 
partnership 
n/a n/a 11/05/2018 n/a 8 retweets 3 likes     X 
COAST n/a n/a 18/05/2018 n/a 5 retweets 4 likes     X 
GMHC n/a n/a 29/05/2018 n/a 1 retweet 2 likes     X 
Boost 3 - paid ad £50 2 days 23/05/2018 25/05/2018 26 likes, 2 comments, 
7 shares 
X  X   
Boost 4 - paid ad £50 2 days 29/05/2018 31/05/2018 X  X   
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Appendix 6: Information sheet for semi-structured interviews with MSM 
service users  
LIVERPOOL JOHN MOORES UNIVERSITY 
Participant Information Sheet 
 
LJMU’s Research Ethics Committee Approval Reference: 
 
YOU WILL BE GIVEN A COPY OF THIS INFORMATION SHEET  
 
Title of Study Qualitative interviews with men who have sex with men (MSM) engaging in sexualised 
drug use: experiences, intentions and service provision. 
 
School/Faculty: Public Health Institute 
 
Name and Contact Details and status of the Principal Investigator:  
Matthew Hibbert, PhD student, m.p.hibbert@2017.ljmu.ac.uk.  
 
Name and Contact Details of the Investigators:  
Caroline Brett, C.E.Brett@ljmu.ac.uk. 
Lorna Porcellato, L.A.Porcellato@ljmu.ac.uk. 
Vivian Hope, V.D.Hope@ljmu.ac.uk (primary supervisor).  
 
You are being invited to take part in a research study. Before you decide it is important for you to 
understand why the study is being done and what participation will involve. Please take time to 
read the following information carefully and discuss it with others if you wish. Ask us if there is 
anything that is not clear or if you would like more information. Take time to decide whether or 
not you wish to take part. Thank you for reading this. 
 
1. What is the purpose of the study? 
The purpose of this PhD study is to investigate the experiences of sexualised drug use among MSM. 
 
This study hopes to answer the following questions… 
a. What experiences do MSM have when engaging in sexualised drug use? 
b. Does intention and behaviour differ around safer sex whilst under the influence of drugs? 





2. Why have I been invited to participate?  
You have been invited because you gave your email with permission to be contacted for future 
research, or you have self-selected from a community organisation or Facebook. 
 
The inclusion criteria are identifying as a man who has sex with men and engaging in one of the 
following substances before or during sex in the past 12 months: 
 Amphetamine (speed) 
 Cocaine 
 Crack cocaine 
 Ecstasy (MDMA) 
 Heroin 
 Ketamine (Vitamin K, K, Special K) 
 GHB/GBL (Gina, Liquid Ecstasy, Liquid G) 
 Mephedrone (Drone, MCAT, meow meow) 
 Meth Amphetamine (Crystal meth, ice/glass, Tina) 




3. Do I have to take part?  
No. It is up to you to decide whether or not to take part. If you do decide to take part you will be 
given this information sheet to keep and be asked to sign a consent form. You can withdraw at 
any time by informing the investigators without giving a reason and without it affecting your 
rights/any future treatment/service you receive. 
 
4. What will happen to me if I take part?  
We will talk you through the study procedures and give you the chance to ask any questions.  
 
The interview will last for approximately one hour in a location best suited to you, ensuring your 
privacy. The researcher will ask you questions regarding your sexual history, drug use, current 
sexual practices, and experiences of sexual health clinics. You will be given a £20 Amazon voucher 
before the interview begins, as reimbursement for your time. You have the right to stop the 
interview at any time and you will get to keep the voucher. 
 
5. Will I be recorded and how will the recorded media be used? 
The audio recordings of your activities made during this study will be used only for analysis. No 
other use will be made of them without your written permission, and no one outside the project 
will be allowed access to the original recordings. 
 
Interviews will be audio recorded on a password protected audio recording device and as soon as 
possible the recording will be transferred to secure storage and deleted from the recording device. 
 
6. What are the possible disadvantages and risks of taking part? 
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The questions asked may be personal and you may not want to answer some questions. If you get 
upset by anything asked or do not want to answer a certain question, please let the researcher 
know and they will move on. Similarly, if you do not want to take part in the interview anymore, 
please let the researcher know and the interview will be stopped without affecting your 
reimbursement.  
 
If you are personally affected by participation in this research, you may wish to seek 
support/advice from: 
 
COAST (Chemsex Open Access Support Team) provides an open-minded, confidential drug, 
alcohol and wellbeing support for men who like men in Liverpool. They run drop-in clinics Monday 
5pm-7pm at the Armistead and Thursday 3pm-6.30pm at the GUM clinic, Royal Liverpool Hospital. 
Online: www.addaction.org.uk 
Telephone: 07790560085 (Sam), 07790560039 (Peter), 01512 476560 (Armistead)  
Email: coast@addaction.org.uk  
 
LGBT Foundation is part of Manchester Integrated Drug and Alcohol Service and offers support to 
LGBT individuals affected by drugs, alcohol and chemsex. They offer one to one support, chemsex 
support, telephone and online support, referral for specialist GBL/GHB and alcohol detox and 
rehab, and access to mutual aid and peer support groups. 
Online: http://lgbt.foundation/how-we-can-help-you/drug-and-alcohol-support  
Telephone: 0345 3 303030  
Email: Tyler.Andrew@lgbt.foundation  
 
The Armistead Centre is a free and confidential support, information and sexual health promotion 
service for the lesbian, gay, bisexual and trans (LGBT) community operated by Mersey Care NHS 
Foundation Trust. They provide a safe space for LGBT groups, one-to-one support, harm reduction 
advice on lifestyle, support for parents and carers of LGBT people, counselling and rapid HIV 
testing. 
Online: https://www.thelivewelldirectory.com/Services/589 
Telephone: 0151 247 6560 
 
 
7. What are the possible benefits of taking part? 
Whilst will be no direct benefits to you for taking part in the study, but it is hoped that this work 
will be used to improve sexual health services for MSM who engage in sexualised drug use.  
 
8. What will happen to the data provided and how will my taking part in this project be kept 
confidential? 
The information you provide as part of the study is the research study data. Any research study 
data from which you can be identified (e.g. from identifiers such as your name, date of birth, 
audio recording etc.), is known as personal data. This includes more sensitive categories of 
personal data (sensitive data) such as your sex life; or sexual orientation. Personal data does not 
include data that cannot be identified to an individual (e.g. data collected anonymously or where 




Personal data will be stored confidentially for 5 years after the study has finished. Personal data 
will be accessible to the principal researcher and primary supervisor only.  
 
You will not be identifiable in any ensuing reports or publications. 
 
We will use pseudonyms in transcripts and reports to help protect the identity of individuals and 
organisations unless you tell us that you would like to be attributed to information/direct quotes 
etc. 
 
9. Limits to confidentiality 
The Investigator will keep confidential anything they learn or observe related to illegal activity 
unless related to the abuse of children or vulnerable adults, money laundering or acts of terrorism. 
 
In certain exceptional circumstances where you or others may be at significant risk of harm, the 
investigator may need to report this to an appropriate authority. This would usually be discussed 
with you first. Examples of those exceptional circumstances when confidential information may 
have to be disclosed are: 
o The investigator believes you are at serious risk of harm, either from yourself or others 
o The investigator suspects a child may be at risk of harm 
o You pose a serious risk of harm to, or threaten or abuse others 
o As a statutory requirement e.g. reporting certain infectious diseases 
o Under a court order requiring the University to divulge information 
o We are passed information relating to an act of terrorism 
 
10. What will happen to the results of the research project? 
The investigator intends to publish the results in a PhD thesis and in a scientific journal article. 
 
11. Who is organising and funding/commissioning the study? 
This study is organised and funded by Liverpool John Moores University.  
 
12. Who has reviewed this study? 
This study has been reviewed by, and received ethics clearance through, the Liverpool John 
Moores University Research Ethics Committee (Reference number: 18/PHI/036). 
 
13. What if something goes wrong? 
If you have a concern about any aspect of this study, please contact the relevant investigator who 
will do their best to answer your query. The researcher should acknowledge your concern within 
10 working days and give you an indication of how they intend to deal with it. If you wish to make 
a complaint, please contact the chair of the Liverpool John Moores University Research Ethics 
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Committee (researchethics@ljmu.ac.uk) and your communication will be re-directed to an 
independent person as appropriate. 
 
14. Data Protection Notice 
The data controller for this study will be Liverpool John Moores University (LJMU). The LJMU Data 
Protection Office provides oversight of LJMU activities involving the processing of personal data, 
and can be contacted at secretariat@ljmu.ac.uk. This means that we are responsible for looking 
after your information and using it properly. LJMU’s Data Protection Officer can also be contacted 
at secretariat@ljmu.ac.uk. The University will process your personal data for the purpose of 
research. Research is a task that we perform in the public interest. 
 
Your rights to access, change or move your information are limited, as we need to manage your 
information in specific ways in order for the research to be reliable and accurate. If you withdraw 
from the study, we will keep the information about you that we have already obtained.  
You can find out more about how we use your information by contacting secretariat@ljmu.ac.uk. 
 
If you are concerned about how your personal data is being processed, please contact LJMU in the 
first instance at secretariat@ljmu.ac.uk. If you remain unsatisfied, you may wish to contact the 
Information Commissioner’s Office (ICO). Contact details, and details of data subject rights, are 
available on the ICO website at: https://ico.org.uk/for-organisations/data-protection-
reform/overview-of-the-gdpr/individuals-rights/  
 
16. Contact for further information 
Matthew Hibbert 
Public Health Institute 
Liverpool John Moores University 







Thank you for reading this information sheet and for considering to take part in this study.  
 
Note: A copy of the participant information sheet should be retained by the participant with a copy of 










Title of Project: Qualitative interviews with MSM engaging in sexualised drug use: experiences, 
intentions and service provision. 
 
Name of Researcher and School/Faculty 
Matthew Hibbert, Public Health Institute. 
 
1. I confirm that I have read and understand the information provided for the above study. 
I have had the opportunity to consider the information, ask questions and have had these 
answered satisfactorily 
 
2. I understand that my participation is voluntary and that I am free to withdraw at any 
time, without giving a reason and that this will not affect my legal rights. 
 
 
3. I understand that any personal information collected during the study will be 
anonymised and remain confidential 
 
 
4. I agree to take part in the above interview 
 
 
5. I understand that the interview will be audio recorded and I am happy to proceed  
 
 
6. I understand that parts of our conversation may be used verbatim in future publications 
or presentations but that such quotes will be anonymised. 
 
 
Name of Participant    Date    Signature 
 
 
Name of Researcher    Date   Signature  




Appendix 8: Semi-structured interview guide for MSM service users 
 Tell me a bit about yourself. 
o Hobbies / interests. 
o What do you do on a weekend? Grindr? 
o How do you identify in terms of sexuality? 
 
 Describe your first sexual experience with a man. 
 
 Describe your last sexual experience with a man. 
o If chems mentioned, probe on no. of partners, types of activity. 
o If chems not mentioned probe on sexual experience with drug use then 
chemsex. 
 
 How does engaging in drug use and sex/chemsex make you feel? 
o Physically during and after. 
o Wellbeing during and after. 
o Motivation 
 
 When you are sober, what are your intentions around safe sex when under the 
influence of [drug], and does this differ in practice? 
o Condoms / PrEP. 
o Why does intentions / practice differ or not? 
 
 Can you describe your most recent experience of a sexual health clinic? 
o Disclosure of chemsex/other drug use? 
o How were you treated by staff? 
o Typical advice / intervention 
o Signposting/condoms/injecting kits 
o Referred to any specialist services? 
o Was this typical of previous experiences? 
 
 If you have sought help for chemsex/drug use, can you describe that process? 
o If not sought help, how would you get help if needed? Perceive any barriers to 
accessing help? 
o If sought help, was this process sufficient? What was good/ what was bad? 
o Ideally, what services would you like to see? 
 
 Is there anything else you would like to add? 
 




Appendix 9: Information sheet for semi-structured interviews with NHS 
sexual health service providers 




YOU WILL BE GIVEN A COPY OF THIS INFORMATION SHEET  
 
Title of Study: Exploring perspectives on provision and accessibility of Pre-exposure 
prophylaxis (PrEP) and care for men who have sex with men (MSM) engaging in chemsex in 
North England and the West Midlands  
 
School/Faculty: Public Health Institute, Faculty of Education, Health & Community 
 
Name and Contact Details and status of the Principal Investigator: Professor Marie Claire 
Van Hout, Professor of Public Health Policy and Practice (M.C.VanHout@ljmu.ac.uk)  
 
Name and Contact Details of the Investigators: Mr Jim McVeigh, Director of Public Health 
Institute and Reader in Substance Use Epidemiology (J.McVeigh@ljmu.ac.uk), Professor Viv 
Hope, Professor of Public Health (V.D.Hope@ljmu.ac.uk), Mrs Jennifer Germain, Researcher, 
(J.s.germain@2014.ljmu.ac.uk)  
 
You are being invited to take part in a research study. Before you decide it is important for 
you to understand why the study us being done and what participation will involve. Please 
take time to read the following information carefully and discuss it with others if you wish. 
Ask us if there is anything that is not clear or if you would like more information. Take time to 
decide whether or not you wish to take part. Thank you for reading this. 
 
15. What is the purpose of the study? 
The project is exploring your awareness, experiences and perspectives of the use of PrEP 
among MSM and their engagement in chemsex, as it relates to current awareness of PrEP 
(including of eligibility, compliance, access, online sourcing of PrEP and sources of 
information); the impact of PrEP on HIV testing uptake and patterns of HIV testing, on 
sexual risk behaviours, hepatitis C risk and awareness, and other STIs; the barriers to 
accessing PrEP, and complexities around optimal PrEP service provision and care 
pathways for MSM engaging in chemsex. 
 
 
16. Why have I been invited to participate?  
 
You have been invited because you have been identified as a potential health professional 
via your NHS trust. Many other people have also been identified as potential participants 
and will be recruited to the research study.  
 
17. Do I have to take part?  
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No. It is up to you to decide whether or not to take part. If you do decide to take part you 
will be given this information sheet to keep and be asked to sign a consent form. You can 
withdraw at any time by informing the investigators without giving a reason and without 
it affecting your rights or access to any future treatment/service you receive. 
 
18. What will happen to me if I take part?  
You will be asked to take part in a one off interview with a researcher. The interview will 
discuss your awareness, experiences and perspectives of the use of PrEP among MSM and 
consolations with MSM engaging in chemsex, as it relates to current awareness of PrEP 
(including of eligibility, compliance, access, online sourcing of PrEP and sources of 
information); the impact of PrEP on HIV testing uptake and patterns of HIV testing, on 
sexual risk behaviours, hepatitis C risk and awareness, and other STIs; the barriers to 
accessing PrEP, and complexities around optimal PrEP service provision. The interview 
should last approximately one to one and a half hours and will be conducted over the 
phone or via skype. You will be able to agree the date and time of the interview to suit 
you. You will be asked to complete a consent form agreeing that your take part in the 
research. Following the interview you will not be contacted by the research team again 
although you may contact us if you have any further question. 
 
 
19. Will I be recorded and how will the recorded media be used? 
 
Yes. However, the audio and/or video recordings of your activities made during this study 
will be used only for analysis and for illustration in conference presentations and lectures. 
No other use will be made of them without your written permission, and no one outside 
the project will be allowed access to the original recordings. 
 
Interviews will be audio recorded on a password protected audio recording device and as 
soon as possible the recording will be transferred to secure storage and deleted from the 
recording device. 
 
20. What are the possible disadvantages and risks of taking part? 
 
There are no disadvantages or risks from taking part in this research. If you are personally 
affected by participation in this research, you may wish to seek support/advice from your 
NHS trust  
 
21. What are the possible benefits of taking part? 
 
Whilst there will be no direct benefits to you for taking part in the study, but it is hoped 
that this work will inform discussion concerning the provision of PrEP in England.  
 
 





The information you provide as part of the study is the research study data. Any research 
study data from which you can be identified (e.g. from identifiers such as your name, 
audio recording etc.), is known as personal data. This includes more sensitive categories 
of personal data (sensitive data) such as your race; ethnic origin; politics; religion; trade 
union membership; genetics; biometrics (where used for ID purposes); health; sex life; or 
sexual orientation.  
Personal data does not include data that cannot be linked to an individual (e.g. data 
collected anonymously or where identifiers have been removed). 
 
If necessary, personal data will be stored confidentially for 5years after the study has 
finished. Personal data will be accessible to only to the research team and will not be 
transferred outside of the European Economic Area.  
 
Personal data collected from you will be recorded using a linked code – the link from the 
code to your identity will be stored securely and separately from the coded data 
 
We will not tell anyone that you have taken part in the interview. We will also not name 
you in any of our reports or publications. You will not be identifiable in any ensuing reports 
or publications. We will use pseudonyms in transcripts and reports to help protect the 
identity of individuals and organisations unless you tell us that you would like to be 
attributed to information/direct quotes etc. 
 
The interview recordings will be transcribed by the research team and stored on password 
protected computers.  
 
Anonymised data might be used for additional or subsequent research studies and we 
might share anonymised data with other investigators (e.g. in online databases). All 
personal information that could identify you will be removed or changed before 
information is shared with other researchers or results are made public. 
 
23. Limits to confidentiality 
 
Please note that confidentiality may not be guaranteed; for example, due to the limited 
size of the participant sample, the position of the participant or information included in 
reports, participants might be indirectly identifiable in transcripts and reports. The 
investigator will work with the participant in an attempt to minimise and manage the 
potential for indirect identification of participants. 
 
The Investigator will keep confidential anything they learn or observe related to illegal 
activity unless related to the abuse of children or vulnerable adults, money laundering or 
acts of terrorism. 
 
In certain exceptional circumstances where you or others may be at significant risk of 
harm, the investigator may need to report this to an appropriate authority. This would 
usually be discussed with you first. Examples of those exceptional circumstances when 
confidential information may have to be disclosed are: 
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o The investigator believes you are at serious risk of harm, either from yourself 
or others 
o The investigator suspects a child may be at risk of harm 
o You pose a serious risk of harm to, or threaten or abuse others 
o As a statutory requirement e.g. reporting certain infectious diseases 
o Under a court order requiring the University to divulge information 
o We are passed information relating to an act of terrorism 
 
 
24. What will happen to the results of the research project? 
 
The investigator intends to publish the results in journal articles and present the findings 
at conferences  
 
 
25. Who is organising and funding/commissioning the study? 
 
This study is organised by Liverpool John Moores University and funded/commissioned by 
The Sexually Transmitted Infection Research Foundation.  
 
26. Who has reviewed this study? 
 
This study has been reviewed by, and received ethics clearance through HRA approval. 
 
27. What if something goes wrong? 
 
If you have a concern about any aspect of this study, please contact the relevant 
investigator who will do their best to answer your query. The researcher should 
acknowledge your concern within 10 working days and give you an indication of how they 
intend to deal with it. If you wish to make a complaint, please contact the chair of the 
Liverpool John Moores University Research Ethics Committee 
(researchethics@ljmu.ac.uk) and your communication will be re-directed to an 
independent person as appropriate. 
 
28. Data Protection Notice 
 
Liverpool John Moores University is the sponsor for this study based in the United Kingdom. 
We will be using information from you in order to undertake this study and will act as the 
data controller for this study. This means that we are responsible for looking after your 
information and using it properly. Liverpool John Moores University will keep identifiable 
information about you for 5 years after the study has finished. 
 
Your rights to access, change or move your information are limited, as we need to manage 
your information in specific ways in order for the research to be reliable and accurate. If you 
withdraw from the study, we will keep the information about you that we have already 





You can find out more about how we use your information by contacting 
secretariat@ljmu.ac.uk . Your NHS site will use your name, and contact details to contact you 
about the research study, and make sure that relevant information about the study is 
recorded for your care, and to oversee the quality of the study. Individuals from Liverpool 
John Moores University and regulatory organisations may look at your medical and research 
records to check the accuracy of the research study. Your NHS site will pass these details to 
Liverpool John Moores University along with the information collected from you. The only 
people in Liverpool John Moores University who will have access to information that identifies 
you will be people who need to contact you to set up interview arrangements or audit the 
data collection process. The people who analyse the information will not be able to identify 
you and will not be able to find out your name, or contact details. Your NHS site will keep 
identifiable information about you from this study for 5 years after the study has finished. 
 
 
16. Contact for further information 
Professor Marie Claire Van Hout 
 
 





Appendix 10: Consent form for semi-structured interviews with NHS 
sexual health service providers 
 
LIVERPOOL JOHN MOORES UNIVERSITY 
CONSENT FORM – Service providers 
 
Exploring perspectives on provision and accessibility of Pre-exposure prophylaxis (PrEP) and care for 
men who have sex with men (MSM) engaging in chemsex in North England and the West Midlands 
 




1. I confirm that I have read and understand the information provided for the above 
study. I have had the opportunity to consider the information, ask questions and have 
had these answered satisfactorily 
 
2. I understand that my participation is voluntary and that I am free to withdraw at 
any time, without giving a reason and that this will not affect my legal rights. 
 
3. I understand that any personal information collected during the study will be 
anonymised and remain confidential 
 
4. I agree to take part in an interview for the above study 
 
 
5. I understand that the interview audio recorded and I am happy to proceed 
 
6. I understand that parts of our conversation may be used verbatim in future 
publications or presentations but that such quotes will be anonymised. 
 
 








Name of Person taking consent Date Signature 
(if different from researcher) 
 
 











 Can you describe the complexities around effective provision of PrEP services for 
MSM in the 
North of England and the West Midlands? 
 
 What are the barriers and enablers to providing PrEP to the MSM community? 
 
 Can you describe optimal ways to support informed decision-making around PrEP 
delivery to MSM? 
 
 Does PrEP have impact on sexual risk taking or on levels of STIs? 
 
 How can we provide equitable PrEP access within the HIV cascade of care to the 
MSM community? 
 
 Can you think of any recommendations to inform policy, practice and health 
professional training around PrEP delivery to MSM in the North of England and the 




 Can you describe a time when you have discussed PrEP with a man who has sex with 
men who engages in chemsex? 
o Perceived barriers e.g. adherence, drug interactions 
o Outcome 
 
 Can you describe generally a consultation with a man who has sex with men who 
engages in chemsex? 
o Frequency 
o Typical advice / intervention 
o Condoms/injecting kits/ sign posting 
 
 Can you draw a referral pathway for a man who has sex with men who engages in 
chemsex? 
 
 How do you decide if someone is in need of further help and support? 
o Information given to those in need/not in need 
 
 What services do you currently provide for MSM engaging in chemsex and do you 
think this is sufficient? 
o Ideally what would you like to provide? 
o Barriers to providing services e.g. time/training 
 
 Is there anything else you would like to add either in terms of PrEP or chemsex? 
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Appendix 12: Screenshot of coding framework after phase 2 of thematic analysis for 
service users  
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Appendix 13: Screenshot of coding framework after phase 2 of thematic analysis for 
service providers 
 
